Home
  >  
Section 59

EurekaMag Full Text Articles Chapter 58,493



References:

Langsted, A.; Nordestgaard, B.ør.G.; Benn, M.; Tybjærg-Hansen, A.; Kamstrup, P.R. 2016: PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. Journal of Clinical Endocrinology and Metabolism 101(9): 3281-3287
Toth, P.P. 2016: PCSK9 and Lipoprotein(a): the Plot Thickens. Circulation Research 119(1): 3-6
Cariou, B.; Ding, Z.; Mehta, J.L. 2016: PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering. Atherosclerosis 253: 275-277
Cui, C.-J.; Li, S.; Li, J.-J. 2015: PCSK9 and its modulation. Clinica Chimica Acta; International Journal of Clinical Chemistry 440: 79-86
Alonso, R.; Mata, P.; Muñiz, O.; Fuentes-Jimenez, F.; Díaz, J.L.; Zambón, D.; Tomás, M.; Martin, C.; Moyon, T.; Croyal, M.ël.; Thedrez, A.él.; Lambert, G. 2016: PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis 254: 249-253
Druce, I.; Abujrad, H.; Ooi, T.C. 2015: PCSK9 and triglyceride-rich lipoprotein metabolism. Journal of Biomedical Research 29(6): 429-436
Gouni-Berthold, I.; Berthold, H.K. 2014: PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients 6(12): 5517-5533
Gouni-Berthold, I. 2015: PCSK9 antibodies: a new class of lipid-lowering drugs. ATHEROSCLEROSIS. Supplements 18: 21-27
Pocoví, M. 2016: PCSK9 continues surprising us. Clinica e Investigacion en Arteriosclerosis: Publicacion Oficial de la Sociedad Espanola de Arteriosclerosis 28(2): 79-81
Roubtsova, A.; Chamberland, A.; Marcinkiewicz, J.; Essalmani, R.; Fazel, A.; Bergeron, J.J.; Seidah, N.G.; Prat, A. 2015: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. Journal of Lipid Research 56(11): 2133-2142
Schmidt, A.F.; Swerdlow, D.I.; Holmes, M.V.; Patel, R.S.; Fairhurst-Hunter, Z.; Lyall, D.M.; Hartwig, F.P.; Horta, B.L.; Hyppönen, E.; Power, C.; Moldovan, M.; van Iperen, E.; Hovingh, G.K.; Demuth, I.; Norman, K.; Steinhagen-Thiessen, E.; Demuth, J.; Bertram, L.; Liu, T.; Coassin, S.; Willeit, J.; Kiechl, S.; Willeit, K.; Mason, D.; Wright, J.; Morris, R.; Wanamethee, G.; Whincup, P.; Ben-Shlomo, Y.; McLachlan, S.; Price, J.F.; Kivimaki, M.; Welch, C.; Sanchez-Galvez, A.; Marques-Vidal, P.; Nicolaides, A.; Panayiotou, A.G.; Onland-Moret, N.C.; van der Schouw, Y.T.; Matullo, G.; Fiorito, G.; Guarrera, S.; Sacerdote, C.; Wareham, N.J.; Langenberg, C.; Scott, R.; Luan, J.'a.; Bobak, M.; Malyutina, S.; Pająk, A.; Kubinova, R.; Tamosiuna 2017: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. LANCET. Diabetes and Endocrinology 5(2): 97-105
Elewa, U.; Fernández-Fernández, B.; Mahillo-Fernández, I.; Martin-Cleary, C.; Sanz, A.B.; Sanchez-Niño, M.D.; Ortiz, A. 2016: PCSK9 in diabetic kidney disease. European Journal of Clinical Investigation 46(9): 779-786
Cheng, J.M.; Oemrawsingh, R.M.; Garcia-Garcia, H.M.; Boersma, E.; van Geuns, R.-J.; Serruys, P.W.; Kardys, I.; Akkerhuis, K.M. 2016: PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 248: 117-122
Lee, J.; Hegele, R.A. 2017: PCSK9 inhibition and diabetes: turning to Mendel for clues. LANCET. Diabetes and Endocrinology 5(2): 78-79
Rallidis, Lοukianos.S.; Lekakis, J. 2016: PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. Hellenic Journal of Cardiology: Hjc 57(2): 86-91
Češka, R. 2015: PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®. Vnitrni Lekarstvi 61(11): 946-951
Desai, N.R.; Sabatine, M.S. 2015: PCSK9 inhibition in patients with hypercholesterolemia. Trends in Cardiovascular Medicine 25(7): 567-574
Blom, D.J.; Dent, R.; Castro, R.C.; Toth, P.P. 2016: PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vascular Health and Risk Management 12: 185-197
Santos, R.D. 2016: PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet. LANCET. Diabetes and Endocrinology 4(5): 377-379
Tavori, H.; Giunzioni, I.; Fazio, S. 2015: PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. Current Opinion in Endocrinology Diabetes and Obesity 22(2): 126-132
Olsson, A. 2015: PCSK9 inhibition--A new era in cholesterol treatment. Lakartidningen 112
Raal, F.J.; Giugliano, R.P.; Sabatine, M.S.; Koren, M.J.; Blom, D.; Seidah, N.G.; Honarpour, N.; Lira, A.; Xue, A.; Chiruvolu, P.; Jackson, S.; Di, M.; Peach, M.; Somaratne, R.; Wasserman, S.M.; Scott, R.; Stein, E.A. 2016: PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research 57(6): 1086-1096
White, K.; Mohan, C.; Rocco, M. 2016: PCSK9 inhibition: a promise fulfilled?. Cleveland Clinic Journal of Medicine 83(11 Suppl 2: S36-S44
Rodriguez, F.; Knowles, J.W. 2015: PCSK9 inhibition: current concepts and lessons from human genetics. Current Atherosclerosis Reports 17(3): 487
Stoekenbroek, R.M.; Kastelein, J.J.P.; Huijgen, R. 2015: PCSK9 inhibition: the way forward in the treatment of dyslipidemia. Bmc Medicine 13: 258
Schlimpert, V. 2015: PCSK9 inhibitor is convincing a large analysis. MMW Fortschritte der Medizin 157(21-22): 90
Gencer, B.; Lambert, G.; Mach, F.ço. 2015: PCSK9 inhibitors. Swiss Medical Weekly 145: W14094
Soška, Vír.; Vrablík, M.; Bláha, Vír.; Cífková, R.; Češka, R.; Freiberger, Táš.; Kraml, P.; Piťha, J.; Rosolová, H.; Štulc, Táš.; Vaverková, H.; Urbanová, Z. 2016: PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement. Vnitrni lekarstvi 62(4): 329-333
Müller-Wieland, D.; Marx, N. 2016: PCSK9 inhibitors : new treatment option in clinical practice. Herz 41(4): 290-295
Laufs, U.; Custodis, F.; Werner, C. 2016: PCSK9 inhibitors : Recommendations for patient selection. Herz 41(4): 296-306
Chapman, M.J.; Stock, J.K.; Ginsberg, H.N. 2015: PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Current Opinion in Lipidology 26(6): 511-520
Sattar, N. 2016: PCSK9 inhibitors and diabetes risk: a question worth asking?. European Heart Journal 37(39): 2990-2992
Swiger, K.J.; Martin, S.S. 2015: PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Safety 38(6): 519-526
Dahagam, C.; Goud, A.; Abdelqader, A.; Hendrani, A.; Feinstein, M.J.; Qamar, A.; Joshi, P.H.; Swiger, K.J.; Byrne, K.; Quispe, R.; Jones, S.R.; Blumenthal, R.S.; Martin, S.S. 2016: PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Future Cardiology 12(2): 149-157
Dahagam, C.; Goud, A.; Abdelqader, A.; Hendrani, A.; Feinstein, M.J.; Qamar, A.; Joshi, P.H.; Swiger, K.J.; Byrne, K.; Quispe, R.; Jones, S.R.; Blumenthal, R.S.; Martin, S.S. 2016: PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology 12(2): 139-148
Parhofer, K.G. 2016: PCSK9 inhibitors in hypercholesterolemia. new hope for patients with diabetes mellitus?. Herz 41(3): 217-223
Latimer, J.; Batty, J.A.; Neely, R.Dermot.G.; Kunadian, V. 2016: PCSK9 inhibitors in the prevention of cardiovascular disease. Journal of Thrombosis and Thrombolysis 42(3): 405-419
Arbel, R.; Hammerman, A.; Triki, N.; Greenberg, D. 2016: PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?. International Journal of Cardiology 220: 242-245
Patel, K.R. 2014: PCSK9 inhibitors on the way. Managed Care 23(11): 43
Mayor, S. 2015: PCSK9 inhibitors reduce cardiovascular events, preliminary data show. Bmj 350: H1508
Reiner, Že. 2015: PCSK9 inhibitors--past, present and future. Expert Opinion on Drug Metabolism and Toxicology 11(10): 1517-1521
Saußele, T. 2015: PCSK9 inhibitors. a new approach for treatment of hypercholesterolemia. Medizinische Monatsschrift für Pharmazeuten 38(7): 250-257
Castilla-Guerra, L.; Fernandez-Moreno, M.C. 2017: PCSK9 inhibitors: A new era in stroke prevention?. European Journal of Internal Medicine 37: E44
Verbeek, R.; Stoekenbroek, R.M.; Hovingh, G.K. 2015: PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. European Journal of Pharmacology 763(Part A): 38-47
Denegri, A.; Petrova-Slater, I.; Pasotti, E.; Rossi, M.G.; Pedrazzini, G.B.; Moccetti, T.; Moccetti, M. 2016: PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy. Journal of Cardiovascular Medicine 17(4): 237-244
Paton, D.M. 2016: PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia. Drugs of Today 52(3): 183-192
Gencer, B.; Rodondi, N.; Mach, F.ço. 2016: PCSK9 inhibitors: new treatment to lower cholesterol. Revue Medicale Suisse 12(508): 440
Jialal, I.; Patel, S.B. 2015: PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering. Metabolic Syndrome and Related Disorders 13(3): 99-101
Ferri, N.; Marchianò, S.; Tibolla, G.; Baetta, R.; Dhyani, A.; Ruscica, M.; Uboldi, P.; Catapano, A.L.; Corsini, A. 2016: PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis 253: 214-224
Lettino, M. 2015: PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program. Giornale Italiano di Cardiologia 16(4): 211-216
Piao, M.-X.; Bai, J.-W.; Zhang, P.-F.; Zhang, Y.-Z. 2015: PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways. International Journal of Clinical and Experimental Pathology 8(3): 2787-2794
Tran, N.T.; Aslibekyan, S.; Tiwari, H.K.; Zhi, D.; Sung, Y.Ju.; Hunt, S.C.; Rao, D.C.; Broeckel, U.; Judd, S.E.; Muntner, P.; Kent, S.T.; Arnett, D.K.; Irvin, M.R. 2015: PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies. Frontiers in Genetics 6: 136
Bridge, S.H.; Sheridan, D.A.; Felmlee, D.J.; Crossey, M.M.E.; Fenwick, F.I.; Lanyon, C.V.; Dubuc, Gève.; Seidah, N.G.; Davignon, J.; Thomas, H.C.; Taylor-Robinson, S.D.; Toms, G.L.; Neely, R.Dermot.G.; Bassendine, M.F. 2015: PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. Journal of Hepatology 62(4): 763-770
Berger, J-Mathieu.; Vaillant, N.; Le May, Cédric.; Calderon, C.; Brégeon, J.; Prieur, X.; Hadchouel, J.; Loirand, G.; Cariou, B. 2015: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis 239(1): 252-259
Burke, A.C.; Dron, J.S.; Hegele, R.A.; Huff, M.W. 2017: PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Annual Review of Pharmacology and Toxicology 57: 223-244
Pedro-Botet, J.; Badimón, L. 2016: PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects. Clinica e Investigacion en Arteriosclerosis: Publicacion Oficial de la Sociedad Espanola de Arteriosclerosis 28(Suppl 2): 3-8
King, S.B. 2014: PCSK9: is it fluoride for cardiology?. JACC. Cardiovascular Interventions 7(11): 1331-1332
Ferguson-Paul, K.; Park, C.; Childress, S.; Arnold, S.; Ault, B.; Bagga, B. 2018: Disseminated histoplasmosis in pediatric kidney transplant recipients-A report of six cases and review of the literature. Pediatric Transplantation 22(7): E13274
Anonymous 2005: PCT freeze on school nursing cash. Nursing Standard 1987) 19(35): 10-10
Bamford, T. 2008: PCT perspective: primary care is more than health. London Journal of Primary Care 1(1): 31-32
Yanagi, T.; Reed, J.C.; Matsuzawa, S.-I. 2014: PCTAIRE1 regulates p27 stability, apoptosis and tumor growth in malignant melanoma. Oncoscience 1(10): 624-633
Yanagi, T.; Shi, R.; Aza-Blanc, P.; Reed, J.C.; Matsuzawa, S.-i. 2015: PCTAIRE1-knockdown sensitizes cancer cells to TNF family cytokines. Plos one 10(3): E0119404
Yanagi, T.; Matsuzawa, S-ichi. 2015: PCTAIRE1/PCTK1/CDK16: a new oncotarget?. Cell Cycle 14(4): 463-464
Warner, C.L.; Behr, J.A.; Gorelov, A. 2014: PCTFE as a solution to birefringence in atom trap viewports. Review of Scientific Instruments 85(11): 113106
Lai, F.-J.; Chang, H.-T.; Wu, W.-S. 2015: PCTFPeval: a web tool for benchmarking newly developed algorithms for predicting cooperative transcription factor pairs in yeast. Bmc Bioinformatics 16(Suppl 18): S2
Iwano, S.; Satou, A.; Matsumura, S.; Sugiyama, N.; Ishihama, Y.; Toyoshima, F. 2015: PCTK1 regulates integrin-dependent spindle orientation via protein kinase a regulatory subunit KAP0 and myosin X. Molecular and Cellular Biology 35(7): 1197-1208
Lipley, N. 2007: PCTs 'fail to appoint' directors. Nursing Management 13(10): 4
Anonymous 2001: PCTs sideline flexible shifts. Nursing Standard 1987) 16(8): 9-9
Schiff, D. 2016: PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity. Neuro-Oncology 18(6): 755-756
Main, D.C.J. 2015: Do codes of conduct matter?. Veterinary Record 176(25): 652-653
Stockmann, C.; Byington, C.L. 2015: PCV13 in the USA: early successes and potential challenges. Lancet. Infectious Diseases 15(3): 254-256
Fedson, D.S. 2016: PCV13 vaccination for older adults: Another view. Vaccine 34(38): 4466
Koinig, H.C.; Talker, S.C.; Stadler, M.; Ladinig, A.; Graage, R.; Ritzmann, M.; Hennig-Pauka, I.; Gerner, W.; Saalmüller, A. 2015: PCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection. Veterinary Research 46: 20
Xiao, C-Ting.; Harmon, K.M.; Halbur, P.G.; Opriessnig, T. 2016: PCV2d-2 is the predominant type of PCV2 DNA in pig samples collected in the U.S. during 2014-2016. Veterinary microbiology 197: 72-77
Kumar, R.; Mishra, B.K.; Lahiri, T.; Kumar, G.; Kumar, N.; Gupta, R.; Pal, M.K. 2017: PCV: An Alignment Free Method for Finding Homologous Nucleotide Sequences and its Application in Phylogenetic Study. Interdisciplinary Sciences Computational Life Sciences 9(2): 173-183
Fletcher, M.A.; Balmer, P.; Bonnet, E.; Dartois, N. 2015: PCVs in individuals at increased risk of pneumococcal disease: a literature review. Expert Review of Vaccines 14(7): 975-1030
Zhang, Y.; Kang, E.; Yuan, M.; Fu, Y.; Zhu, L. 2015: PCaP2 regulates nuclear positioning in growing Arabidopsis thaliana root hairs by modulating filamentous actin organization. Plant Cell Reports 34(8): 1317-1330
Cheng, S.; Zhang, Y.; Brooks, C.L. 2015: PCalign: a method to quantify physicochemical similarity of protein-protein interfaces. Bmc Bioinformatics 16: 33
Ramanathan, N.; Sankaran, K.; Sundararajan, K. 2016: PCl3-C6H6 heterodimers: evidence for Pπ phosphorus bonding at low temperatures. Physical Chemistry Chemical Physics: Pccp 18(28): 19350-19358
Liu, M.; Xu, S.; Wang, Y.; Li, Y.; Li, Y.; Zhang, H.; Liu, H.; Chen, J. 2016: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget 7(51): 84951-84964
Lin, Z.; Chen, X.; Li, Z.; Luo, Y.; Fang, Z.; Xu, B.; Han, M. 2016: PD-1 Antibody Monotherapy for Malignant Melanoma: a Systematic Review and Meta-Analysis. Plos one 11(8): E0160485
Schneiderbauer, R.; Schneiderbauer, M.; Wick, W.; Enk, A.H.; Haenssle, H.A.; Hassel, J.C. 2017: PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Dermato-Venereologica 97(3): 395-396
Gettinger, S.; Politi, K. 2016: PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(18): 4539-4541
Shi, L.; Chen, L.; Wu, C.; Zhu, Y.; Xu, B.; Zheng, X.; Sun, M.; Wen, W.; Dai, X.; Yang, M.; Lv, Q.; Lu, B.; Jiang, J. 2016: PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(5): 1173-1184
Quan, L.; Chen, X.; Liu, A.; Zhang, Y.; Guo, X.; Yan, S.; Liu, Y. 2015: PD-1 Blockade can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in Vitro. Plos one 10(9): E0136476
Ribas, A.; Shin, D.S.; Zaretsky, J.; Frederiksen, J.; Cornish, A.; Avramis, E.; Seja, E.; Kivork, C.; Siebert, J.; Kaplan-Lefko, P.; Wang, X.; Chmielowski, B.; Glaspy, J.A.; Tumeh, P.C.; Chodon, T.; Pe'er, D.; Comin-Anduix, B.ña. 2016: PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research 4(3): 194-203
Davar, D.; Wilson, M.; Pruckner, C.; Kirkwood, J.M. 2015: PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Reports in Oncological Medicine 2015: 737389
Bhatia, S.; Thompson, J.A. 2016: PD-1 Blockade in Melanoma: a Promising Start, but a Long way to go. JAMA 315(15): 1573-1575
Diaz, L.A.; Le, D.T. 2015: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine 373(20
Nghiem, P.T.; Bhatia, S.; Lipson, E.J.; Kudchadkar, R.R.; Miller, N.J.; Annamalai, L.; Berry, S.; Chartash, E.K.; Daud, A.; Fling, S.P.; Friedlander, P.A.; Kluger, H.M.; Kohrt, H.E.; Lundgren, L.; Margolin, K.; Mitchell, A.; Olencki, T.; Pardoll, D.M.; Reddy, S.A.; Shantha, E.M.; Sharfman, W.H.; Sharon, E.; Shemanski, L.R.; Shinohara, M.M.; Sunshine, J.C.; Taube, J.M.; Thompson, J.A.; Townson, S.M.; Yearley, J.H.; Topalian, S.L.; Cheever, M.A. 2016: PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine 374(26): 2542-2552
Wolchok, J.D. 2015: PD-1 Blockers. Cell 162(5): 937
Karyampudi, L.; Lamichhane, P.; Krempski, J.; Kalli, K.R.; Behrens, M.D.; Vargas, D.M.; Hartmann, L.C.; Janco, J.Marie.T.; Dong, H.; Hedin, K.E.; Dietz, A.B.; Goode, E.L.; Knutson, K.L. 2016: PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Research 76(2): 239-250
Zander, R.A.; Obeng-Adjei, N.; Guthmiller, J.J.; Kulu, D.I.; Li, J.; Ongoiba, A.; Traore, B.; Crompton, P.D.; Butler, N.S. 2015: PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host and Microbe 17(5): 628-641
Pollock, K.M.; Montamat-Sicotte, D.J.; Grass, L.; Cooke, G.S.; Kapembwa, M.S.; Kon, O.M.; Sampson, R.D.; Taylor, G.P.; Lalvani, A. 2016: PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection. Plos one 11(1): E0146905
Nishino, M.; Ramaiya, N.H.; Awad, M.M.; Sholl, L.M.; Maattala, J.A.; Taibi, M.; Hatabu, H.; Ott, P.A.; Armand, P.F.; Hodi, F.S. 2016: PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(24): 6051-6060
Medina, P.J.; Adams, V.R. 2016: PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. PharmacoTherapy 36(3): 317-334
Park, S.S.; Dong, H.; Liu, X.; Harrington, S.M.; Krco, C.J.; Grams, M.P.; Mansfield, A.S.; Furutani, K.M.; Olivier, K.R.; Kwon, E.D. 2015: PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunology Research 3(6): 610-619
Ren, Z.; Peng, H.; Fu, Y.-X. 2016: PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Cancer Discovery 6(5): 477-478
Haro, M.A.; Littrell, C.A.; Yin, Z.; Huang, X.; Haas, K.M. 2016: PD-1 Suppresses Development of Humoral Responses that Protect against Tn-Bearing Tumors. Cancer Immunology Research 4(12): 1027-1037
Webb, J.R.; Milne, K.; Nelson, B.H. 2015: PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunology Research 3(8): 926-935
Schmidt, L.H.; Kümmel, A.; Görlich, D.; Mohr, M.; Bröckling, S.; Mikesch, J.H.; Grünewald, I.; Marra, A.; Schultheis, A.M.; Wardelmann, E.; Müller-Tidow, C.; Spieker, T.; Schliemann, C.; Berdel, W.E.; Wiewrodt, R.; Hartmann, W. 2015: PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. Plos one 10(8): E0136023
Joseph, R.W.; Millis, S.Z.; Carballido, E.M.; Bryant, D.; Gatalica, Z.; Reddy, S.; Bryce, A.H.; Vogelzang, N.J.; Stanton, M.L.; Castle, E.P.; Ho, T.H. 2015: PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research 3(12): 1303-1307
Tsai, K.K.; Zarzoso, I.és.; Daud, A.I. 2014: PD-1 and PD-L1 antibodies for melanoma. Human Vaccines and Immunotherapeutics 10(11): 3111-3116
Lote, H.; Cafferkey, C.; Chau, I. 2015: PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews 41(10): 893-903
Lee, J.; Kefford, R.; Carlino, M. 2016: PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. ImmunoTherapy 8(6): 733-746
Qiu, M.-K.; Wang, S.-C.; Dai, Y.-X.; Wang, S.-Q.; Ou, J.-M.; Quan, Z.-W. 2015: PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis. Plos one 10(6): E0128523
Yu, G.-T.; Bu, L.-L.; Huang, C.-F.; Zhang, W.-F.; Chen, W.-J.; Gutkind, J.S.; Kulkarni, A.B.; Sun, Z.-J. 2015: PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget 6(39): 42067-42080
Antonios, J.P.; Soto, H.; Everson, R.G.; Orpilla, J.; Moughon, D.; Shin, N.; Sedighim, S.; Yong, W.H.; Li, G.; Cloughesy, T.F.; Liau, L.M.; Prins, R.M. 2016: PD-1 blockade enhances the vaccination-induced immune response in glioma. Jci Insight 1(10)
Allen, P.Blair.; Gordon, L.I. 2016: PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. Expert Review of Hematology 9(10): 939-949
Harshman, L.C.; Drake, C.G.; Choueiri, T.K. 2014: PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunology Research 2(12): 1132-1141
Massari, F.; Santoni, M.; Ciccarese, C.; Santini, D.; Alfieri, S.; Martignoni, G.; Brunelli, M.; Piva, F.; Berardi, R.; Montironi, R.; Porta, C.; Cascinu, S.; Tortora, G. 2015: PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treatment Reviews 41(2): 114-121
Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; Rodig, S.J.; Chapuy, B.; Ligon, A.H.; Zhu, L.; Grosso, J.F.; Kim, S.Young.; Timmerman, J.M.; Shipp, M.A.; Armand, P. 2015: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine 372(4): 311-319
Winkler, J.K.; Bender, C.; Kratochwil, C.; Enk, A.; Hassel, J.C. 2017: PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma. British Journal of Dermatology 176(1): 216-219
Liu, T.; Lu, X.; Zhao, C.; Fu, X.; Zhao, T.; Xu, W. 2015: PD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine. Infection and Immunity 83(5): 2011-2017
Simon, S.; Vignard, V.; Florenceau, L.; Dreno, B.; Khammari, A.; Lang, F.; Labarriere, N. 2016: PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology 5(1): E1104448
Lim, T.Seng.; Chew, V.; Sieow, J.Lin.; Goh, S.; Yeong, J.Poh-Sheng.; Soon, A.Ling.; Ricciardi-Castagnoli, P. 2016: PD-1 expression on dendritic cells suppresses CD8 + T cell function and antitumor immunity. Oncoimmunology 5(3): E1085146
Zhang, W.; Bai, J-Fei.; Zuo, M-Xuan.; Cao, X-Xin.; Chen, M.; Zhang, Y.; Han, X.; Zhong, D-Rong.; Zhou, D-Bin. 2016: PD-1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Medicine 5(11): 3077-3084
Bai, J.F.; Zuo, M.X.; Zhang, Y.; Feng, J.; Han, X.; Zhou, D.B.; Zhang, W. 2016: PD-1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with peripheral T/NK cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 37(10): 916-918
Chiku, V.M.; Silva, K.L.O.; de Almeida, B.F.M.; Venturin, G.L.; Leal, A.A.C.; de Martini, C.C.; de Rezende Eugênio, F.; Dos Santos, P.S.P.; de Lima, V.ér.M.ça.F. 2016: PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis. Immunobiology 221(8): 879-888
Jazirehi, A.R.; Lim, A.; Dinh, T. 2016: PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. American Journal of Cancer Research 6(10): 2117-2128
Baker, H. 2016: PD-1 inhibition in advanced Merkel-cell carcinoma. LANCET. Oncology 17(6): E225
Nishino, M.; Ramaiya, N.H.; Hatabu, H.; Hodi, F.S.; Armand, P.F. 2018: PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. British Journal of Haematology 180(5): 752-755
Anonymous 2015: PD-1 inhibitors effective in hodgkin lymphoma. Cancer Discovery 5(2): 102-103
Wakade, D.V.; Carlos, G.; Hwang, S.J.E.; Chou, S.; Hui, R.; Fernandez-Peñas, P. 2016: PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Research 26(4): 421-424
Lowther, D.E.; Goods, B.A.; Lucca, L.E.; Lerner, B.A.; Raddassi, K.; van Dijk, D.; Hernandez, A.L.; Duan, X.; Gunel, M.; Coric, V.; Krishnaswamy, S.; Love, J.C.; Hafler, D.A. 2016: PD-1 marks dysfunctional regulatory T cells in malignant gliomas. Jci Insight 1(5)
Beldi-Ferchiou, A.; Lambert, M.; Dogniaux, S.ép.; Vély, F.éd.ér.; Vivier, E.; Olive, D.; Dupuy, S.ép.; Levasseur, F.; Zucman, D.; Lebbé, C.él.; Sène, D.; Hivroz, C.; Caillat-Zucman, S. 2016: PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7(45): 72961-72977
Rekoske, B.T.; Smith, H.A.; Olson, B.M.; Maricque, B.B.; McNeel, D.G. 2015: PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunology Research 3(8): 946-955
Luke, J.J.; Ott, P.A. 2015: PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6(6): 3479-3492
Martinov, T.; Spanier, J.A.; Pauken, K.E.; Fife, B.T. 2016: PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes. Immunoendocrinology 3
Ren, H.-T.; Li, Y.-M.; Wang, X.-J.; Kang, H.-F.; Jin, T.-B.; Ma, X.-B.; Liu, X.-H.; Wang, M.; Liu, K.; Xu, P.; Yao, Q.-L.; Dai, Z.-J. 2016: PD-1 rs2227982 Polymorphism Is Associated with the Decreased Risk of Breast Cancer in Northwest Chinese Women: a Hospital-Based Observational Study. Medicine 95(21): E3760
McKay, J.T.; Egan, R.P.; Yammani, R.D.; Chen, L.; Shin, T.; Yagita, H.; Haas, K.M. 2015: PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. Journal of Immunology 194(5): 2289-2299
Park, H.J.; Park, J.S.; Jeong, Y.H.; Son, J.; Ban, Y.H.; Lee, B.-H.; Chen, L.; Chang, J.; Chung, D.H.; Choi, I.; Ha, S.-J. 2015: PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. Journal of Immunology 194(12): 5801-5811
Severson, J.J.; Serracino, H.S.; Mateescu, V.; Raeburn, C.D.; McIntyre, R.C.; Sams, S.B.; Haugen, B.R.; French, J.D. 2015: PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunology Research 3(6): 620-630
Dors, A.; Czyżewska-Dors, E.; Wasyl, D.; Pomorska-Mól, M. 2016: Prevalence and factors associated with the occurrence of bacterial enteropathogens in suckling piglets in farrow-to-finish herds. Veterinary Record 179(23): 598
Hassan, S.S.; Akram, M.; King, E.C.; Dockrell, H.M.; Cliff, J.M. 2015: PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment. Plos one 10(9): E0137646
Yang, S.; Zhang, Q.; Liu, S.; Wang, A.R.; You, Z. 2016: PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. American Journal of Clinical and Experimental Urology 4(1): 1-8
Schroder, P.M.; Khattar, M.; Baum, C.E.; Miyahara, Y.; Chen, W.; Vyas, R.; Muralidharan, S.; Mierzejewska, B.; Stepkowski, S.M. 2015: PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy. Diabetologia 58(6): 1309-1318
Ma, S.-D.; Xu, X.; Jones, R.; Delecluse, H.-J.; Zumwalde, N.A.; Sharma, A.; Gumperz, J.E.; Kenney, S.C. 2016: PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. Plos Pathogens 12(5): E1005642
Zamani, M.R.; Aslani, S.; Salmaninejad, A.; Javan, M.R.; Rezaei, N. 2016: PD-1/PD-L and autoimmunity: a growing relationship. Cellular Immunology 310: 27-41
Seifert, A.M.; Zeng, S.; Zhang, J.Q.; Kim, T.S.; Cohen, N.A.; Beckman, M.J.; Medina, B.D.; Maltbaek, J.H.; Loo, J.K.; Crawley, M.H.; Rossi, F.; Besmer, P.; Antonescu, C.R.; DeMatteo, R.P. 2017: PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23(2): 454-465
Zhang, L.; Xia, C-Qing. 2016: PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells. Journal of Immunology Research 2016: 2419621
Hamanishi, J.; Mandai, M.; Matsumura, N.; Abiko, K.; Baba, T.; Konishi, I. 2016: PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology 21(3): 462-473
Jing, W.; Li, M.; Zhang, Y.; Teng, F.; Han, A.; Kong, L.; Zhu, H. 2016: PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Oncotargets and Therapy 9: 489-502
Mandai, M. 2016: PD-1/PD-L1 blockage in cancer treatment-from basic research to clinical application. International Journal of Clinical Oncology 21(3): 447
Li, T.; Ma, R.; Zhu, J.Y.; Wang, F.S.; Huang, L.; Leng, X.S. 2015: PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance. Transplantation Proceedings 47(1): 165-170
Erlmeier, F.; Hartmann, A.; Autenrieth, M.; Wiedemann, M.; Ivanyi, P.; Steffens, S.; Weichert, W. 2016: PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. Medical Oncology 33(11): 120
Crescenzi, A.; Annibali, O.; Bianchi, A.; Pagano, A.; Donati, M.; Grifoni, A.; Avvisati, G. 2016: PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma. Leukemia Research 49: 98-101
Ji, M.; Liu, Y.; Li, Q.; Li, X.; Ning, Z.; Zhao, W.; Shi, H.; Jiang, J.; Wu, C. 2016: PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biology and Therapy 17(4): 407-413
Liu, L.; Zheng, Q.; Lee, J.; Ma, Z.; Zhu, Q.; Wang, Z. 2015: PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. Journal of Cellular and Molecular Medicine 19(6): 1223-1233
Bagley, S.J.; Bauml, J.M.; Langer, C.J. 2015: PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. Clinical Advances in Hematology and Oncology: H&o 13(10): 676-683
Sunshine, J.; Taube, J.M. 2015: PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology 23: 32-38
Ji, M.; Liu, Y.; Li, Q.; Li, X.-D.; Zhao, W.-Q.; Zhang, H.; Zhang, X.; Jiang, J.-T.; Wu, C.-P. 2015: PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine 13: 5
Xiao, W.; Jiang, L.F.; Deng, X.Z.; Zhu, D.Y.; Pei, J.P.; Xu, M.L.; Li, B.J.; Wang, C.J.; Zhang, J.H.; Zhang, Q.; Zhou, Z.X.; Ding, W.L.; Xu, X.D.; Yue, M. 2016: PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. Immunologic Research 64(2): 412-423
Miller, R.A.; Miller, T.N.; Cagle, P.T. 2016: PD-1/PD-L1, Only a Piece of the Puzzle. Archives of Pathology and Laboratory Medicine 140(11): 1187-1188
Gasser, M.; Grimm, M.; Nichiporuk, E.; Bueter, M.; Lutz, J.; Lebedeva, T.; Koenigshausen, M.; Thiede, A.; Heemann, U.; Meyer, D.; Waaga-Gasser, A. 2016: PD-1/PDL-1 expression in colorectal cancer and its implications for tumor immune evasion. Journal of Clinical Oncology 24(18_Suppl): 10046-10046
Li, J.; Jie, H.-B.; Lei, Y.; Gildener-Leapman, N.; Trivedi, S.; Green, T.; Kane, L.P.; Ferris, R.L. 2015: PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Research 75(3): 508-518
Kim, H.R.; Park, H.J.; Ha, S.-J. 2015: PD-1: Dual guard for immunopathology. Oncotarget 6(26): 21783-21784
Kalathil, S.G.; Lugade, A.A.; Miller, A.; Iyer, R.; Thanavala, Y. 2016: PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. Jci Insight 1(11)
Xiao, X.; Lao, X.-M.; Chen, M.-M.; Liu, R.-X.; Wei, Y.; Ouyang, F.-Z.; Chen, D.-P.; Zhao, X.-Y.; Zhao, Q.; Li, X.-F.; Liu, C.-L.; Zheng, L.; Kuang, D.-M. 2016: PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma that Promotes Disease Progression. Cancer Discovery 6(5): 546-559
Zou, W.; Wolchok, J.D.; Chen, L. 2016: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine 8(328): 328rv4
Cimino-Mathews, A.; Thompson, E.; Taube, J.M.; Ye, X.; Lu, Y.; Meeker, A.; Xu, H.; Sharma, R.; Lecksell, K.; Cornish, T.C.; Cuka, N.; Argani, P.; Emens, L.A. 2016: PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology 47(1): 52-63
Mahoney, K.M.; Sun, H.; Liao, X.; Hua, P.; Callea, M.; Greenfield, E.A.; Hodi, F.S.; Sharpe, A.H.; Signoretti, S.; Rodig, S.J.; Freeman, G.J. 2015: PD-L1 Antibodies to its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research 3(12): 1308-1315
Yaziji, H.; Taylor, C.R. 2017: PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need for Realistic Economic and Practice Expectations. Applied Immunohistochemistry and Molecular Morphology: Aimm 25(1): 1-3
Peligero, C.; Argilaguet, J.; Güerri-Fernandez, R.; Torres, B.; Ligero, C.; Colomer, P.; Plana, M.; Knobel, H.; García, F.; Meyerhans, A. 2015: PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. Plos Pathogens 11(12): E1005270
Ma, D.; Duan, W.; Li, Y.; Wang, Z.; Li, S.; Gong, N.; Chen, G.; Chen, Z.; Wan, C.; Yang, J. 2016: PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice. Plos one 11(3): E0152087
Lesniak, W.G.; Chatterjee, S.; Gabrielson, M.; Lisok, A.; Wharram, B.; Pomper, M.G.; Nimmagadda, S. 2016: PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjugate Chemistry 27(9): 2103-2110
Wimberly, H.; Brown, J.R.; Schalper, K.; Haack, H.; Silver, M.R.; Nixon, C.; Bossuyt, V.; Pusztai, L.; Lannin, D.R.; Rimm, D.L. 2015: PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research 3(4): 326-332
Li, Z.; Dong, P.; Ren, M.; Song, Y.; Qian, X.; Yang, Y.; Li, S.; Zhang, X.; Liu, F. 2016: PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer 7(7): 784-793
Sorensen, S.F.; Zhou, W.; Dolled-Filhart, M.; Georgsen, J.B.; Wang, Z.; Emancipator, K.; Wu, D.; Busch-Sørensen, M.; Meldgaard, P.; Hager, H. 2016: PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Translational Oncology 9(1): 64-69
Kakavand, H.; Wilmott, J.S.; Menzies, A.M.; Vilain, R.; Haydu, L.E.; Yearley, J.H.; Thompson, J.F.; Kefford, R.F.; Hersey, P.; Long, G.V.; Scolyer, R.A. 2015: PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(14): 3140-3148
Patel, S.P.; Kurzrock, R. 2015: PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics 14(4): 847-856
Bhaijee, F.; Anders, R.A. 2016: PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?. JAMA Oncology 2(1): 54-55
Yu, H.; Batenchuk, C.; Badzio, A.; Boyle, T.A.; Czapiewski, P.; Chan, D.C.; Lu, X.; Gao, D.; Ellison, K.; Kowalewski, A.A.; Rivard, C.J.; Dziadziuszko, R.; Zhou, C.; Hussein, M.; Richards, D.; Wilks, S.; Monte, M.; Edenfield, W.; Goldschmidt, J.; Page, R.; Ulrich, B.; Waterhouse, D.; Close, S.; Jassem, J.; Kulig, K.; Hirsch, F.R. 2017: PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 12(1): 110-120
Pinto, A.; Mackrides, N.; Nadji, M. 2018: PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: a Potentially Actionable Biomarker. Applied Immunohistochemistry and Molecular Morphology: Aimm 26(6): 393-397
Veras, E.; Kurman, R.J.; Wang, T.-L.; Shih, I.-M. 2017: PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 36(2): 146-153
Yu, H.; Boyle, T.A.; Zhou, C.; Rimm, D.L.; Hirsch, F.R. 2016: PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11(7): 964-975
Akhmetzyanova, I.; Drabczyk, M.; Neff, C.P.; Gibbert, K.; Dietze, K.K.; Werner, T.; Liu, J.; Chen, L.; Lang, K.S.; Palmer, B.E.; Dittmer, U.; Zelinskyy, G. 2015: PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. Plos Pathogens 11(10): E1005224
Botti, G.; Scognamiglio, G.è; Cantile, M. 2016: PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the use of Tissue Micro Arrays. International Journal of Molecular Sciences 17(7)
Hirsch, F.R.; McElhinny, A.; Stanforth, D.; Ranger-Moore, J.; Jansson, M.; Kulangara, K.; Richardson, W.; Towne, P.; Hanks, D.; Vennapusa, B.; Mistry, A.; Kalamegham, R.; Averbuch, S.; Novotny, J.; Rubin, E.; Emancipator, K.; McCaffery, I.; Williams, J.A.; Walker, J.; Longshore, J.; Tsao, M.S.; Kerr, K.M. 2017: PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 12(2): 208-222
Ikeda, S.; Okamoto, T.; Okano, S.; Umemoto, Y.; Tagawa, T.; Morodomi, Y.; Kohno, M.; Shimamatsu, S.; Kitahara, H.; Suzuki, Y.; Fujishita, T.; Maehara, Y. 2016: PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 11(1): 62-71
Bodhankar, S.; Chen, Y.; Lapato, A.; Dotson, A.L.; Wang, J.; Vandenbark, A.A.; Saugstad, J.A.; Offner, H. 2015: PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke 46(10): 2926-2934
Madore, J.; Strbenac, D.; Vilain, R.; Menzies, A.M.; Yang, J.Y.H.; Thompson, J.F.; Long, G.V.; Mann, G.J.; Scolyer, R.A.; Wilmott, J.S. 2016: PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage IIi Melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(15): 3915-3923
Vranic, S.; Ghosh, N.; Kimbrough, J.; Bilalovic, N.; Bender, R.; Arguello, D.; Veloso, Y.; Dizdarevic, A.; Gatalica, Z. 2016: PD-L1 Status in Refractory Lymphomas. Plos one 11(11): E0166266
Pennell, N.A. 2016: PD-L1 Testing and Lack of Benefit to Guide Treatment with Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. JAMA Oncology 2(5): 569-570
Hansen, A.R.; Siu, L.L. 2016: PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. JAMA Oncology 2(1): 15-16
Colwell, J. 2015: FDA approves first biosimilar, zarxio. Cancer Discovery 5(5): 460
Sabbatino, F.; Villani, V.; Yearley, J.H.; Deshpande, V.; Cai, L.; Konstantinidis, I.T.; Moon, C.; Nota, S.; Wang, Y.; Al-Sukaini, A.; Zhu, A.X.; Goyal, L.; Ting, D.T.; Bardeesy, N.; Hong, T.S.; Fernandez-del Castillo, C.; Tanabe, K.K.; Lillemoe, K.D.; Ferrone, S.; Ferrone, C.R. 2016: PD-L1 and HLA Class i Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(2): 470-478
Borczuk, A.C.; Allen, T.C. 2016: PD-L1 and Lung Cancer: the Era of Precision-ish Medicine?. Archives of Pathology and Laboratory Medicine 140(4): 351-354
Roemer, M.G.M.; Advani, R.H.; Ligon, A.H.; Natkunam, Y.; Redd, R.A.; Homer, H.; Connelly, C.F.; Sun, H.H.; Daadi, S.E.; Freeman, G.J.; Armand, P.; Chapuy, B.; de Jong, D.; Hoppe, R.T.; Neuberg, D.S.; Rodig, S.J.; Shipp, M.A. 2016: PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34(23): 2690-2697
Wu, P.; Wu, D.; Li, L.; Chai, Y.; Huang, J. 2015: PD-L1 and Survival in Solid Tumors: a Meta-Analysis. Plos one 10(6): E0131403
Ameratunga, M.; Asadi, K.; Lin, X.; Walkiewicz, M.; Murone, C.; Knight, S.; Mitchell, P.; Boutros, P.; John, T. 2016: PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. Plos one 11(4): E0153954
Miao, L.; Lu, Y.; Xu, Y.; Zhang, G.; Huang, Z.; Gong, L.; Fan, Y. 2016: PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget (): -
Gray, S.G.; Cuffe, S.éa.; Finn, S.P. 2016: PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) be Considered?. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11(11): E142-E144
Grigg, C.; Rizvi, N.A. 2016: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. Journal for ImmunoTherapy of Cancer 4: 48
Azad, A.; Yin Lim, S.; D'Costa, Z.; Jones, K.; Diana, A.; Sansom, O.J.; Kruger, P.; Liu, S.; McKenna, W.G.; Dushek, O.; Muschel, R.J.; Fokas, E. 2017: PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. Embo Molecular Medicine 9(2): 167-180
Ibrahim, R.; Stewart, R.; Shalabi, A. 2015: PD-L1 blockade for cancer treatment: MEDI4736. Seminars in Oncology 42(3): 474-483
Liu, Q.; Lv, Y.; Zhao, M.; Jin, Y.; Lu, J. 2015: PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes. International Journal of Clinical and Experimental Pathology 8(2): 1374-1383
Kater, A.P.; van der Windt, G.J.W. 2015: PD-L1 blockade: rejuvenating T cells in CLL. Blood 126(2): 126-128
McClanahan, F.; Hanna, B.; Miller, S.; Clear, A.James.; Lichter, P.; Gribben, J.G.; Seiffert, M. 2015: PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 126(2): 203-211
Goldmann, T.; Kugler, C.; Reinmuth, N.; Vollmer, E.; Reck, M. 2016: PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology 27(1): 206-207
Guo, L.; Li, W.; Zhu, X.; Ling, Y.; Qiu, T.; Dong, L.; Fang, Y.; Yang, H.; Ying, J. 2016: PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus 5(1): 805
Abdel-Rahman, O. 2016: PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. ImmunoTherapy 8(9): 1081-1089
Nduom, E.K.; Wei, J.; Yaghi, N.K.; Huang, N.; Kong, L.-Y.; Gabrusiewicz, K.; Ling, X.; Zhou, S.; Ivan, C.; Chen, J.Q.; Burks, J.K.; Fuller, G.N.; Calin, G.A.; Conrad, C.A.; Creasy, C.; Ritthipichai, K.; Radvanyi, L.; Heimberger, A.B. 2016: PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology 18(2): 195-205
Fusi, A.; Festino, L.; Botti, G.; Masucci, G.; Melero, I.; Lorigan, P.; Ascierto, P.A. 2015: PD-L1 expression as a potential predictive biomarker. LANCET. Oncology 16(13): 1285-1287
Chen, C-Long.; Pan, Q-Zhong.; Zhao, J-Jing.; Wang, Y.; Li, Y-Qiang.; Wang, Q-Jing.; Pan, K.; Weng, D-Sheng.; Jiang, S-Shan.; Tang, Y.; Zhang, X-Fei.; Zhang, H-Xia.; Zhou, Z-Qi.; Zeng, Y-Xin.; Xia, J-Chuan. 2016: PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology 5(7): E1176653
Passiglia, F.; Bronte, G.; Bazan, V.; Natoli, C.; Rizzo, S.; Galvano, A.; Listì, A.; Cicero, G.; Rolfo, C.; Santini, D.; Russo, A. 2016: PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 7(15): 19738-19747
Rosell, R.; Palmero, R.ón. 2015: PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors. Cancer Biology and Medicine 12(2): 71-73
David, R. 2015: PD-L1 expression by circulating breast cancer cells. LANCET. Oncology 16(7): E321
Xing, W.; Dresser, K.; Zhang, R.; Evens, A.M.; Yu, H.; Woda, B.A.; Chen, B.J. 2016: PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 7(37): 59976-59986
Gandini, S.; Massi, D.; Mandalà, M. 2016: PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 100: 88-98
Slater, N.A.; Googe, P.B. 2016: PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. Journal of Cutaneous Pathology 43(8): 663-670
Wang, X.; Teng, F.; Kong, L.; Yu, J. 2016: PD-L1 expression in human cancers and its association with clinical outcomes. Oncotargets and Therapy 9: 5023-5039
Madore, J.; Vilain, R.E.; Menzies, A.M.; Kakavand, H.; Wilmott, J.S.; Hyman, J.; Yearley, J.H.; Kefford, R.F.; Thompson, J.F.; Long, G.V.; Hersey, P.; Scolyer, R.A. 2015: PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell and Melanoma Research 28(3): 245-253
Dondero, A.; Pastorino, F.; Della Chiesa, M.; Corrias, M.Valeria.; Morandi, F.; Pistoia, V.; Olive, D.; Bellora, F.; Locatelli, F.; Castellano, A.; Moretta, L.; Moretta, A.; Bottino, C.; Castriconi, R. 2016: PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology 5(1): E1064578
Scheel, A.H.; Ansén, S.; Schultheis, A.M.; Scheffler, M.; Fischer, R.N.; Michels, S.; Hellmich, M.; George, J.; Zander, T.; Brockmann, M.; Stoelben, E.; Groen, H.; Timens, W.; Perner, S.; von Bergwelt-Baildon, M.; Büttner, R.; Wolf, Jürgen. 2016: PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology 5(5): E1131379
Al-Ahmadie, H. 2016: PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. Annals of Oncology: Official Journal of the European Society for Medical Oncology 27(9): 1658-1659
Leite, K.R.M.; Reis, S.T.; Junior, J.é P.; Zerati, M.; Gomes, D.d.O.; Camara-Lopes, L.H.; Srougi, M. 2015: PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagnostic Pathology 10: 189
Komiya, T.; Madan, R. 2015: PD-L1 expression in small cell lung cancer. European Journal of Cancer 51(13): 1853-1855
Schultheis, A.M.; Scheel, A.H.; Ozretić, L.; George, J.; Thomas, R.K.; Hagemann, T.; Zander, T.; Wolf, J.ür.; Buettner, R. 2015: PD-L1 expression in small cell neuroendocrine carcinomas. European Journal of Cancer 51(3): 421-426
Hong, A.M.; Vilain, R.E.; Romanes, S.; Yang, J.; Smith, E.; Jones, D.; Scolyer, R.A.; Lee, C.S.; Zhang, M.; Rose, B. 2016: PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget 7(47): 77010-77020
Prall, F.; Hühns, M. 2016: PD-L1 expression in tumour buds of colorectal carcinoma. Histopathology 69(1): 158-160
Cooper, W.A.; Tran, T.; Vilain, R.E.; Madore, J.; Selinger, C.I.; Kohonen-Corish, M.; Yip, P.; Yu, B.; O'Toole, S.A.; McCaughan, B.C.; Yearley, J.H.; Horvath, L.G.; Kao, S.; Boyer, M.; Scolyer, R.A. 2015: PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2): 181-188
Chen, Z.; Mei, J.; Liu, L.; Wang, G.; Li, Z.; Hou, J.; Zhang, Q.; You, Z.; Zhang, L. 2016: PD-L1 expression is associated with advanced non-small cell lung cancer. Oncology Letters 12(2): 921-927
Ock, C.-Y.; Kim, S.; Keam, B.; Kim, M.; Kim, T.M.; Kim, J.-H.; Jeon, Y.K.; Lee, J.-S.; Kwon, S.K.; Hah, J.H.; Kwon, T.-K.; Kim, D.-W.; Wu, H.-G.; Sung, M.-W.; Heo, D.S. 2016: PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 7(13): 15901-15914
Kim, S.; Koh, J.; Kim, M.-Y.; Kwon, D.; Go, H.; Kim, Y.A.; Jeon, Y.K.; Chung, D.H. 2016: PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology 58: 7-14
Li, Z.; Lai, Y.; Sun, L.; Zhang, X.; Liu, R.; Feng, G.; Zhou, L.; Jia, L.; Huang, X.; Kang, Q.; Lin, D.; Gao, J.; Shen, L. 2016: PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology 55: 182-189
Webb, J.R.; Milne, K.; Kroeger, D.R.; Nelson, B.H. 2016: PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecologic Oncology 141(2): 293-302
Richmond, O.; Cecere, T.E.; Erdogan, E.; Meng, X.J.; Piñeyro, P.; Subramaniam, S.; Todd, S.M.; LeRoith, T. 2015: PD-L1 expression is increased in monocyte derived dendritic cells in response to porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus infections. Veterinary Immunology and Immunopathology 168(1-2): 24-29
Ruf, M.; Moch, H.; Schraml, P. 2016: PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. International Journal of Cancer 139(2): 396-403
Chen, S.; Wang, R.-X.; Liu, Y.; Yang, W.-T.; Shao, Z.-M. 2017: PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. International Journal of Cancer 140(6): 1384-1395
Miyoshi, H.; Kiyasu, J.; Kato, T.; Yoshida, N.; Shimono, J.; Yokoyama, S.; Taniguchi, H.; Sasaki, Y.; Kurita, D.; Kawamoto, K.; Kato, K.; Imaizumi, Y.; Seto, M.; Ohshima, K. 2016: PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 128(10): 1374-1381
Adam, J.; Planchard, D.; Marabelle, A.él.; Soria, J.-C.; Scoazec, J.-Y.; Lantuéjoul, S. 2016: PD-L1 expression: An emerging biomarker in non-small cell lung cancer. Annales de Pathologie 36(1): 94-102
Cheng, S.; Zheng, J.; Zhu, J.; Xie, C.; Zhang, X.; Han, X.; Song, B.; Ma, Y.; Liu, J. 2015: PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer. International Journal of Biological Markers 30(4): E364-E368
Smit, E.F.; van den Heuvel, M.M. 2016: PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. Lancet 387(10030): 1795-1796
Wang, Y.; Wang, H.; Zhao, Q.; Xia, Y.; Hu, X.; Guo, J. 2015: PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Medical Oncology 32(8): 212
Cha, E.; Wallin, J.; Kowanetz, M. 2015: PD-L1 inhibition with MPDL3280A for solid tumors. Seminars in Oncology 42(3): 484-487
Böger, C.; Behrens, H.-M.; Mathiak, M.; Krüger, S.; Kalthoff, H.; Röcken, C. 2016: PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 7(17): 24269-24283
Bishop, J.L.; Sio, A.; Angeles, A.; Roberts, M.E.; Azad, A.A.; Chi, K.N.; Zoubeidi, A. 2015: PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6(1): 234-242
Chang, Y.-L.; Yang, C.-Y.; Lin, M.-W.; Wu, C.-T.; Yang, P.-C. 2015: PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: a potential rationale for immunotherapy. Lung Cancer 88(3): 254-259
Fang, W.; Hong, S.; Chen, N.; He, X.; Zhan, J.; Qin, T.; Zhou, T.; Hu, Z.; Ma, Y.; Zhao, Y.; Tian, Y.; Yang, Y.; Xue, C.; Tang, Y.; Huang, Y.; Zhao, H.; Zhang, L. 2015: PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget 6(32): 33019-33032
Bi, X.-W.; Wang, H.; Zhang, W.-W.; Wang, J.-H.; Liu, W.-J.; Xia, Z.-J.; Huang, H.-Q.; Jiang, W.-Q.; Zhang, Y.-J.; Wang, L. 2016: PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Journal of Hematology and Oncology 9(1): 109
Hecht, M.; Büttner-Herold, M.; Erlenbach-Wünsch, K.; Haderlein, M.; Croner, R.; Grützmann, R.; Hartmann, A.; Fietkau, R.; Distel, L.V. 2016: PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. European Journal of Cancer 65: 52-60
Guan, H.; Lan, Y.; Wan, Y.; Wang, Q.; Wang, C.; Xu, L.; Chen, Y.; Liu, W.; Zhang, X.; Li, Y.; Gu, Y.; Wang, Z.; Xie, F. 2016: PD-L1 mediated the differentiation of tumor-infiltrating CD19 + B lymphocytes and T cells in Invasive breast cancer. Oncoimmunology 5(2): E1075112
Meniawy, T.M.; Lake, R.A.; McDonnell, A.M.; Millward, M.J.; Nowak, A.K. 2016: PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer 93: 9-16
Zhou, Z.-J.; Zhan, P.; Song, Y. 2015: PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research 4(2): 203-208
Munir Ahmad, S.; Martinenaite, E.; Hansen, M.; Junker, N.; Borch, T.Holz.; Met, Özcan.; Donia, M.; Svane, I.Marie.; Andersen, M.Hald. 2016: PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 5(8): E1202391
Gevensleben, H.; Holmes, E.E.; Goltz, D.; Dietrich, J.ör.; Sailer, V.; Ellinger, J.ör.; Dietrich, D.; Kristiansen, G. 2016: PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget 7(48): 79943-79955
Ali, H.R.; Glont, S.-E.; Blows, F.M.; Provenzano, E.; Dawson, S.-J.; Liu, B.; Hiller, L.; Dunn, J.; Poole, C.J.; Bowden, S.; Earl, H.M.; Pharoah, P.D.P.; Caldas, C. 2015: PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology: Official Journal of the European Society for Medical Oncology 26(7): 1488-1493
Cree, I.A.; Booton, R.; Cane, P.; Gosney, J.; Ibrahim, M.; Kerr, K.; Lal, R.; Lewanski, C.; Navani, N.; Nicholson, A.G.; Nicolson, M.; Summers, Y. 2016: PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 69(2): 177-186
Marchevsky, A.M.; Walts, A.E. 2017: PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. Human Pathology 60: 16-23
Luo, Q.; Huang, Z.; Ye, J.; Deng, Y.; Fang, L.; Li, X.; Guo, Y.; Jiang, H.; Ju, B.; Huang, Q.; Li, J. 2016: PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. Arthritis Research and Therapy 18: 47
Ahmad, S.M.; Borch, T.H.; Hansen, M.; Andersen, M.H. 2016: PD-L1-specific T cells. Cancer Immunology Immunotherapy: Cii 65(7): 797-804
Crompton, P.D.; Pierce, S.K. 2016: PD-L2 Elbows out PD-L1 to Rescue T Cell Immunity to Malaria. Immunity 45(2): 231-233
Stempin, C.C.; Motrán, C.C.; Aoki, M.ía.P.; Falcón, C.R.; Cerbán, F.M.; Cervi, L. 2016: PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepatica infection. Oncotarget 7(47): 77721-77731
Ahmed, I.S.; El-Hosary, R.; Shalaby, S.; Abd-Rabo, M.M.; Elkhateeb, D.G.; Nour, S. 2016: PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles. International Journal of Pharmaceutics 504(1-2): 70-79
Dumont, B.; Forest, F.; Dal Col, P.; Karpathiou, G.; Stephan, J.-L.; Vassal, F.ço.; Péoc'h, M. 2017: PD1 and PD-L1 in ependymoma might not be therapeutic targets. Clinical Neuropathology 36(2): 90-92
Abedin, S.; Platanias, L.C. 2017: PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. Leukemia and Lymphoma 58(4): 764-765
Guo, Y.; Feng, X.; Jiang, Y.; Shi, X.; Xing, X.; Liu, X.; Li, N.; Fadeel, B.; Zheng, C. 2016: PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. Oncotarget 7(30): 48360-48374
Pike, R.; Thomas, N.; Workman, S.; Ambrose, L.; Guzman, D.; Sivakumaran, S.; Johnson, M.; Thorburn, D.; Harber, M.; Chain, B.; Stauss, H.J. 2016: PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. Frontiers in Immunology 7: 126
Gralla, R.J.; Spigel, D.; Bennett, B.; Taylor, F.; Penrod, J.R.; Derosa, M.; Dastani, H.; Orsini, L.; Mathias, C.; Reck, M. 2016: PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057. Journal of Thoracic Oncology 11(10s): S171
Aguiar, P.; Lopes, G.; Santoro, I.; Tadokoro, H.; Barreto, C.; De Mello, R. 2016: PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. Journal of Thoracic Oncology 11(10s): S171-S172
Lopes, G.; Prado, E. 2016: PD1.03 (also presented as P1.12): EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater Public Health Awareness of Molecular Testing. Journal of Thoracic Oncology 11(10s): S172-S173
De La Iglesia, P.X.; Dalurzo, L.; Labanca, M.J. 2016: PD1.04 (also presented as P2.19): Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation With Fish Analysis. Journal of Thoracic Oncology 11(10s): S173
Gitlitz, B.; Addario, B.; Sable-Hunt, A.; Novello, S.; Vavala, T.; Chen, R.; Bittoni, M.; Park, S.Lani.; Jennings, M.; Oxnard, G. 2016: PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. Journal of Thoracic Oncology 11(10s): S174
Herbst, R.S.; Baas, P.; Perez-Gracia, J.L.; Felip, E.; Kim, D-Wan.; Han, J-Youn.; Molina, J.; Kim, J-Hang.; Arvis, C.Dubos.; Ahn, M-Ju.; Majem, M.; Fidler, M.Jo.; Surmont, V.; De Castro, G.; Garrido, M.; Shentu, Y.; Dolled-Filhart, M.; Im, E.; Garon, E.B. 2016: PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal of Thoracic Oncology 11(10s): S174-S175
Nagasaka, M.; Zaki, M.; Kim, H.; Raza, S.Naweed.; Yoo, G.; Lin, H-Sheng.; Sukari, A. 2016: PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. Journal for ImmunoTherapy of Cancer 4: 83
Własiuk, P.; Putowski, M.; Giannopoulos, K. 2016: PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers. Postepy Higieny i Medycyny Doswiadczalnej 70: 1044-1058
Luo, T.; Yue, R.; Hu, H.; Zhou, Z.; Yiu, K.Hang.; Zhang, S.; Xu, L.; Li, K.; Yu, Z. 2015: PD150606 protects against ischemia/reperfusion injury by preventing μ-calpain-induced mitochondrial apoptosis. Archives of Biochemistry and Biophysics 586: 1-9
Anreddy, N.; Patel, A.; Sodani, K.; Kathawala, R.J.; Chen, E.P.; Wurpel, J.N.D.; Chen, Z.-S. 2014: PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharmaceutica Sinica. B 4(3): 202-207
Raez, L.E.; Santos, E.S.; Mourafetis, J.; Kim, A.Y.; Hunis, B.; Sareli, C.; Castillero, L.; Velis, E. 2016: PD2.01 (also presented as P1.13): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar. Journal of Thoracic Oncology 11(10s): S176
Leal, T.; Wakelee, H.; Infante, J.; Blumenschein, G.; Reckamp, K.; Carter, C.; Waqar, S.; Gockerman, J.; Lovly, C.; Dukart, G.; Harrow, K.; Liang, C.; Gibbons, J.; Horn, L. 2016: PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology 11(10s): S176-S177
Rojas, L.; Cardona, Aés.F.; Arrieta, O.; Wills, B.; Corrales-Rodriguez, L.; Carranza, Hán.; Vargas, C.; Otero, J.; Martin, C.; Cuello, M.; Ortiz, C.; Rosell, R. 2016: PD2.04 (also presented as P1.42): PEM/CBP/BEV Followed by Maintenance PEM/BEV in Hispanic Patients With NSCLC: Outcomes According to TS, ERCC1 and VEGF. Journal of Thoracic Oncology 11(10s): S177-S178
Amendola, B.; Wolf, A.; Coy, S. 2016: PD2.05 (also presented as P1.43): Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update. Journal of Thoracic Oncology 11(10s): S178
Lopes, G. 2016: PD2.06 (also presented as P1.41): Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology 11(10s): S178-S179
Rojewska, E.; Popiolek-Barczyk, K.; Kolosowska, N.; Piotrowska, A.; Zychowska, M.; Makuch, W.; Przewlocka, B.; Mika, J. 2015: PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy. Plos one 10(10): E0138583
Nguyen Thi, P.A.; Chen, M.-H.; Li, N.; Zhuo, X.-J.; Xie, L. 2016: PD98059 Protects Brain against Cells Death Resulting from ROS/ERK Activation in a Cardiac Arrest Rat Model. Oxidative Medicine and Cellular Longevity 2016: 3723762
Yamaguchi, K.; Takahashi, S. 2016: Epidemiological trend of prostate cancer in Japan. Nihon Rinsho. Japanese Journal of Clinical Medicine 74 Suppl 3(5): 27-33
Buhlmann, B.; Dole, M.; Kaufmann, Z. 2016: PDA Points to Consider: Fundamental Concepts in Data Integrity. PDA Journal of Pharmaceutical Science and Technology 70(5): 482-488
Oveissi, F.; Sitter, T.; Fatehi, P. 2016: PDADMAC as a flocculant for lignosulfonate of NSSC pulping process. Biotechnology Progress 32(3): 686-691
McNerney, T.; Thomas, A.; Senczuk, A.; Petty, K.; Zhao, X.; Piper, R.; Carvalho, J.; Hammond, M.; Sawant, S.; Bussiere, J. 2015: PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies. Mabs 7(2): 413-428
Jin, X.; Awale, M.; Zasso, M.ël.; Kostro, D.; Patiny, L.; Reymond, J.-L. 2015: PDB-Explorer: a web-based interactive map of the protein data bank in shape space. Bmc Bioinformatics 16: 339
Mavridis, L.; Janes, R.W. 2017: PDB2CD: a web-based application for the generation of circular dichroism spectra from protein atomic coordinates. Bioinformatics 33(1): 56-63
Niknam, N.; Khakzad, H.; Arab, S.S.; Naderi-Manesh, H. 2016: PDB2Graph: a toolbox for identifying critical amino acids map in proteins based on graph theory. Computers in Biology and Medicine 72: 151-159
Hrabe, T.; Li, Z.; Sedova, M.; Rotkiewicz, P.; Jaroszewski, L.; Godzik, A. 2016: PDBFlex: exploring flexibility in protein structures. Nucleic Acids Research 44(D1): D423-D428
Velankar, S.; van Ginkel, G.; Alhroub, Y.; Battle, G.M.; Berrisford, J.M.; Conroy, M.J.; Dana, J.M.; Gore, S.P.; Gutmanas, A.; Haslam, P.; Hendrickx, P.M.S.; Lagerstedt, I.; Mir, S.; Fernandez Montecelo, M.A.; Mukhopadhyay, A.; Oldfield, T.J.; Patwardhan, A.; Sanz-García, E.; Sen, S.; Slowley, R.A.; Wainwright, M.E.; Deshpande, M.S.; Iudin, A.; Sahni, G.; Salavert Torres, J.; Hirshberg, M.; Mak, L.; Nadzirin, N.; Armstrong, D.R.; Clark, A.R.; Smart, O.S.; Korir, P.K.; Kleywegt, G.J. 2016: PDBe: improved accessibility of macromolecular structure data from PDB and EMDB. Nucleic Acids Research 44(D1): D385-D395
Gonçalves, W.R.S.; Gonçalves-Almeida, V.M.; Arruda, A.L.; Meira, W.; da Silveira, C.H.; Pires, D.E.V.; de Melo-Minardi, R.C. 2015: PDBest: a user-friendly platform for manipulating and enhancing protein structures. Bioinformatics 31(17): 2894-2896
Nagarajan, R.; Archana, A.; Thangakani, A.M.; Jemimah, S.; Velmurugan, D.; Gromiha, M.M. 2016: PDBparam: Online Resource for Computing Structural Parameters of Proteins. Bioinformatics and Biology Insights 10: 73-80
Wang, L.; Qu, X.; Yu, X. 2015: PDCA Applied in Special Rectification of Medical Instrument Clinical Trial. Zhongguo Yi Liao Qi Xie Za Zhi 39(4): 288-291
Dmitrieva-Zdorova, E.V.; Gabaeva, M.V.; Seregin, Y.A.; Bodoev, N.V.; Voronko, O.E. 2017: PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients. Journal of Asthma: Official Journal of the Association for the Care of Asthma 54(1): 46-52
Mahmoudi, M.; Rezaiemanesh, A.; Salmaninejad, A.; Harsini, S.; Poursani, S.; Bahrami, T.; Tahghighi, F.; Ziaee, V.; Rezaei, N. 2015: PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus. Autoimmunity 48(7): 488-493
Stamatovic, S.M.; Sladojevic, N.; Keep, R.F.; Andjelkovic, A.V. 2015: PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk. Acta Neuropathologica 130(5): 731-750
Wang, W.; Song, X.-W.; Bu, X.-M.; Zhang, N.; Zhao, C.-H. 2016: PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors. Cellular Oncology 39(2): 129-137
Wang, L.; Zhao, M.; Guo, C.; Wang, G.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Chen, Y.H.; Zhang, L. 2016: PDCD4 Deficiency Aggravated Colitis and Colitis-associated Colorectal Cancer Via Promoting IL-6/STAT3 Pathway in Mice. Inflammatory Bowel Diseases 22(5): 1107-1118
Jo, S.-H.; Kim, D.E.; Clocchiatti, A.; Dotto, G.P. 2016: PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation. Oncotarget 7(37): 58717-58727
Zhuge, C.; Sun, X.; Chen, Y.; Lei, J. 2016: PDCD5 functions as a regulator of p53 dynamics in the DNA damage response. Journal of Theoretical Biology 388: 1-10
Zhang, S.; Li, G.; Fu, X.; Qi, Y.; Li, M.; Lu, G.; Hu, J.; Wang, N.; Chen, Y.; Bai, Y.; Cui, M. 2015: PDCD5 protects against cardiac remodeling by regulating autophagy and apoptosis. Biochemical and Biophysical Research Communications 461(2): 321-328
Fan, G.-L.; Yao, Y.; Yao, L.; Li, Y. 2015: PDCD5 transfection increases cisplatin sensitivity and decreases invasion in hepatic cancer cells. Oncology Letters 9(1): 411-417
Lee, W.-J.; Wu, S.-L.; Li, J.-Y.; Chen, C.-C.; Lin, J.-J.; Peng, G.-S.; Lin, T.-K.; Wang, S.-J.; Chen, R.-S.; Yang, Y.-H.; Tsai, C.-H.; Hsu, J.-L.; Liao, Y.-C.; Chen, S.-P.; Fuh, J.-L. 2016: PDD-5S: a useful screening tool for Parkinson's disease dementia. Parkinsonism and Related Disorders 25: 85-90
Kim, K.-H.; Kim, H.-K.; Hwang, I.-C.; Cho, H.-J.; Je, N.; Kwon, O.-M.; Choi, S.-J.; Lee, S.-P.; Kim, Y.-J.; Sohn, D.-W. 2015: PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial. American Heart Journal 169(6): 813-822.E3
Hodneland, E.; Tai, X.-C.; Kalisch, H. 2016: PDE Based Algorithms for Smooth Watersheds. IEEE Transactions on Medical Imaging 35(4): 957-966
Heckman, P.R.A.; Blokland, A.; Ramaekers, J.; Prickaerts, J. 2015: PDE and cognitive processing: beyond the memory domain. Neurobiology of Learning and Memory 119: 108-122
Vanhoutte, P.M. 2014: PDE and sGC hand in hand to see the light. Proceedings of the National Academy of Sciences of the United States of America 111(50): 17704-17705
Aherrahrou, N.; Tairi, H. 2015: PDE based scheme for multi-modal medical image watermarking. Biomedical Engineering Online 14: 108
Chamakuri, N.; Kunisch, K.; Plank, G. 2016: PDE constrained optimization of electrical defibrillation in a 3D ventricular slice geometry. International Journal for Numerical Methods in Biomedical Engineering 32(4): E02742
Choi, C.H.; Schoenfeld, B.P.; Weisz, E.D.; Bell, A.J.; Chambers, D.B.; Hinchey, J.; Choi, R.J.; Hinchey, P.; Kollaros, M.; Gertner, M.J.; Ferrick, N.J.; Terlizzi, A.M.; Yohn, N.; Koenigsberg, E.; Liebelt, D.A.; Zukin, R.S.; Woo, N.H.; Tranfaglia, M.R.; Louneva, N.; Arnold, S.E.; Siegel, S.J.; Bolduc, F.V.; McDonald, T.V.; Jongens, T.A.; McBride, S.M.J. 2015: PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 35(1): 396-408
Brousil, P.; Shabbir, M.; Zacharakis, E.; Sahai, A. 2015: PDE-5 Inhibitors for BPH-Associated LUTS. Current Drug Targets 16(11): 1180-1186
Labairu-Huerta, L.; Padilla-Fernández, B.ár.; Arrondo-Arrondo, J.é L.; Valverde-Martínez, L.S.án.; Martín-Rodríguez, A.ín.; Silva-Abuín, J.M.; García-Cenador, M.ía.B.ña.; Mirón-Canelo, J.é A.; Lorenzo-Gómez, M.ía.F. 2015: PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction. Archivio Italiano di Urologia Andrologia: Organo Ufficiale di Societa Italiana di Ecografia Urologica e Nefrologica 87(3): 204-209
Friedmann, E. 2015: PDE/ODE modeling and simulation to determine the role of diffusion in long-term and -range cellular signaling. Bmc Biophysics 8: 10
Megens, A.A.H.P.; Hendrickx, H.M.R.; Mahieu, M.M.A.; Wellens, A.L.Y.; de Boer, P.; Vanhoof, G. 2014: PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways. Pharmacology Research and Perspectives 2(4): E00057
Hegde, S.; Ji, H.; Oliver, D.; Patel, N.S.; Poupore, N.; Shtutman, M.; Kelly, M.P. 2016: PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain. Neuroscience 335: 151-169
Knight, W.E.; Chen, S.; Zhang, Y.; Oikawa, M.; Wu, M.; Zhou, Q.; Miller, C.L.; Cai, Y.; Mickelsen, D.M.; Moravec, C.; Small, E.M.; Abe, J.; Yan, C. 2016: PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction. Proceedings of the National Academy of Sciences of the United States of America 113(45): E7116-E7125
Satoh, K.; Kikuchi, N.; Kurosawa, R.; Shimokawa, H. 2015: PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circulation Research 116(7): 1098-1100
Soler, F.; Fernández-Belda, F.; Pérez-Schindler, J.ín.; Handschin, C.; Fuente, T.; Hernandez-Cascales, J.ús. 2015: PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects. Experimental Biology and Medicine 240(9): 1205-1213
Julià, A.; Rodríguez, J.ús.; Fernández-Sueiro, J.é L.; Gratacós, J.; Queiró, R.én.; Montilla, C.; Torre-Alonso, J.C.; Pérez-Venegas, J.é J.; Manrique-Arija, S.; Muñoz-Fernández, S.; González, C.; Roig, D.; Zarco, P.; Erra, A.; Castañeda, S.; García, A.; Salvador, G.; Díaz-Torne, C.és.; Blanco, R.; Domínguez, A.W.; Mosquera, J.é A.; Vela, P.; Tornero, J.ús.; Sánchez-Fernández, S.ón.; Corominas, H.éc.; Ramírez, J.; Avila, G.; Alonso, A.; Tortosa, R.ül.; López-Lasanta, M.ía.; Cañete, J.D.; Marsal, S. 2014: PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics 15(14): 1763-1769
Chamseddine, A.N.; Cabrero, M.; Wei, Y.; Ganan-Gomez, I.; Colla, S.; Takahashi, K.; Yang, H.; Bohannan, Z.S.; Garcia-Manero, G. 2016: PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients with Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 16 Suppl: S67-S73
Koga, H.; Recke, A.; Vidarsson, G.; Pas, H.H.; Jonkman, M.F.; Hashimoto, T.; Kasprick, A.; Ghorbanalipoor, S.; Tenor, H.; Zillikens, D.; Ludwig, R.J. 2016: PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology 136(11): 2211-2220
Joe, I-Seul.; Cho, G-Won. 2016: PDE4 Inhibition by Rolipram Promotes Neuronal Differentiation in Human Bone Marrow Mesenchymal Stem Cells. Cellular Reprogramming 18(4): 224-229
Lehrke, M.; Kahles, F.; Makowska, A.; Tilstam, P.V.; Diebold, S.; Marx, J.; Stöhr, R.; Hess, K.; Endorf, E.B.; Bruemmer, D.; Marx, N.; Findeisen, H.M. 2015: PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. Journal of Molecular and Cellular Cardiology 81: 23-33
Pearse, D.D.; Hughes, Z.ë A. 2016: PDE4B as a microglia target to reduce neuroinflammation. Glia 64(10): 1698-1709
Mika, D.; Conti, M. 2016: PDE4D phosphorylation: a coincidence detector integrating multiple signaling pathways. Cellular Signalling 28(7): 719-724
Teich, A.F.; Sakurai, M.; Patel, M.; Holman, C.; Saeed, F.; Fiorito, J.; Arancio, O. 2016: PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. Journal of Alzheimer's Disease: Jad 52(1): 295-302
Fiore, D.; Gianfrilli, D.; Giannetta, E.; Galea, N.; Panio, G.; di Dato, C.; Pofi, R.; Pozza, C.; Sbardella, E.; Carbone, I.; Naro, F.; Lenzi, A.; Venneri, M.A.; Isidori, A.M. 2016: PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence from the CECSID Trial. Journal of Clinical Endocrinology and Metabolism 101(4): 1525-1534
Sponziello, M.; Verrienti, A.; Rosignolo, F.; De Rose, R.F.; Pecce, V.; Maggisano, V.; Durante, C.; Bulotta, S.; Damante, G.; Giacomelli, L.; Di Gioia, C.R.T.; Filetti, S.; Russo, D.; Celano, M. 2015: PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 50(2): 434-441
Akkerman, S.; Blokland, A.; van Goethem, N.P.; Cremers, P.; Shaffer, C.L.; Osgood, S.M.; Steinbusch, H.W.M.; Prickaerts, J. 2015: PDE5 inhibition improves acquisition processes after learning via a central mechanism. Neuropharmacology 97: 233-239
Das, A.; Durrant, D.; Salloum, F.N.; Xi, L.; Kukreja, R.C. 2015: PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacology and Therapeutics 147: 12-21
Booth, L.; Roberts, J.L.; Poklepovic, A.; Gordon, S.; Dent, P. 2017: PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8(1): 1449-1468
Li, N.; Yuan, Y.; Li, S.; Zeng, C.; Yu, W.; Shen, M.; Zhang, R.; Li, C.; Zhang, Y.; Wang, H. 2016: PDE5 inhibitors protect against post-infarction heart failure. Frontiers in Bioscience 21(6): 1194-1210
Marchal-Escalona, C.; Herrera-Imbroda, B.; Clemente-Postigo, M.; Alcaide-Torres, J.; Quiñonero, A.; Marchal, M.; Queipo-Ortuño, M.ía.I.; Aragón, I.M.ía.; Martín-Morales, A.; Lara, M.ía.F.; Cardona, F. 2016: PDE5A Polymorphisms Influence on Sildenafil Treatment Success. Journal of Sexual Medicine 13(7): 1104-1110
Lee, J.-J.; Seo, S. 2015: PDE6D binds to the C-terminus of RPGR in a prenylation-dependent manner. Embo Reports 16(12): 1581-1582
Mestre, L.; Redondo, M.; Carrillo-Salinas, F.J.; Morales-García, J.A.; Alonso-Gil, S.; Pérez-Castillo, A.; Gil, C.; Martínez, A.; Guaza, C. 2015: PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology 172(17): 4277-4290
Porcelli, S.; Balzarro, B.; Lee, S.-J.; Han, C.; Patkar, A.A.; Pae, C.-U.; Serretti, A. 2016: PDE7B, NMBR and EPM2A Variants and Schizophrenia: a Case-Control and Pharmacogenetics Study. Neuropsychobiology 73(3): 160-168
Xia, Y.; Wang, F.; Qian, M.; Qin, Z.; Deng, M. 2015: PDEGEM: Modeling non-uniform read distribution in RNA-Seq data. Bmc Medical Genomics 8(Suppl 2): S14
Jansen, C.; Kooistra, A.J.; Kanev, G.K.; Leurs, R.; de Esch, I.J.P.; de Graaf, C. 2016: PDEStrIAn: a Phosphodiesterase Structure and Ligand Interaction Annotated Database as a Tool for Structure-Based Drug Design. Journal of Medicinal Chemistry 59(15): 7029-7065
Mezan, S.; Feuz, J.Daniel.; Deplancke, B.; Kadener, S. 2016: PDF Signaling Is an Integral Part of the Drosophila Circadian Molecular Oscillator. Cell Reports 17(3): 708-719
Bui, D.Duc.An.; Del Fiol, G.; Jonnalagadda, S. 2016: PDF text classification to leverage information extraction from publication reports. Journal of Biomedical Informatics 61: 141-148
Gong, J.; Rutland, C.J. 2015: PDF-based heterogeneous multiscale filtration model. Environmental Science and Technology 49(8): 4963-4970
Rahme, G.J.; Zhang, Z.; Young, A.L.; Cheng, C.; Bivona, E.J.; Fiering, S.N.; Hitoshi, Y.; Israel, M.A. 2016: PDGF Engages an E2F-USP1 Signaling Pathway to Support ID2-Mediated Survival of Proneural Glioma Cells. Cancer Research 76(10): 2964-2976
Chang, F-Pei.; Cho, C.Hsin-Hua.; Shen, C-Rui.; Chien, C-Yun.; Ting, L-Wen.; Lee, H-Shu.; Shen, C-Ning. 2016: PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3. Cell Transplantation 25(10): 1893-1909
Peyre, M.; Salaud, C.él.; Clermont-Taranchon, E.; Niwa-Kawakita, M.; Goutagny, S.; Mawrin, C.; Giovannini, M.; Kalamarides, M. 2015: PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget 6(32): 32713-32722
Sysol, J.R.; Natarajan, V.; Machado, R.F. 2016: PDGF induces SphK1 expression via Egr-1 to promote pulmonary artery smooth muscle cell proliferation. American Journal of Physiology. Cell Physiology 310(11): C983-C992
Davies, O.G.; Grover, L.M.; Lewis, M.P.; Liu, Y. 2018: PDGF is a potent initiator of bone formation in a tissue engineered model of pathological ossification. Journal of Tissue Engineering and Regenerative Medicine 12(1): E355-E367
Rezza, A.él.; Sennett, R.; Tanguy, M.; Clavel, C.; Rendl, M. 2015: PDGF signalling in the dermis and in dermal condensates is dispensable for hair follicle induction and formation. Experimental Dermatology 24(6): 468-470
Agrawal, S.; Ganguly, S.; Hajian, P.; Cao, J.-N.; Agrawal, A. 2015: PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget 6(30): 28621-28632
Gallini, R.; Lindblom, P.; Bondjers, C.; Betsholtz, C.; Andrae, J. 2016: PDGF-A and PDGF-B induces cardiac fibrosis in transgenic mice. Experimental Cell Research 349(2): 282-290
Watts, T.L.; Cui, R.; Szaniszlo, P.; Resto, V.A.; Powell, D.W.; Pinchuk, I.V. 2016: PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment. Journal of Translational Medicine 14(1): 337
Li, A.; Xia, X.; Yeh, J.; Kua, H.; Liu, H.; Mishina, Y.; Hao, A.; Li, B. 2014: PDGF-AA promotes osteogenic differentiation and migration of mesenchymal stem cell by down-regulating PDGFRα and derepressing BMP-Smad1/5/8 signaling. Plos one 9(12): E113785
Mifude, C.; Kaseda, K. 2015: PDGF-AA-induced filamentous mitochondria benefit dermal papilla cells in cellular migration. International Journal of Cosmetic Science 37(3): 266-271
Chandrakanthan, V.; Yeola, A.; Kwan, J.C.; Oliver, R.A.; Qiao, Q.; Kang, Y.C.; Zarzour, P.; Beck, D.; Boelen, L.; Unnikrishnan, A.; Villanueva, J.E.; Nunez, A.C.; Knezevic, K.; Palu, C.; Nasrallah, R.; Carnell, M.; Macmillan, A.; Whan, R.; Yu, Y.; Hardy, P.; Grey, S.T.; Gladbach, A.; Delerue, F.; Ittner, L.; Mobbs, R.; Walkley, C.R.; Purton, L.E.; Ward, R.L.; Wong, J.W.H.; Hesson, L.B.; Walsh, W.; Pimanda, J.E. 2016: PDGF-AB and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells. Proceedings of the National Academy of Sciences of the United States of America 113(16): E2306-E2315
Liu, G.-S. 2016: PDGF-B/PDGFR-β Signaling: a new Potential Therapeutic Target of Atrial Fibrillation. Cardiology 134(1): 19-21
Paglia, D.N.; Singh, H.; Karukonda, T.; Drissi, H.; Moss, I.L. 2016: PDGF-BB Delays Degeneration of the Intervertebral Discs in a Rabbit Preclinical Model. Spine 41(8): E449-E458
Lee, J-Young.; Yun, M.; Paik, J-Sun.; Lee, S-Beom.; Yang, S-Woo. 2016: PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. Investigative Ophthalmology and Visual Science 57(3): 908-913
Cho, J.S.; Fang, T.C.; Reynolds, T.L.; Sofia, D.J.; Hamann, S.; Burkly, L.C. 2016: PDGF-BB Promotes Type i IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis. Plos one 11(9): E0162758
Sun, Q.; Liu, L.; Mandal, J.; Molino, A.; Stolz, D.; Tamm, M.; Lu, S.; Roth, M. 2016: PDGF-BB induces PRMT1 expression through ERK1/2 dependent STAT1 activation and regulates remodeling in primary human lung fibroblasts. Cellular Signalling 28(4): 307-315
Cabezas, R.; Avila, M.F.; González, J.; El-Bachá, R.S.; Barreto, G.E. 2015: PDGF-BB protects mitochondria from rotenone in T98G cells. Neurotoxicity Research 27(4): 355-367
Zheng, L.; Zhao, C.; Du, Y.; Lin, X.; Jiang, Y.; Lee, C.; Tian, G.; Mi, J.; Li, X.; Chen, Q.; Ye, Z.; Huang, L.; Wang, S.; Ren, X.; Xing, L.; Chen, W.; Huang, D.; Gao, Z.; Zhang, S.; Lu, W.; Tang, Z.; Wang, B.; Ju, R.; Li, X. 2016: PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently. Oncotarget 7(47): 77902-77915
Alehagen, U.; Olsen, R.S.; Länne, T.; Matussek, A.; Wågsäter, D. 2016: PDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men. Bmc Medical Genetics 17(1): 62
Qin, Z.; Feng, J.; Liu, Y.; Deng, L.-L.; Lu, C. 2016: PDGF-D promotes dermal fibroblast invasion in 3-dimensional extracellular matrix via Snail-mediated MT1-MMP upregulation. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 37(1): 591-599
Borkham-Kamphorst, E.; Meurer, S.K.; Van de Leur, E.; Haas, U.; Tihaa, L.; Weiskirchen, R. 2015: PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β. Cellular Signalling 27(7): 1305-1314
Zhang, H.; Sun, J.-D.; Yan, L.-J.; Zhao, X.-P. 2016: PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway. Biochemical and Biophysical Research Communications 478(2): 845-851
Takahashi, J.; Orcholski, M.; Yuan, K.; de Jesus Perez, V. 2016: PDGF-dependent β-catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension. Febs Letters 590(1): 101-109
Kajimura, S. 2016: PDGFA Makes Thin Skin Thicker: Molecular Regulation of Adipose Progenitor Maintenance. Cell Stem Cell 19(6): 675-676
Augello, C.; Gianelli, U.; Falcone, R.; Tabano, S.; Savi, F.; Bonaparte, E.; Ciboddo, M.; Paganini, L.; Parafioriti, A.; Ricca, D.; Lonati, S.; Cattaneo, D.; Fracchiolla, N.S.; Iurlo, A.; Cortelezzi, A.; Bosari, S.; Miozzo, M.; Sirchia, S.M. 2015: PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis. Leukemia Research 39(2): 236-241
Bruzelius, M.; Iglesias, M.J.; Hong, M.-G.; Sanchez-Rivera, L.; Gyorgy, B.; Souto, J.C.; Frånberg, M.; Fredolini, C.; Strawbridge, R.J.; Holmström, M.; Hamsten, A.; Uhlén, M.; Silveira, A.; Soria, J.M.; Smadja, D.M.; Butler, L.M.; Schwenk, J.M.; Morange, P.-E.; Trégouët, D.-A.; Odeberg, J. 2016: PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood 128(23): E59-E66
Chen, W.; Baylink, D.J.; Brier-Jones, J.; Neises, A.; Kiroyan, J.B.; Rundle, C.H.; Lau, K.-H.W.; Zhang, X.-B. 2015: PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proceedings of the National Academy of Sciences of the United States of America 112(29): E3893-E3900
Hall, A.P.; Ashton, S.; Horner, J.; Wilson, Z.; Reens, J.; Richmond, G.H.P.; Barry, S.T.; Wedge, S.R. 2016: PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary. Toxicologic Pathology 44(1): 98-111
Huang, C.H.; Williamson, S.K.; VanVeldhuizen, P.J.; Hsueh, C.T.; Allen, A.; Smith, H.; Mayo, M.; Tawfik, O.; Uypeckcuat, A.M.; Kelly, K. 2016: PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. Journal of Clinical Oncology 26(15_Suppl): 19055-19055
Matei, D.; Lai, Y-C.; Rao, J.; Emerson, R.; Donner, D. 2016: PDGFR is activated through an autocrine mechanism in ovarian cancer. Journal of Clinical Oncology 23(16_Suppl): 5073-5073
D'Arcangelo, D.; Facchiano, F.; Nassa, G.; Stancato, A.; Antonini, A.; Rossi, S.; Senatore, C.; Cordella, M.; Tabolacci, C.; Salvati, A.; Tarallo, R.; Weisz, A.; Facchiano, A.M.; Facchiano, A. 2016: PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget 7(47): 77257-77275
Goscinski, M.A.; Larsen, S.G.; Giercksky, K.-E.; Nesland, J.M.; Suo, Z. 2015: PDGFR-α and CD117 Expression Pattern in Esophageal Carcinomas. Anticancer Research 35(7): 3793-3799
Schimanski, C.; Wehler, T.; Galle, P.; Gockel, I.; Moehler, M. 2016: PDGFR-α/β expression correlates with the metastatic behavior of human colorectal cancer-A rationale for a molecular targeting strategy?. Journal of Clinical Oncology 26(15_Suppl): 22019-22019
Sato, H.; Ishii, Y.; Yamamoto, S.; Azuma, E.; Takahashi, Y.; Hamashima, T.; Umezawa, A.; Mori, H.; Kuroda, S.; Endo, S.; Sasahara, M. 2016: PDGFR-β Plays a Key Role in the Ectopic Migration of Neuroblasts in Cerebral Stroke. Stem Cells 34(3): 685-698
Lu, B. 2016: PDGFR-β expression in small cell lung cancer patients. Journal of Clinical Oncology 24(18_Suppl): 17128-17128
Baskin, Y.; Kocal, G.Calibasi.; Kucukzeybek, B.Bolat.; Akbarpour, M.; Kayacik, N.; Sagol, O.; Ellidokuz, H.; Oztop, I. 2016: PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1. Oncology Research 24(1): 41-53
Aminkeng, F. 2015: PDGFRB mutation causes autosomal-dominant Penttinen syndrome. Clinical Genetics 88(6): 531
Iussich, S.; Maniscalco, L.; Di Sciuva, A.; Iotti, B.; Morello, E.; Martano, M.; Gattino, F.; Buracco, P.; De Maria, R. 2017: PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis. Veterinary and Comparative Oncology 15(2): 462-469
Dai, K.; Yang, Z.; Xu, S-Nian.; Zhang, J-Min.; Chen, J-Ping. 2015: PDGFRα Participates in Basic Fibroblast Growth Factor-mediated Recovery of Human Bone Marrow Mesenchymal Stem Cell Proliferation and Osteogenic Differentiation after Irradiation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23(6): 1709-1715
Lopez-Campistrous, A.; Adewuyi, E.E.; Benesch, M.G.K.; Ko, Y.M.; Lai, R.; Thiesen, A.; Dewald, J.; Wang, P.; Chu, K.; Ghosh, S.; Williams, D.C.; Vos, L.J.; Brindley, D.N.; McMullen, T.P.W. 2016: PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer. Ebiomedicine 12: 86-97
Meng, F.; Speyer, C.L.; Zhang, B.; Zhao, Y.; Chen, W.; Gorski, D.H.; Miller, F.R.; Wu, G. 2015: PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. Cancer Research 75(3): 584-593
Cenciarelli, C.; Marei, H.E.; Felsani, A.; Casalbore, P.; Sica, G.; Puglisi, M.A.; Cameron, A.J.M.; Olivi, A.; Mangiola, A. 2016: PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals. Oncotarget 7(33): 53047-53063
Kikuchi, A.; Monga, S.P. 2015: PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expression 16(3): 109-127
Iwayama, T.; Steele, C.; Yao, L.; Dozmorov, M.G.; Karamichos, D.; Wren, J.D.; Olson, L.E. 2015: PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. Genes and Development 29(11): 1106-1119
Ieronimakis, N.; Hays, A.; Prasad, A.; Janebodin, K.; Duffield, J.S.; Reyes, M. 2016: PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. Journal of Pathology 240(4): 410-424
Kartha, V.K.; Stawski, L.; Han, R.; Haines, P.; Gallagher, G.; Noonan, V.; Kukuruzinska, M.; Monti, S.; Trojanowska, M. 2016: PDGFRβ Is a Novel Marker of Stromal Activation in Oral Squamous Cell Carcinomas. Plos one 11(4): E0154645
Nielsen, B.S.; Malinda, R.R.; Schmid, F.M.; Pedersen, S.F.; Christensen, S.ør.T.; Pedersen, L.B. 2015: PDGFRβ and oncogenic mutant PDGFRα D842V promote disassembly of primary cilia through a PLCγ- and AURKA-dependent mechanism. Journal of Cell Science 128(19): 3543-3549
Fantauzzo, K.A.; Soriano, P. 2016: PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα. Genes and Development 30(21): 2443-2458
Garbelli, R.; de Bock, F.; Medici, V.; Rousset, M.C.; Villani, F.; Boussadia, B.; Arango-Lievano, M.; Jeanneteau, F.; Daneman, R.; Bartolomei, F.; Marchi, N. 2015: PDGFRβ(+) cells in human and experimental neuro-vascular dysplasia and seizures. Neuroscience 306: 18-27
Cai, S.; Zhang, W.; Chen, W. 2016: PDGFRβ+/c-kit+ pulp cells are odontoblastic progenitors capable of producing dentin-like structure in vitro and in vivo. Bmc Oral Health 16(1): 113
Da Rocha-Azevedo, B.; Ho, C.-H.; Grinnell, F. 2015: PDGF‑stimulated dispersal of cell clusters and disruption of fibronectin matrix on three-dimensional collagen matrices requires matrix metalloproteinase-2. Molecular Biology of the Cell 26(6): 1098-1105
Nath, M.; Garg, B.; Sahoo, R.K.; Tuteja, N. 2015: PDH45 overexpressing transgenic tobacco and rice plants provide salinity stress tolerance via less sodium accumulation. Plant Signaling and Behavior 10(4): E992289
Nath, M.; Yadav, S.; Kumar Sahoo, R.; Passricha, N.; Tuteja, R.; Tuteja, N. 2016: PDH45 transgenic rice maintain cell viability through lower accumulation of Na(+), ROS and calcium homeostasis in roots under salinity stress. Journal of Plant Physiology 191: 1-11
Li, Y.; Li, X.; Li, X.; Zhong, Y.; Ji, Y.; Yu, D.; Zhang, M.; Wen, J-Guo.; Zhang, H.; Goscinski, M.Adam.; Nesland, J.M.; Suo, Z. 2016: PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. Oncotarget 7(33): 53837-53852
Shahani, L. 2018: Disseminated histoplasmosis mimicking relapsed chronic lymphocytic leukaemia. BMJ Case Reports
He, K.; Cunningham, C.N.; Manickam, N.; Liu, M.; Arvan, P.; Tsai, B. 2015: Pdi reductase acts on Akita mutant proinsulin to initiate retrotranslocation along the Hrd1/Sel1L-p97 axis. Molecular Biology of the Cell 26(19): 3413-3423
Zhang, X.-q.; Pan, Y.; Yu, C.-h.; Xu, C.-f.; Xu, L.; Li, Y.-m.; Chen, W.-x. 2015: PDIA3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis. Plos one 10(7): E0133882
Ramos, F.S.; Serino, L.T.R.; Carvalho, C.M.S.; Lima, R.S.; Urban, C.A.; Cavalli, I.J.; Ribeiro, E.M.S.F. 2015: PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genetics and Molecular Research: Gmr 14(2): 6960-6967
Zhuang, Z.; Zhang, L.; Wang, X.; Tao, L.; Lv, B. 2016: PDIA3 gene induces visceral hypersensitivity in rats with irritable bowel syndrome through the dendritic cell-mediated activation of T cells. Peerj 4: E2644
Gao, H.; Sun, B.; Fu, H.; Chi, X.; Wang, F.; Qi, X.; Hu, J.; Shao, S. 2016: PDIA6 promotes the proliferation of Hela cells through activating the Wnt/β-catenin signaling pathway. Oncotarget 7(33): 53289-53298
Eletto, D.; Eletto, D.; Boyle, S.; Argon, Y. 2016: PDIA6 regulates insulin secretion by selectively inhibiting the RIDD activity of IRE1. Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 30(2): 653-665
Kim, T.-W.; Ryu, H.-H.; Li, S.-Y.; Li, C.-H.; Lim, S.-H.; Jang, W.-Y.; Jung, S. 2017: PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells. Journal of Neurosurgery 126(6): 1829-1838
Wang, C.; Hu, G.; Wang, K.; Brylinski, M.; Xie, L.; Kurgan, L. 2016: PDID: database of molecular-level putative protein-drug interactions in the structural human proteome. Bioinformatics 32(4): 579-586
Wang, X.; Zhang, S.; Zheng, R.; Yue, F.; Lin, S.H.S.; Rahmeh, A.A.; Lee, E.Y.C.; Zhang, Z.; Lee, M.Y.W.T. 2016: PDIP46 (DNA polymerase δ interacting protein 46) is an activating factor for human DNA polymerase δ. Oncotarget 7(5): 6294-6313
Ribeiro, J.; Melo, F.; Schüller, A. 2015: PDIviz: analysis and visualization of protein-DNA binding interfaces. Bioinformatics 31(16): 2751-2753
Zheng, N.; Ding, X.; Sun, A.; Jahan, R. 2015: PDK1 Activity Regulates Proliferation, Invasion and Growth of Hemangiomas. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology Biochemistry and Pharmacology 36(5): 1903-1910
Münzer, P.; Walker-Allgaier, B.; Geue, S.; Geuss, E.; Hron, G.; Rath, D.; Eißler, D.; Winter, S.; Schaeffeler, E.; Meinert, M.; Schaller, M.; Greinacher, A.; Schwab, M.; Geisler, T.; Kleinschnitz, C.; Lang, F.; Gawaz, M.; Borst, O. 2016: PDK1 Determines Collagen-Dependent Platelet Ca2+ Signaling and Is Critical to Development of Ischemic Stroke in Vivo. Arteriosclerosis Thrombosis and Vascular Biology 36(8): 1507-1516
Dainichi, T.; Hayden, M.S.; Park, S-Gyoo.; Oh, H.; Seeley, J.J.; Grinberg-Bleyer, Y.; Beck, K.M.; Miyachi, Y.; Kabashima, K.; Hashimoto, T.; Ghosh, S. 2016: PDK1 Is a Regulator of Epidermal Differentiation that Activates and Organizes Asymmetric Cell Division. Cell Reports 15(8): 1615-1623
Scortegagna, M.; Lau, E.; Zhang, T.; Feng, Y.; Sereduk, C.; Yin, H.; De, S.K.; Meeth, K.; Platt, J.T.; Langdon, C.G.; Halaban, R.; Pellecchia, M.; Davies, M.A.; Brown, K.; Stern, D.F.; Bosenberg, M.; Ronai, Z'ev.A. 2015: PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Research 75(7): 1399-1412
Hossen, M.J.; Kim, S.C.; Yang, S.; Kim, H.G.; Jeong, D.; Yi, Y.-S.; Sung, N.Y.; Lee, J.-O.; Kim, J.-H.; Cho, J.Y. 2015: PDK1 disruptors and modulators: a patent review. Expert Opinion on Therapeutic Patents 25(5): 513-537
Hossen, M.Jahangir.; Cho, J.Youl.; Kim, D. 2016: PDK1 in NF-κB signaling is a target of Xanthium strumarium methanolic extract-mediated anti-inflammatory activities. Journal of Ethnopharmacology 19(0): 251-260
Lian, S.; Shao, Y.; Liu, H.; He, J.; Lu, W.; Zhang, Y.; Jiang, Y.; Zhu, J. 2015: PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer. Oncotarget 6(30): 29076-29086
Lohneis, P.; Darb-Esfahani, S.; Dietel, M.; Braicu, I.; Sehouli, J.; Arsenic, R. 2015: PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Anticancer Research 35(11): 6329-6334
Wada, M.; Horinaka, M.; Yasuda, S.; Masuzawa, M.; Sakai, T.; Katoh, N. 2015: PDK1 is a potential therapeutic target against angiosarcoma cells. Journal of Dermatological Science 78(1): 44-50
Yang, M.; Li, D.; Chang, Z.; Yang, Z.; Tian, Z.; Dong, Z. 2015: PDK1 orchestrates early NK cell development through induction of E4BP4 expression and maintenance of IL-15 responsiveness. Journal of Experimental Medicine 212(2): 253-265
Liu, T.; Yin, H. 2017: PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer. Oncology Reports 37(1): 193-200
Di Blasio, L.; Gagliardi, P.A.; Puliafito, A.; Sessa, R.; Seano, G.; Bussolino, F.; Primo, L. 2015: PDK1 regulates focal adhesion disassembly by modulating endocytosis of αvβ3 integrin. Journal of Cell Science 128(5): 863-877
Itoh, Y.; Higuchi, M.; Oishi, K.; Kishi, Y.; Okazaki, T.; Sakai, H.; Miyata, T.; Nakajima, K.; Gotoh, Y. 2016: PDK1-Akt pathway regulates radial neuronal migration and microtubules in the developing mouse neocortex. Proceedings of the National Academy of Sciences of the United States of America 113(21): E2955-E2964
Dupuy, F.; Tabariès, Sébastien.; Andrzejewski, S.; Dong, Z.; Blagih, J.; Annis, M.G.; Omeroglu, A.; Gao, D.; Leung, S.; Amir, E.; Clemons, M.; Aguilar-Mahecha, A.; Basik, M.; Vincent, E.E.; St-Pierre, J.; Jones, R.G.; Siegel, P.M. 2015: PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metabolism 22(4): 577-589
Castel, P.; Ellis, H.; Bago, R.; Toska, E.; Razavi, P.; Carmona, F.J.; Kannan, S.; Verma, C.S.; Dickler, M.; Chandarlapaty, S.; Brogi, E.; Alessi, D.R.; Baselga, J.é; Scaltriti, M. 2016: PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell 30(2): 229-242
Qi, L.; Toyoda, H.; Xu, D.-Q.; Zhou, Y.; Sakurai, N.; Amano, K.; Kihira, K.; Hori, H.; Azuma, E.; Komada, Y. 2015: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell International 15: 91
Fang, R.; Cui, Q.; Sun, J.; Duan, X.; Ma, X.; Wang, W.; Cheng, B.; Liu, Y.; Hou, Y.; Bai, G. 2015: PDK1/Akt/PDE4D axis identified as a target for asthma remedy synergistic with β2 AR agonists by a natural agent arctigenin. Allergy 70(12): 1622-1632
Gagliardi, P.A.; di Blasio, L.; Primo, L. 2015: PDK1: a signaling hub for cell migration and tumor invasion. Biochimica et Biophysica Acta 1856(2): 178-188
Ren, Y.C.; Jin, T.B.; Sun, X.D.; Geng, T.T.; Zhang, M.X.; Wang, L.; Feng, T.; Kang, L.L.; Chen, C. 2016: PDK2 and ABCG2 genes polymorphisms are correlated with blood glucose levels and uric acid in Tibetan gout patients. Genetics and Molecular Research: Gmr 15(1)
Gang, H.; Dhingra, R.; Lin, J.; Hai, Y.; Aviv, Y.; Margulets, V.; Hamedani, M.; Thanasupawat, T.; Leygue, E.; Klonisch, T.; Davie, J.R.; Kirshenbaum, L.A. 2015: PDK2-mediated alternative splicing switches Bnip3 from cell death to cell survival. Journal of Cell Biology 210(7): 1101-1115
Feng, L.; Yang, R.; Liu, D.; Wang, X.; Song, Y.; Cao, H.; He, D.; Gan, Y.; Kou, X.; Zhou, Y. 2016: PDL Progenitor-Mediated PDL Recovery Contributes to Orthodontic Relapse. Journal of Dental Research 95(9): 1049-1056
Zhu, W.; Zhang, Q.; Zhang, Y.; Cen, L.; Wang, J. 2015: PDL regeneration via cell homing in delayed replantation of avulsed teeth. Journal of Translational Medicine 13: 357
Lim, M.S. 2016: PDL structural rearrangements in B-cell NHL. Blood 128(9): 1159-1161
Daneshmandi, S.; Pourfathollah, A.A.; Karimi, M.H.; Emadi-Baygi, M. 2015: PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity. ImmunoTherapy 7(11): 1145-1158
Sponaas, A.-M.; Moharrami, N.N.; Feyzi, E.; Standal, T.; Holth Rustad, E.; Waage, A.; Sundan, A. 2015: PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. Plos one 10(10): E0139867
Cortez, M.A.; Ivan, C.; Valdecanas, D.; Wang, X.; Peltier, H.J.; Ye, Y.; Araujo, L.; Carbone, D.P.; Shilo, K.; Giri, D.K.; Kelnar, K.; Martin, D.; Komaki, R.; Gomez, D.R.; Krishnan, S.; Calin, G.A.; Bader, A.G.; Welsh, J.W. 2016: PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute 108(1)
Bertucci, F.ço.; Finetti, P.; Colpaert, C.éc.; Mamessier, E.; Parizel, M.; Dirix, L.; Viens, P.; Birnbaum, D.; van Laere, S. 2015: PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 6(15): 13506-13519
Bertucci, Fçois.; Finetti, P.; Mamessier, E.; Pantaleo, M.Abbondanza.; Astolfi, A.; Ostrowski, J.; Birnbaum, D. 2015: PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology 4(5): E1002729
Chen, H-Ning.; Yuan, K.; Xie, N.; Wang, K.; Huang, Z.; Chen, Y.; Dou, Q.; Wu, M.; Nice, E.C.; Zhou, Z-Guang.; Huang, C. 2016: PDLIM1 Stabilizes the E-Cadherin/β-Catenin Complex to Prevent Epithelial-Mesenchymal Transition and Metastatic Potential of Colorectal Cancer Cells. Cancer Research 76(5): 1122-1134
Maryáš, J.; Bouchal, P. 2015: PDLIM2 and its Role in Oncogenesis--Tumor Suppressor or Oncoprote?. Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti 28(Suppl 2): 2s40-2s46
Kang, M.; Lee, K.-H.; Lee, H.S.; Park, Y.H.; Jeong, C.W.; Ku, J.H.; Kim, H.H.; Kwak, C. 2016: PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Prostate 76(3): 273-285
Ren, B.; Li, X.; Zhang, J.; Fan, J.; Duan, J.; Chen, Y. 2015: PDLIM5 mediates PKCε translocation in PMA-induced growth cone collapse. Cellular Signalling 27(3): 424-435
D'Cruz, R.; Plant, P.J.; Pablo, L.A.; Lin, S.; Chackowicz, J.; Correa, J.; Bain, J.; Batt, J. 2016: PDLIM7 is a novel target of the ubiquitin ligase Nedd4-1 in skeletal muscle. Biochemical Journal 473(3): 267-276
Bejarano, J.; Detsch, R.; Boccaccini, A.R.; Palza, H. 2017: PDLLA scaffolds with Cu- and Zn-doped bioactive glasses having multifunctional properties for bone regeneration. Journal of Biomedical Materials Research. Part a 105(3): 746-756
Le, Y.H.; Kurkure, U.; Kakadiaris, I.A. 2015: PDM-ENLOR for segmentation of mouse brain gene expression images. Medical Image Analysis 20(1): 19-33
Ode, T.; Podyma-Inoue, K.A.; Terasawa, K.; Inokuchi, J.-I.; Kobayashi, T.; Watabe, T.; Izumi, Y.; Hara-Yokoyama, M. 2017: PDMP, a ceramide analogue, acts as an inhibitor of mTORC1 by inducing its translocation from lysosome to endoplasmic reticulum. Experimental Cell Research 350(1): 103-114
Brockman, T.A. 2015: PDMP, the Sequel. Journal of the Oklahoma State Medical Association 108(2): 46-47
Cheng, Q.; Sun, Z.; Meininger, G.; Almasri, M. 2013: PDMS Elastic Micropost Arrays for Studying Vascular Smooth Muscle Cells. Sensors and Actuators. B Chemical 188: 1055-1063
Vajrala, V.S.; Suraniti, E.; Rigoulet, M.; Devin, A.; Sojic, N.; Arbault, S.ép. 2016: PDMS microwells for multi-parametric monitoring of single mitochondria on a large scale: a study of their individual membrane potential and endogenous NADH. Integrative Biology: Quantitative Biosciences from Nano to Macro 8(8): 836-843
Prauzner-Bechcicki, S.; Raczkowska, J.; Madej, E.; Pabijan, J.; Lukes, J.; Sepitka, J.; Rysz, J.; Awsiuk, K.; Bernasik, A.; Budkowski, A.; Lekka, M.łg. 2015: PDMS substrate stiffness affects the morphology and growth profiles of cancerous prostate and melanoma cells. Journal of the Mechanical Behavior of Biomedical Materials 41: 13-22
Jeong, S.H.; Zhang, S.; Hjort, K.; Hilborn, J.ön.; Wu, Z. 2016: PDMS-Based Elastomer Tuned Soft, Stretchable, and Sticky for Epidermal Electronics. Advanced Materials 28(28): 5830-5836
Almeida, J.C.; Wacha, A.ás.; Gomes, P.S.; Fernandes, M.H.R.; Fernandes, M.H.V.; Salvado, I.M.M. 2016: PDMS-SiO2-TiO2-CaO hybrid materials - Cytocompatibility and nanoscale surface features. Materials Science and Engineering. C Materials for Biological Applications 64: 74-86
You, J.B.; Kang, K.; Tran, T.T.; Park, H.; Hwang, W.R.; Kim, J.M.; Im, S.G. 2015: PDMS-based turbulent microfluidic mixer. Lab on a Chip 15(7): 1727-1735
Ning, X.; Yang, J.; Zhao, C.L.; Chan, C.C. 2016: PDMS-coated fiber volatile organic compounds sensors. Applied Optics 55(13): 3543-3548
Younesi, E.; Malhotra, A.; Gündel, M.; Scordis, P.; Kodamullil, A.Tom.; Page, M.; Müller, B.; Springstubbe, S.; Wüllner, U.; Scheller, D.; Hofmann-Apitius, M. 2015: PDON: Parkinson's disease ontology for representation and modeling of the Parkinson's disease knowledge domain. Theoretical Biology and Medical Modelling 12: 20
Chatterjee, P.; Basu, S.; Zubek, J.; Kundu, M.; Nasipuri, M.; Plewczynski, D. 2016: PDP-CON: prediction of domain/linker residues in protein sequences using a consensus approach. Journal of Molecular Modeling 22(4): 72
Anonymous 2016: PDQ (Physician Data Query). Journal of the National Cancer Institute 108(7): -
Anonymous 2016: PDQ (Physician Data Query). Journal of the National Cancer Institute 108(8): -
Kim, M.M.; Darafsheh, A.; Ahmad, M.; Finlay, J.C.; Zhu, T.C. 2016: PDT Dose Dosimeter for Pleural Photodynamic Therapy. Proceedings of Spie--the International Society for Optical Engineering 9694: 96940y
Filho, Jé.D.Vollet.; Andrade, C.T.; Buzza, H.H.; Blanco, K.; Carbinatto, F.; Bagnato, V.S.; Allison, R.R. 2017: PDT and emerging therapies for Actinic Keratosis-A resource letter. Photodiagnosis and Photodynamic Therapy 17: 205-207
Sharikova, A.V.; Finlay, J.C.; Liang, X.; Zhu, T.C. 2013: PDT dose dosimetry for pleural photodynamic therapy. Proceedings of Spie--the International Society for Optical Engineering 8568
Cengel, K.A.; Simone, C.B.; Glatstein, E. 2016: PDT: What's Past Is Prologue. Cancer Research 76(9): 2497-2499
Widiger, T.A. 2016: PDTRT special section: Current trends in borderline personality disorder research. Personality disorders 7(4): 315
Pedica, F.; Beccari, S.; Pedron, S.; Montagna, L.; Piccoli, P.; Doglioni, C.; Chilosi, M. 2014: PDX-1 (pancreatic/duodenal homeobox-1 protein 1). Pathologica 106(4): 315-321
Marzioni, M.; Germani, U.; Agostinelli, L.; Bedogni, G.; Saccomanno, S.; Marini, F.; Bellentani, S.; Barbera, C.; De Minicis, S.; Rychlicki, C.; Santinelli, A.; Ferretti, M.; Di Maira, P.V.; Baroni, G.S.; Benedetti, A.; Caletti, G.; Lorenzini, I.; Fusaroli, P. 2015: PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: perspectives in the diagnosis of pancreatic cancer. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 47(2): 138-143
Wang, W.; Shi, Q.; Guo, T.; Yang, Z.; Jia, Z.; Chen, P.; Zhou, C. 2016: PDX1 and ISL1 differentially coordinate with epigenetic modifications to regulate insulin gene expression in varied glucose concentrations. Molecular and Cellular Endocrinology 428: 38-48
Yu, J.; Liu, S-He.; Sanchez, R.; Nemunaitis, J.; Rozengurt, E.; Brunicardi, F.Charles. 2016: PDX1 associated therapy in translational medicine. Annals of Translational Medicine 4(11): 214
Teo, A.K.K.; Tsuneyoshi, N.; Hoon, S.; Tan, E.K.; Stanton, L.W.; Wright, C.V.E.; Dunn, N.R. 2015: PDX1 binds and represses hepatic genes to ensure robust pancreatic commitment in differentiating human embryonic stem cells. Stem Cell Reports 4(4): 578-590
Gunawardana, D. 2016: PDZ Binding Domains, Structural Disorder and Phosphorylation: a Menage-a-trois Tailing Dcp2 mRNA Decapping Enzymes. Protein and Peptide Letters 23(7): 612-618
Mohanty, S.; Ovee, M.; Banerjee, M. 2015: PDZ Domain Recognition: Insight from Human Tax-Interacting Protein 1 (TIP-1) Interaction with Target Proteins. Biology 4(1): 88-103
Giansanti, F.; Sabatini, D.; Pennacchio, M.R.; Scotti, S.; Angelucci, F.; Dhez, A.-C.è; Antonosante, A.; Cimini, A.; Giordano, A.; Ippoliti, R. 2015: PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a Tool for targeting Cancer Cells. Journal of Cellular Biochemistry 116(7): 1256-1266
Dunn, H.A.; Ferguson, S.S.G. 2015: PDZ Protein Regulation of G Protein-Coupled Receptor Trafficking and Signaling Pathways. Molecular Pharmacology 88(4): 624-639
Holcomb, J.; Spellmon, N.; Trescott, L.; Sun, F.; Li, C.; Yang, Z. 2015: PDZ Structure and Implication in Selective Drug Design against Cystic Fibrosis. Current Drug Targets 16(9): 945-950
Wang, M.-Y.; Lin, Z.-R.; Cao, Y.; Zheng, L.-S.; Peng, L.-X.; Sun, R.; Meng, D.-F.; Xie, P.; Yang, J.-P.; Cao, L.; Xu, L.; Huang, B.-J.; Qian, C.-N. 2016: PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival. Oncotarget 7(18): 26604-26616
Yu, Y.; Liu, M.; Ng, T.T.; Huang, F.; Nie, Y.; Wang, R.; Yao, Z.-P.; Li, Z.; Xia, J. 2016: PDZ-Reactive Peptide Activates Ephrin-B Reverse Signaling and Inhibits Neuronal Chemotaxis. Acs Chemical Biology 11(1): 149-158
Vishchuk, O.S.; Sun, H.; Wang, Z.; Ermakova, S.P.; Xiao, J.; Lu, T.; Xue, P.; Zvyagintseva, T.N.; Xiong, H.; Shao, C.; Yan, W.; Duan, Q.; Zhu, F. 2016: PDZ-binding kinase/T-LAK cell-originated protein kinase is a target of the fucoidan from brown alga Fucus evanescens in the prevention of EGF-induced neoplastic cell transformation and colon cancer growth. Oncotarget 7(14): 18763-18773
Yin, X.-H.; Yan, J.-Z.; Yang, G.; Chen, L.; Xu, X.-F.; Hong, X.-P.; Wu, S.-L.; Hou, X.-Y.; Zhang, G. 2016: PDZ1 inhibitor peptide protects neurons against ischemia via inhibiting GluK2-PSD-95-module-mediated Fas signaling pathway. Brain Research 1637: 64-70
Booth, K.T.; Azaiez, H.; Kahrizi, K.; Simpson, A.C.; Tollefson, W.T.A.; Sloan, C.M.; Meyer, N.C.; Babanejad, M.; Ardalani, F.; Arzhangi, S.; Schnieders, M.J.; Najmabadi, H.; Smith, R.J.H. 2015: PDZD7 and hearing loss: more than just a modifier. American Journal of Medical Genetics. Part a 167a (12): 2957-2965
Morgan, C.P.; Krey, J.F.; Grati, M.'h.; Zhao, B.; Fallen, S.; Kannan-Sundhari, A.; Liu, X.Z.; Choi, D.; Müller, U.; Barr-Gillespie, P.G. 2016: PDZD7-MYO7A complex identified in enriched stereocilia membranes. Elife 5
Lee, W.Ru.; Sacharidou, A.; Behling-Kelly, E.; Oltmann, S.C.; Zhu, W.; Ahmed, M.; Gerard, R.D.; Hui, D.Y.; Abe, J-ichi.; Shaul, P.W.; Mineo, C. 2015: PDZK1 prevents neointima formation via suppression of breakpoint cluster region kinase in vascular smooth muscle. Plos one 10(4): E0124494
Walther, C.; Caetano, F.A.; Dunn, H.A.; Ferguson, S.S.G. 2015: PDZK1/NHERF3 differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2A receptor signaling and endocytosis. Cellular Signalling 27(3): 519-531
Hu, T.; Yang, H.; Han, Z.-G. 2015: PDZRN4 acts as a suppressor of cell proliferation in human liver cancer cell lines. Cell Biochemistry and Function 33(7): 443-449
Zhao, Z.; Li, Y.; Chen, H.; Lu, J.; Thompson, P.M.; Chen, J.; Wang, Z.; Xu, J.; Xu, C.; Li, X. 2014: PD_NGSAtlas: a reference database combining next-generation sequencing epigenomic and transcriptomic data for psychiatric disorders. Bmc Medical Genomics 7: 71
Kendrick, J.; Burnett, A.D. 2016: PDielec: the calculation of infrared and terahertz absorption for powdered crystals. Journal of Computational Chemistry 37(16): 1491-1504
Beckers, R.K.; Selinger, C.; Vilain, R.; Madore, J.; Wilmott, J.S.; Harvey, K.; Holliday, A.; Cooper, C.L.; Robbins, E.; Gillet, D.; Kennedy, C.W.; Gluch, L.; Carmalt, H.; Mak, C.; Warrier, S.; Gee, H.E.; Chan, C.; McLean, A.; Walker, E.; McNeil, C.M.; Beith, J.M.; Swarbrick, A.; Scolyer, R.A.; O'Toole, S.A. 2016: PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Pathology 48(Suppl 1): S146-S147
Bronikowski, M.; Bronikowska, M.; Laudańska-Krzemińska, I.; Kantanista, A.; Morina, B.; Vehapi, S. 2015: PE Teacher and Classmate Support in Level of Physical Activity: The Role of Sex and BMI Status in Adolescents from Kosovo. BioMed research international 2015: 290349
Leite, N.ál.B.; Aufderhorst-Roberts, A.; Palma, M.S.; Connell, S.D.; Ruggiero Neto, J.ão.; Beales, P.A. 2015: PE and PS Lipids Synergistically Enhance Membrane Poration by a Peptide with Anticancer Properties. Biophysical Journal 109(5): 936-947
Bataman, C. 2016: PE hospital turmoil: CEO leaves, nurses snore in patient beds. South African Medical Journal 106(4): 16
Liu, J.Y. 2015: PE-Swab Direct STR Amplification of Forensic Touch DNA Samples. Journal of Forensic Sciences 60(3): 693-701
Deng, W.; Zeng, J.; Xiang, X.; Li, P.; Xie, J. 2015: PE11 (Rv1169c) selectively alters fatty acid components of Mycobacterium smegmatis and host cell interleukin-6 level accompanied with cell death. Frontiers in Microbiology 6: 613
Okuda, M.; Hijikuro, I.; Fujita, Y.; Wu, X.; Nakayama, S.; Sakata, Y.; Noguchi, Y.; Ogo, M.; Akasofu, S.; Ito, Y.; Soeda, Y.; Tsuchiya, N.; Tanaka, N.; Takahashi, T.; Sugimoto, H. 2015: PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. Plos one 10(2): E0117511
Parrella, E.; Porrini, V.; Iorio, R.; Benarese, M.; Lanzillotta, A.; Mota, M.; Fusco, M.; Tonin, P.; Spano, P.; Pizzi, M. 2016: PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia. Brain Research 1648(Part A): 409-417
Shin, M.; Lee, K.-E.; Yang, E.G.; Jeon, H.; Song, H.K. 2015: PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells. Febs Letters 589(9): 1033-1039
Kherrouche, Z.; Monte, D.; Werkmeister, E.; Stoven, L.; De Launoit, Y.; Cortot, A.B.; Tulasne, D.; Chotteau-Lelievre, A. 2015: PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells. Molecular Oncology 9(9): 1852-1867
Robinson, M.-A. 2015: A catalyst for change. Alberta Rn 71(3): 42
Nash, D.B. 2015: PEACE Time. American Health and Drug Benefits 8(9): 467-468
Agajanian, M.; Campeau, A.; Hoover, M.; Hou, A.; Brambilla, D.; Kim, S.L.; Klemke, R.L.; Kelber, J.A. 2015: PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer. Plos one 10(8): E0135748
Yu, W.; Cho, G.Y.; Hong, S.; Lee, Y.; Kim, Y.B.; An, J.; Cha, S.W. 2016: PEALD YSZ-based bilayer electrolyte for thin film-solid oxide fuel cells. Nanotechnology 27(41): 415402
Calabrò, R.S.; Naro, A.; De Luca, R.; Leonardi, S.; Russo, M.; Marra, A.; Bramanti, P. 2016: PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study!. Aging Clinical and Experimental Research 28(6): 1279-1282
Olivi, L.; Vandenbriele, C.; Gu, Y.-M.; Salvi, E.; Carpini, S.D.; Liu, Y.-P.; Jacobs, L.; Jin, Y.; Thijs, L.; Citterio, L.; Cusi, D.; Verhamme, P.; Staessen, J.A. 2015: PEAR1 is not a human hypertension-susceptibility gene. Blood Pressure 24(1): 61-64
McAvoy, B.R.; Buckley, A. 2016: PEARLS: a locally-produced resource for New Zealand primary care with a global reach. Journal of Primary Health Care 8(2): 180-181
Sela-Culang, I.; Ashkenazi, S.; Peters, B.; Ofran, Y. 2015: PEASE: predicting B-cell epitopes utilizing antibody sequence. Bioinformatics 31(8): 1313-1315
Li, Y.-L.; Weng, J.-C.; Hsiao, C.-C.; Chou, M.-T.; Tseng, C.-W.; Hung, J.-H. 2015: PEAT: an intelligent and efficient paired-end sequencing adapter trimming algorithm. Bmc Bioinformatics 16(Suppl 1): S2
Noh, H.Sook.; Hah, Y-Sool.; Zada, S.; Ha, J.Hye.; Sim, G.; Hwang, J.Seok.; Lai, T.Huyen.; Nguyen, H.Quoc.; Park, J-Yong.; Kim, H.Joon.; Byun, J-Ho.; Hahm, J.Ryeal.; Kang, K.Ryeon.; Kim, D.Ryong. 2016: PEBP1, a RAF kinase inhibitory protein, negatively regulates starvation-induced autophagy by direct interaction with LC3. Autophagy 12(11): 2183-2196
Zhang, D.; Dai, Y.; Cai, Y.; Suo, T.; Liu, H.; Wang, Y.; Cheng, Z.; Liu, H. 2016: PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 37(2): 1699-1705
Li, W.; Dong, Y.; Zhang, B.; Kang, Y.; Yang, X.; Wang, H. 2016: PEBP4 silencing inhibits hypoxia-induced epithelial-to-mesenchymal transition in prostate cancer cells. Biomedicine and PharmacoTherapy 81: 1-6
Park, S.; Sorenson, C.M.; Sheibani, N. 2015: PECAM-1 isoforms, eNOS and endoglin axis in regulation of angiogenesis. Clinical Science 129(3): 217-234
Xu, S.; Ha, C.H.; Wang, W.; Xu, X.; Yin, M.; Jin, F.Q.; Mastrangelo, M.; Koroleva, M.; Fujiwara, K.; Jin, Z.G. 2016: PECAM1 regulates flow-mediated Gab1 tyrosine phosphorylation and signaling. Cellular Signalling 28(3): 117-124
Cortazar, A.R.; Oguiza, J.é A.; Aransay, A.M.; Lavín, J.é L. 2015: PECAS: prokaryotic and eukaryotic classical analysis of secretome. Amino Acids 47(12): 2659-2663
Ortolon, K. 2010: PECOS Confusion: Who Has to Enroll? Don't Ask. Texas Medicine 106(6): 49-54
Jiang, J.; Yao, L.; Yu, Y.; Liang, Y.; Jiang, J.; Ye, N.; Miao, Y.; Cao, J. 2014: PECTATE LYASE-LIKE 9 from Brassica campestris is associated with intine formation. Plant Science: An International Journal of Experimental Plant Biology 229: 66-75
Leroux, C.; Bouton, S.; Kiefer-Meyer, M.-C.; Fabrice, T.N.; Mareck, A.; Guénin, S.ép.; Fournet, F.ço.; Ringli, C.; Pelloux, J.ér.ôm.; Driouich, A.; Lerouge, P.; Lehner, A.; Mollet, J.-C. 2015: PECTIN METHYLESTERASE48 is involved in Arabidopsis pollen grain germination. Plant Physiology 167(2): 367-380
Lionetti, V. 2015: PECTOPLATE: the simultaneous phenotyping of pectin methylesterases, pectinases, and oligogalacturonides in plants during biotic stresses. Frontiers in Plant Science 6: 331
Pirog, T.P.; Shevchuk, T.A.; Beregova, K.A.; Kudrya, N.V. 2015: Peculiarities of Glucose and Glycerol Metabolism in Nocardia Vaccinii Imb B-7405. Ukrainian Biochemical Journal 87(2): 66-75
Denisenko, A.I. 2015: Peculiarities of Perioperative Management of Patients in Endovideosurgical Interventions. Part Ii. Gas Exchange, Mechanics of the Lungs, Central Nervous System, Function of the Liver, Kidneys, Selection of Anesthetics, Intensive Therapy, Contraindications. Klinichna Khirurhiia 2015(8): 62-67
Shimao, T. 2016: Peculiarity of National Tuberculosis Program, Japan--Public-Private Mix from the very Beginning, and Provision of X-Ray Apparatus in Most General Practitioner's Clinics. Kekkaku: 91(2): 69-74
Neofytou, K.; Famularo, S.; Khan, A.Z. 2015: PEComa in a Young Patient with Known Li-Fraumeni Syndrome. Case Reports in Medicine 2015: 906981
Wejman, Jław.; Nowak, K.; Gielniewska, L.; Komorowska, M.; Dąbrowski, W. 2015: PEComa of the mesentery coexisting with colon cancer: a case report. Diagnostic Pathology 10: 31
Hasan, H.; Howard, A.F.; Alassiri, A.H.; Ng, T.L.; McGregor, G.; Goddard, K. 2015: PEComa of the terminal ileum mesentery as a secondary tumour in an adult survivor of embryonal rhabdomyosarcoma. Current Oncology 22(5): E383-E386
Han, Y.; Liu, T-ting.; Qiu, X-shan.; Li, Q-chang.; Zhao, Y.; Pang, X-Yan.; Wang, E-hua. 2015: PEComa of the uterus with coexistence of situs inversus totalis, a case report and literature review. Diagnostic Pathology 10: 142
Thway, K.; Fisher, C. 2015: PEComa: morphology and genetics of a complex tumor family. Annals of Diagnostic Pathology 19(5): 359-368
Martignoni, G.; Pea, M.; Zampini, C.; Brunelli, M.; Segala, D.; Zamboni, G.; Bonetti, F. 2015: PEComas of the kidney and of the genitourinary tract. Seminars in Diagnostic Pathology 32(2): 140-159
Anonymous 2016: PED to be made notifiable in Scotland. Veterinary Record 178(5): 106
Fiory, F.; Parrillo, L.; Raciti, G.A.; Zatterale, F.; Nigro, C.; Mirra, P.; Falco, R.; Ulianich, L.; Di Jeso, B.; Formisano, P.; Miele, C.; Beguinot, F. 2014: PED/PEA-15 inhibits hydrogen peroxide-induced apoptosis in Ins-1E pancreatic beta-cells via PLD-1. Plos one 9(12): E113655
Zhang, H.; Wei, T.; Jiang, X.; Li, Z.; Cui, H.; Pan, J.; Zhuang, W.; Sun, T.; Liu, Z.; Zhang, Z.; Dong, H. 2016: PEDF and 34-mer inhibit angiogenesis in the heart by inducing tip cells apoptosis via up-regulating PPAR-γ to increase surface FasL. Apoptosis: an international journal on programmed cell death 21(1): 60-68
Zhuang, W.; Zhang, H.; Pan, J.; Li, Z.; Wei, T.; Cui, H.; Liu, Z.; Guan, Q.; Dong, H.; Zhang, Z. 2016: PEDF and PEDF-derived peptide 44mer inhibit oxygen-glucose deprivation-induced oxidative stress through upregulating PPARγ via PEDF-R in H9c2 cells. Biochemical and biophysical research communications 472(3): 482-488
Zhang, H.; Sun, T.; Jiang, X.; Yu, H.; Wang, M.; Wei, T.; Cui, H.; Zhuang, W.; Liu, Z.; Zhang, Z.; Dong, H. 2015: PEDF and PEDF-derived peptide 44mer stimulate cardiac triglyceride degradation via ATGL. Journal of Translational Medicine 13: 68
He, X.; Cheng, R.; Benyajati, S.; Ma, J.-x. 2015: PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clinical Science 128(11): 805-823
Wang, X.; Zhang, Y.; Lu, P.; Zhang, H.; Li, Y.; Dong, H.; Zhang, Z. 2015: PEDF attenuates hypoxia-induced apoptosis and necrosis in H9c2 cells by inhibiting p53 mitochondrial translocation via PEDF-R. Biochemical and Biophysical Research Communications 465(3): 394-401
Carnagarin, R.; Dharmarajan, A.M.; Dass, C.R. 2016: PEDF attenuates insulin-dependent molecular pathways of glucose homeostasis in skeletal myocytes. Molecular and Cellular Endocrinology 422: 115-124
Thangaraj, G.; Christophel, J.; Bachmann, G.; Greif, A.; Layer, P.G. 2015: PEDF counteracts DL-α-aminoadipate toxicity and rescues gliotoxic damages in RPE-free chicken retinal explants. Experimental Eye Research 134: 111-122
Zhang, H.; Wang, Z.; Feng, S.-J.; Xu, L.; Shi, H.-X.; Chen, L.-L.; Yuan, G.-D.; Yan, W.; Zhuang, W.; Zhang, Y.-Q.; Zhang, Z.-M.; Dong, H.-Y. 2015: PEDF improves cardiac function in rats with acute myocardial infarction via inhibiting vascular permeability and cardiomyocyte apoptosis. International Journal of Molecular Sciences 16(3): 5618-5634
Principe, D.R.; DeCant, B.; Diaz, A.M.; Mangan, R.J.; Hwang, R.; Lowy, A.; Shetuni, B.B.; Sreekumar, B.K.; Chung, C.; Bentrem, D.J.; Munshi, H.G.; Jung, B.; Grippo, P.J.; Bishehsari, F. 2016: PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 7(19): 28218-28234
Ho, T.-C.; Chiang, Y.-P.; Chuang, C.-K.; Chen, S.-L.; Hsieh, J.-W.; Lan, Y.-W.; Tsao, Y.-P. 2015: PEDF-derived peptide promotes skeletal muscle regeneration through its mitogenic effect on muscle progenitor cells. American Journal of Physiology. Cell Physiology 309(3): C159-C168
Carnagarin, R.; Dharmarajan, A.M.; Dass, C.R. 2015: PEDF-induced alteration of metabolism leading to insulin resistance. Molecular and Cellular Endocrinology 401: 98-104
Eagle, A. 2015: PEDIATRIC DESIGN: Child's Play (and a Whole Lot More). Hospitals and Health Networks 89(12): 32-34; 36
Fan, X.; Luo, C.; Lamb, J.; Zhu, Y.; Xu, K.; Wang, C. 2015: PEDOT Encapsulated FeOF Nanorod Cathodes for High Energy Lithium-Ion Batteries. Nano Letters 15(11): 7650-7656
Casado, N.; Hernández, G.; Veloso, A.; Devaraj, S.; Mecerreyes, D.; Armand, M. 2016: PEDOT Radical Polymer with Synergetic Redox and Electrical Properties. Acs Macro Letters 5(1): 59-64
Kim, Y.; Na, J.; Park, C.; Shin, H.; Kim, E. 2015: PEDOT as a Flexible Organic Electrode for a Thin Film Acoustic Energy Harvester. Acs Applied Materials and Interfaces 7(30): 16279-16286
Li, L.; Liu, Y.; Hao, P.; Wang, Z.; Fu, L.; Ma, Z.; Zhou, J. 2015: PEDOT nanocomposites mediated dual-modal photodynamic and photothermal targeted sterilization in both NIR i and Ii window. Biomaterials 41: 132-140
Samba, R.; Herrmann, T.; Zeck, G. 2015: PEDOT-CNT coated electrodes stimulate retinal neurons at low voltage amplitudes and low charge densities. Journal of Neural Engineering 12(1): 016014
Zhao, Z.; Richardson, G.F.; Meng, Q.; Zhu, S.; Kuan, H.-C.; Ma, J. 2016: PEDOT-based composites as electrode materials for supercapacitors. Nanotechnology 27(4): 042001
Yu, Z.; Xia, Y.; Du, D.; Ouyang, J. 2016: PEDOT:PSS Films with Metallic Conductivity through a Treatment with Common Organic Solutions of Organic Salts and their Application as a Transparent Electrode of Polymer Solar Cells. Acs Applied Materials and Interfaces 8(18): 11629-11638
Cellot, G.; Lagonegro, P.; Tarabella, G.; Scaini, D.; Fabbri, F.; Iannotta, S.; Prato, M.; Salviati, G.; Ballerini, L. 2015: PEDOT:PSS Interfaces Support the Development of Neuronal Synaptic Networks with Reduced Neuroglia Response in vitro. Frontiers in Neuroscience 9: 521
Hempel, F.; Law, J.K.-Y.; Nguyen, T.C.; Munief, W.; Lu, X.; Pachauri, V.; Susloparova, A.; Vu, X.T.; Ingebrandt, S. 2017: PEDOT:PSS organic electrochemical transistor arrays for extracellular electrophysiological sensing of cardiac cells. Biosensors and Bioelectronics 93: 132-138
Guo, Y.; Otley, M.T.; Li, M.; Zhang, X.; Sinha, S.K.; Treich, G.M.; Sotzing, G.A. 2016: PEDOT:PSS "Wires" Printed on Textile for Wearable Electronics. Acs Applied Materials and Interfaces 8(40): 26998-27005
Marks, W.; Bailey, L.; Sanger, T.D. 2017: PEDiDBS: The pediatric international deep brain stimulation registry project. European Journal of Paediatric Neurology: Ejpn: Official Journal of the European Paediatric Neurology Society 21(1): 218-222
Armijo-Olivo, S.; da Costa, B.R.; Cummings, G.G.; Ha, C.; Fuentes, J.; Saltaji, H.; Egger, M. 2015: PEDro or Cochrane to Assess the Quality of Clinical Trials? a Meta-Epidemiological Study. Plos one 10(7): E0132634
Deveza, R.C.; Elkins, M.; Saragiotto, B.T. 2017: PEDro systematic review update: exercise for coronary heart disease. British Journal of Sports Medicine 51(9): 755-756
Higashioka, H.; Miyake, Y. 2016: PEEC (psychiatric evaluation in emergency care). Nihon Rinsho. Japanese Journal of Clinical Medicine 74(2): 325-328
Neulicht, A.T.; Berens, D.E. 2015: PEEDS-RAPEL: a case conceptualization model for evaluating pediatric cases with acquired brain injury. Neurorehabilitation 36(3): 275
Schimmel, J.J.P.; Poeschmann, M.S.; Horsting, P.P.; Schönfeld, D.H.W.; van Limbeek, J.; Pavlov, P.W. 2016: PEEK Cages in Lumbar Fusion: Mid-term Clinical Outcome and Radiologic Fusion. Clinical Spine Surgery 29(5): E252-E258
Schulz, C.; Mauer, U.M.; Mathieu, R. 2017: PEEK cage fusion after anterior cervical corpectomy : Clinical and radiological results in patients with spondylotic myelopathy. Der Orthopade 46(3): 242-248
Xiang, X.; Shang, B.; Wang, X.; Chen, Q. 2017: PEEK tube-based online solid-phase microextraction-high-performance liquid chromatography for the determination of yohimbine in rat plasma and its application in pharmacokinetics study. Biomedical Chromatography: Bmc 31(4)
Phan, K.; Hogan, J.A.; Assem, Y.; Mobbs, R.J. 2016: PEEK-Halo effect in interbody fusion. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 24: 138-140
Cowie, R.M.; Briscoe, A.; Fisher, J.; Jennings, L.M. 2016: PEEK-OPTIMA™ as an alternative to cobalt chrome in the femoral component of total knee replacement: a preliminary study. Proceedings of the Institution of Mechanical Engineers. Part H Journal of Engineering in Medicine 230(11): 1008-1015
Appendini, L.; Esquinas, A.; Launaro, N.; Purro, A. 2016: PEEP and Mechanical Ventilation: we Are Warned, we Cannot Ignore. Respiratory Care 61(5): 720-721
Van IJzendoorn, M.C.O.; Kuiper, M.A. 2015: PEEP in ICU patients without ARDS in the Netherlands: not a closed case. Netherlands Journal of Medicine 73(4): 194
Beitler, J.R.; Guérin, C.; Ayzac, L.; Mancebo, J.; Bates, D.M.; Malhotra, A.; Talmor, D. 2015: PEEP titration during prone positioning for acute respiratory distress syndrome. Critical Care 19: 436
Hainline, C.; Rosales, D.; Parikh, P.; Louie, E.; Howard, J.; Kim, N.; Galetta, S.L. 2016: Disseminated HSV-2 presenting with relapsing encephalomyelitis. Neurology. Clinical Practice 6(6): E46-E48
Wang, F.; Anderson, M.; Bernards, M.T.; Hunt, H.K. 2015: PEG Functionalization of Whispering Gallery Mode Optical Microresonator Biosensors to Minimize Non-Specific Adsorption during Targeted, Label-Free Sensing. Sensors 15(8): 18040-18060
Lu, M.; Wang, Y.-K.; Zhao, J.; Lu, H.; Stenzel, M.H.; Xiao, P. 2016: PEG Grafted-Nanodiamonds for the Delivery of Gemcitabine. Macromolecular Rapid Communications 37(24): 2023-2029
Ayman, A.R.; Khoury, T.; Cohen, J.; Chen, S.; Yaari, S.; Daher, S.; Benson, A.A.; Mizrahi, M. 2017: PEG Insertion in Patients with Dementia Does not Improve Nutritional Status and Has Worse Outcomes as Compared with PEG Insertion for other Indications. Journal of Clinical Gastroenterology 51(5): 417-420
Carlisle, B.J.; Craft, G.; Harmon, J.P.; Ilkevitch, A.; Nicoghosian, J.; Sheyner, I.; Stewart, J.T. 2016: PEG and Thickeners: a Critical Interaction Between Polyethylene Glycol Laxative and Starch-Based Thickeners. Journal of the American Medical Directors Association 17(9): 860-861
Chanphai, P.; Agudelo, D.; Tajmir-Riahi, H.A. 2017: PEG and mPEG-anthracene conjugate with trypsin and trypsin inhibitor: hydrophobic and hydrophilic contacts. Journal of Biomolecular Structure and Dynamics 35(10): 2257-2268
Muhammad, Z.; Raza, A.; Ghafoor, S.; Naeem, A.; Naz, S.Sohaila.; Riaz, S.; Ahmed, W.; Rana, N.Fatima. 2016: PEG capped methotrexate silver nanoparticles for efficient anticancer activity and biocompatibility. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 91: 251-255
Ogawa, M.; Uchino, R.; Kawai, A.; Kosugi, M.; Magata, Y. 2015: PEG modification on (111)In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques. Nuclear Medicine and Biology 42(3): 299-304
Oberoi, H.S.; Yorgensen, Y.M.; Morasse, A.; Evans, J.T.; Burkhart, D.J. 2016: PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination. Journal of Controlled Release: Official Journal of the Controlled Release Society 223: 64-74
Veiman, K.-L.; Künnapuu, K.; Lehto, T.õn.; Kiisholts, K.; Pärn, K.; Langel, Ül.; Kurrikoff, K. 2015: PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. Journal of Controlled Release: Official Journal of the Controlled Release Society 209: 238-247
Heikkilä, V.-P. 2015: PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation. British Journal of Radiology 88(1055): 20150421
Zoetebier, B.; Sohrabi, A.; Lou, B.; Hempenius, M.A.; Hennink, W.E.; Vancso, G.J. 2016: PEG stabilized DNA - poly(ferrocenylsilane) polyplexes for gene delivery. Chemical Communications 52(49): 7707-7710
Malhi, H.; Thompson, R. 2014: PEG tubes: dealing with complications. Nursing Times 110(45): 18-21
Li, Y.; Lin, R.; Wang, L.; Huang, J.; Wu, H.; Cheng, G.; Zhou, Z.; MacDonald, T.; Yang, L.; Mao, H. 2015: PEG- b -AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting. Journal of Materials Chemistry. B 3(17): 3591-3603
Basu, A.; Veprinsky-Zuzulia, I.; Levinman, M.; Barkan, Y.; Golenser, J.; Domb, A.J. 2016: PEG-Biscyanoacrylate Crosslinker for Octyl Cyanoacrylate Bioadhesive. Macromolecular Rapid Communications 37(3): 251-256
Zhao, M.; Huang, Y.; Chen, Y.; Xu, J.; Li, S.; Guo, X. 2016: PEG-Fmoc-Ibuprofen Conjugate as a Dual Functional Nanomicellar Carrier for Paclitaxel. Bioconjugate Chemistry 27(9): 2198-2205
Enomoto, H.; Nishiguchi, S. 2015: PEG-IFN/IFN monotherapy. Nihon Rinsho. Japanese Journal of Clinical Medicine 73(2): 280-284
De Guzman, R.C.; Rabbany, S.Y. 2016: PEG-Immobilized Keratin for Protein Drug Sequestration and pH-Mediated Delivery. Journal of Drug Delivery 2016: 7843951
Milara, J.; Outeda-Macias, M.; Aumente-Rubio, M.D.; Más-Serrano, P.; Aldaz, A.; Calvo, M.V.; García-Simón, M.S.; Martin-Barbero, M.; Padullés-Zamora, N.úr.; Schoenenberger, J.A.; Saavedra-Aldrich, M.; Tévar-Alfonso, E.; Saval, A.; Pastor-Clerigues, A.; García, M.; Margusino-Framiñan, L.; Montero-Alvarez, J.L.; Merino, E.; Herrero, J.I.; Beunza, M.ón.; Conesa-Zamora, P.; Gimenez-Manzorro, A.; Comas-Sugrañes, D.; Cano-Marron, M.; Jiménez-Mutiloa, E.; Díaz-Ruíz, P.; Cortijo, J. 2015: PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 39(1): 29-43
Liu, Y.; Yang, X.; Lei, Q.; Li, Z.; Hu, J.; Wen, X.; Wang, H.; Liu, Z. 2015: PEG-PEI/siROCK2 Protects Against Aβ42-Induced Neurotoxicity in Primary Neuron Cells for Alzheimer Disease. Cellular and Molecular Neurobiology 35(6): 841-848
Diao, J.; Wang, H.; Chang, N.; Zhou, X-Hai.; Zhu, X.; Wang, J.; Xiong, J-Wei. 2015: PEG-PLA nanoparticles facilitate siRNA knockdown in adult zebrafish heart. Developmental Biology 406(2): 196-202
Timor, R.; Weitman, H.; Waiskopf, N.; Banin, U.; Ehrenberg, B. 2015: PEG-Phospholipids Coated Quantum Rods as Amplifiers of the Photosensitization Process by FRET. Acs Applied Materials and Interfaces 7(38): 21107-21114
Park, M.H.; Moon, H.J.; Park, J.H.; Shinde, U.P.; Ko, D.Y.; Jeong, B. 2015: PEG-Poly(L-alanine) thermogel as a 3D scaffold of bone-marrow-derived mesenchymal stem cells. Macromolecular Bioscience 15(4): 464-472
Galindo, R.J.; Yoon, J.; Devoe, C.; Myers, A.K. 2016: PEG-asparaginase induced severe hypertriglyceridemia. Archives of Endocrinology and Metabolism 60(2): 173-177
Wang, J.; Wang, Y.; Wu, L.; Zhang, J.; Lai, W.; Wang, Z. 2016: PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Journal of Hematology and Oncology 9(1): 84
Cho, H.; Gao, J.; Kwon, G.S. 2016: PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 240: 191-201
Zhu, Q.; Trau, D. 2017: PEG-based autonomous capillary system with integrated microbead array for immunoassay. Materials Science and Engineering. C Materials for Biological Applications 70(Part 2): 1031-1038
Cai, X.Y.; Li, J.Z.; Li, N.N.; Chen, J.C.; Kang, E.-T.; Xu, L.Q. 2016: PEG-based hydrogels prepared by catalyst-free thiol-yne addition and their post-antibacterial modification. Biomaterials Science 4(11): 1663-1672
Xiao, C.; Ding, J.; Zhuang, X.; Chen, X. 2015: PEG-based thermo-responsive poly (β-thioether ester) for ROS-triggered drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 213: E22
Zhang, L.; Guo, S.; Wang, M.; He, L. 2015: PEG-based ultrasound-assisted enzymatic extraction of polysaccharides from Ginkgo biloba leaves. International Journal of Biological Macromolecules 80: 644-650
Sukhoverkov, K.V.; Kudryashova, E.V. 2015: PEG-chitosan and glycol-chitosan for improvement of biopharmaceutical properties of recombinant L-asparaginase from Erwinia carotovora. BIOCHEMISTRY. Biokhimiia 80(1): 113-119
Kudryashova, E.V.; Suhoverkov, K.V.; Sokolov, N.N. 2015: PEG-chitosan branched copolymers to improve the biocatalytic properties of Erwinia carotovora recombinant L-asparaginase. Biomeditsinskaia Khimiia 61(4): 480-487
Chang, F.-C.; Tsao, C.-T.; Lin, A.; Zhang, M.; Levengood, S.L.; Zhang, M. 2016: PEG-chitosan hydrogel with tunable stiffness for study of drug response of breast cancer cells. Polymers 8(4)
Chu, B.; Qu, Y.; Huang, Y.; Zhang, L.; Chen, X.; Long, C.; He, Y.; Ou, C.; Qian, Z. 2016: PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. International Journal of Pharmaceutics 500(1-2): 345-359
Pradhan, S.; Hassani, I.; Seeto, W.J.; Lipke, E.A. 2017: PEG-fibrinogen hydrogels for three-dimensional breast cancer cell culture. Journal of Biomedical Materials Research. Part a 105(1): 236-252
Chakraborti, S.; Chakraborty, S.; Saha, S.; Manna, A.; Banerjee, S.; Adhikary, A.; Sarwar, S.; Hazra, T.K.; Das, T.; Chakrabarti, P. 2017: PEG-functionalized zinc oxide nanoparticles induce apoptosis in breast cancer cells through reactive oxygen species-dependent impairment of DNA damage repair enzyme NEIL2. Free Radical Biology and Medicine 103: 35-47
Monsalve, Y.; Tosi, G.; Ruozi, B.; Belletti, D.; Vilella, A.; Zoli, M.; Vandelli, M.Angela.; Forni, F.; López, B.L.; Sierra, L. 2015: PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine 10(11): 1735-1750
Quan, S.; Tang, Y.P.; Wang, Z.X.; Jiang, Z.X.; Wang, R.G.; Liu, Y.Y.; Shao, L. 2015: PEG-imbedded PEO membrane developed by a novel highly efficient strategy toward superior gas transport performance. Macromolecular Rapid Communications 36(5): 490-495
Nolan, V.ón.; Sánchez, J.M.; Perillo, M.ía.A. 2015: PEG-induced molecular crowding leads to a relaxed conformation, higher thermal stability and lower catalytic efficiency of Escherichia coli β-galactosidase. Colloids and Surfaces. B Biointerfaces 136: 1202-1206
Búfalo, J.; Rodrigues, T.M.; de Almeida, L.F.R.; Tozin, L.R.D.S.; Marques, M.O.M.; Boaro, C.S.F. 2016: PEG-induced osmotic stress in Mentha x piperita L.: Structural features and metabolic responses. Plant Physiology and Biochemistry (Paris) 105: 174-184
Gill, K.K.; Kaddoumi, A.; Nazzal, S. 2015: PEG-lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication. Journal of Drug Targeting 23(3): 222-231
Atmaca, A.; Al-Batran, S-E.; Meerpohl, H-G.; Grischke, E-M.; Lerbs, W.; Knuth, A.; Jäger, E. 2016: PEG-liposomal doxorubicin (PLD) at 40mg/m 2 versus 50mg/m 2 every month for patients with metastatic breast cancer: A comparative analysis of two prospective phase II studies. Journal of Clinical Oncology 23(16_Suppl): 700-700
Mahmoudi, N.; Reed, L.; Moix, A.; Alshammari, N.; Hestekin, J.; Servoss, S.L. 2017: PEG-mimetic peptoid reduces protein fouling of polysulfone hollow fibers. Colloids and Surfaces. B Biointerfaces 149: 23-29
Radhakrishnan, A.; Jose, G.M.; Kurup, M. 2015: PEG-penetrated chitosan-alginate co-polysaccharide-based partially and fully cross-linked hydrogels as ECM mimic for tissue engineering applications. Progress in Biomaterials 4(2-4): 101-112
Lv, S.; Tang, Z.; Li, M.; Song, W.; Chen, X. 2015: PEG-polypeptide conjugated with LHRH as an efficient vehicle for targeted delivery of doxorubicin to breast cancer. Journal of Controlled Release: Official Journal of the Controlled Release Society 213: E99
Chan, I.H.; Wu, V.; Bilardello, M.; Jorgenson, B.; Bal, H.; McCauley, S.; Van Vlasselaer, P.; Mumm, J.B. 2016: PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO. Oncoimmunology 5(7): E1197458
Glyk, A.; Scheper, T.; Beutel, S. 2015: PEG-salt aqueous two-phase systems: an attractive and versatile liquid-liquid extraction technology for the downstream processing of proteins and enzymes. Applied Microbiology and Biotechnology 99(16): 6599-6616
Li, X.; Xiao, R.; Tembo, K.; Hao, L.; Xiong, M.; Pan, S.; Yang, X.; Yuan, W.; Xiong, J.; Zhang, Q. 2016: PEG10 promotes human breast cancer cell proliferation, migration and invasion. International Journal of Oncology 48(5): 1933-1942
He, H.; Ye, A.; Kim, H.; Kim, J. 2016: PEG3 Interacts with KAP1 through KRAB-A. Plos one 11(11): E0167541
Ye, A.; He, H.; Kim, J. 2016: PEG3 binds to H19-ICR as a transcriptional repressor. Epigenetics 11(12): 889-900
Li, S.; Pausch, H.; Venhoranta, H.; Adamowicz, K.; Andersson, M.; Zwierzchowski, L.; Kind, A.; Schnieke, A.; Flisikowski, K. 2016: PEG3 domain gene expression in maternal and foetal placenta in intrauterine growth restricted bovine foetuses. Animal Genetics 47(1): 106-109
Carrino, S.; Caon, M.; Angelini, L.; Mugellini, E.; Abou Khaled, O.; Orte, S.; Vargiu, E.; Coulson, N.; Serrano, J.é C.E.; Tabozzi, S.; Lafortuna, C.; Rizzo, G. 2014: PEGASO: a Personalised and Motivational ICT System to Empower Adolescents Towards Healthy Lifestyles. Studies in Health Technology and Informatics 207: 350-359
Špinar, Jřich.; Špinarová, L.; Vítovec, Jří. 2015: PEGASUS - Ticagrelor in secondary prevention on patients after a myocardial infarction. Vnitrni Lekarstvi 61(6): 511-515
De Luca, L. 2017: PEGASUS study: who would benefit from prolonged DUAL antiplatelet therapy?. Journal of Cardiovascular Medicine 18(Suppl 1): E100-E104
Eshel-Green, T.; Eliyahu, S.; Avidan-Shlomovich, S.; Bianco-Peled, H. 2016: PEGDA hydrogels as a replacement for animal tissues in mucoadhesion testing. International Journal of Pharmaceutics 506(1-2): 25-34
Garcia, J.é H.P.; Araújo Filho, A.ôn.H.d.; Braga, L.L.B.C.; Viana, C.F.G.; Rocha, T.D.S.; Pereira, K.B.ão. 2015: Pegylated Interferon and Ribavirin for Treatment of Recurrent Hepatitis C after Liver Transplantation: a Single-Liver Transplant Center Experience in Brazil. Arquivos de Gastroenterologia 52(3): 216-221
Jiang, Y.; Lu, H.; Chen, F.; Callari, M.; Pourgholami, M.; Morris, D.L.; Stenzel, M.H. 2016: PEGylated Albumin-Based Polyion Complex Micelles for Protein Delivery. Biomacromolecules 17(3): 808-817
Luan, J.; Liu, K.-K.; Tadepalli, S.; Jiang, Q.; Morrissey, J.J.; Kharasch, E.D.; Singamaneni, S. 2016: PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. Acs Applied Materials and Interfaces 8(36): 23509-23516
Perinelli, D.R.; Cespi, M.; Bonacucina, G.; Naylor, A.; Whitaker, M.; Lam, J.K.W.; Howdle, S.M.; Casettari, L.; Palmieri, G.F. 2016: PEGylated Biodegradable Polyesters for PGSS Microparticles Formulation: Processability, Physical and Release Properties. Current Drug Delivery 13(5): 673-681
Ivens, I.A.; Achanzar, W.; Baumann, A.; Brändli-Baiocco, A.; Cavagnaro, J.; Dempster, M.; Depelchin, B.O.; Rovira, A.R.I.; Dill-Morton, L.; Lane, J.H.; Reipert, B.M.; Salcedo, T.; Schweighardt, B.; Tsuruda, L.S.; Turecek, P.L.; Sims, J. 2015: PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicologic Pathology 43(7): 959-983
Akocak, S.; Alam, M.R.; Shabana, A.M.; Sanku, R.K.K.; Vullo, D.; Thompson, H.; Swenson, E.R.; Supuran, C.T.; Ilies, M.A. 2016: PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas. Journal of Medicinal Chemistry 59(10): 5077-5088
Abuchowski, A. 2016: PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and use in Patients. Advances in Experimental Medicine and Biology 876: 461-467
Rammohan, A.; Mishra, G.; Mahaling, B.; Tayal, L.; Mukhopadhyay, A.; Gambhir, S.; Sharma, A.; Sivakumar, S. 2016: PEGylated Carbon Nanocapsule: A Universal Reactor and Carrier for In Vivo Delivery of Hydrophobic and Hydrophilic Nanoparticles. Acs Applied Materials and Interfaces 8(1): 350-362
Palesch, D.; Boldt, F.; Müller, J.A.; Eisele, K.; Stürzel, C.M.; Wu, Y.; Münch, J.; Weil, T. 2016: PEGylated Cationic Serum Albumin for Boosting Retroviral Gene Transfer. Chembiochem: a European Journal of Chemical Biology 17(16): 1504-1508
Li, K.-C.; Chu, H.-C.; Lin, Y.; Tuan, H.-Y.; Hu, Y.-C. 2016: PEGylated Copper Nanowires as a Novel Photothermal Therapy Agent. Acs Applied Materials and Interfaces 8(19): 12082-12090
Zhou, S.-M.; Ma, D.-K.; Zhang, S.-H.; Wang, W.; Chen, W.; Huang, S.-M.; Yu, K. 2016: PEGylated Cu3BiS3 hollow nanospheres as a new photothermal agent for 980 nm-laser-driven photothermochemotherapy and a contrast agent for X-ray computed tomography imaging. Nanoscale 8(3): 1374-1382
Ito, T.; Takada, H.; Isobe, K.; Suzuki, M.; Kitaura, Y.; Hemmi, H.; Matsuda, T.; Sasabe, J.; Yoshimura, T. 2015: PEGylated D-serine dehydratase as a D-serine reducing agent. Journal of Pharmaceutical and Biomedical Analysis 116: 34-39
She, W.; Pan, D.; Luo, K.; He, B.; Cheng, G.; Zhang, C.; Gu, Z. 2015: PEGylated Dendrimer-Doxorubicin Cojugates as pH-Sensitive Drug Delivery Systems: Synthesis and in Vitro Characterization. Journal of Biomedical Nanotechnology 11(6): 964-978
Sahu, N.K.; Gupta, J.; Bahadur, D. 2015: PEGylated FePt-Fe3O4 composite nanoassemblies (CNAs): in vitro hyperthermia, drug delivery and generation of reactive oxygen species (ROS). Dalton Transactions 44(19): 9103-9113
Zhang, P.; Huang, Y.; Kwon, Y.T.; Li, S. 2015: PEGylated Fmoc-Amino Acid Conjugates as Effective Nanocarriers for Improved Drug Delivery. Molecular Pharmaceutics 12(5): 1680-1690
Akbarzadehlaleh, P.; Mirzaei, M.; Mashahdi-Keshtiban, M.; Shamsasenjan, K.; Heydari, H. 2016: PEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization Methods. Advanced Pharmaceutical Bulletin 6(3): 309-317
Khan, U.T.; Tanasescu, R.; Constantinescu, C.S. 2015: PEGylated IFNβ-1a in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy 15(7): 1077-1084
Chan, I.H.; Van Hoof, D.; Abramova, M.; Bilardello, M.; Mar, E.; Jorgensen, B.; McCauley, S.; Bal, H.; Oft, M.; Van Vlasselaer, P.; Mumm, J.B. 2016: PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia. Plos one 11(6): E0156229
Dzieciuch, M.; Rissanen, S.; Szydłowska, N.; Bunker, A.; Kumorek, M.; Jamróz, D.; Vattulainen, I.; Nowakowska, M.; Róg, T.; Kepczynski, M. 2015: PEGylated Liposomes as Carriers of Hydrophobic Porphyrins. Journal of Physical Chemistry. B 119(22): 6646-6657
MacLeod, M.J.; Johnson, J.A. 2015: PEGylated N-Heterocyclic Carbene Anchors Designed To Stabilize Gold Nanoparticles in Biologically Relevant Media. Journal of the American Chemical Society 137(25): 7974-7977
Ni, D.; Zhang, J.; Bu, W.; Zhang, C.; Yao, Z.; Xing, H.; Wang, J.; Duan, F.; Liu, Y.; Fan, W.; Feng, X.; Shi, J. 2016: PEGylated NaHoF4 nanoparticles as contrast agents for both X-ray computed tomography and ultra-high field magnetic resonance imaging. Biomaterials 76: 218-225
Colombo, C.; Morosi, L.; Bello, E.; Ferrari, R.; Licandro, S.Andrea.; Lupi, M.; Ubezio, P.; Morbidelli, M.; Zucchetti, M.; D'Incalci, M.; Moscatelli, D.; Frapolli, R. 2016: PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics 13(1): 40-46
Luong, D.; Kesharwani, P.; Deshmukh, R.; Mohd Amin, M.C.I.; Gupta, U.; Greish, K.; Iyer, A.K. 2016: PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomaterialia 43: 14-29
Sánchez-López, E.; Egea, M.A.; Cano, A.; Espina, M.; Calpena, A.C.; Ettcheto, M.; Camins, A.; Souto, E.B.; Silva, A.M.; García, M.L. 2016: PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. Colloids and Surfaces. B Biointerfaces 145: 241-250
Wu, H.; Huang, J. 2016: PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging. Current Protein and Peptide Science 17(6): 582-595
Jiang, Y.; Lv, L.; Shi, H.; Hua, Y.; Lv, W.; Wang, X.; Xin, H.; Xu, Q. 2016: PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma. Colloids and Surfaces. B Biointerfaces 147: 242-249
Wongpinyochit, T.; Uhlmann, P.; Urquhart, A.J.; Seib, F.Philipp. 2015: PEGylated Silk Nanoparticles for Anticancer Drug Delivery. Biomacromolecules 16(11): 3712-3722
Scheeren, Lís.E.; Nogueira, D.R.; Macedo, Lícia.B.; Vinardell, M.Pilar.; Mitjans, M.; Infante, M.Rosa.; Rolim, C.M.B. 2016: PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release. Colloids and Surfaces. B Biointerfaces 138: 117-127
Kooijmans, S.A.A.; Fliervoet, L.A.L.; van der Meel, R.; Fens, M.H.A.M.; Heijnen, H.F.G.; van Bergen En Henegouwen, P.M.P.; Vader, P.; Schiffelers, R.M. 2016: PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. Journal of Controlled Release: Official Journal of the Controlled Release Society 224: 77-85
Byeon, H.J.; Kim, I.; Choi, J.S.; Lee, E.S.; Shin, B.S.; Youn, Y.S. 2015: PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy. International Journal of Nanomedicine 10: 739-748
Dal Bosco, L.; Weber, G.E.B.; Parfitt, G.M.; Paese, K.; Gonçalves, C.O.F.; Serodre, T.M.; Furtado, C.íd.A.; Santos, A.P.; Monserrat, J.é M.; Barros, D.M. 2015: PEGylated carbon nanotubes impair retrieval of contextual fear memory and alter oxidative stress parameters in the rat hippocampus. Biomed Research International 2015: 104135
Fraga, M.; Bruxel, F.; Diel, D.; de Carvalho, T.G.; Perez, C.A.; Magalhães-Paniago, R.ér.; Malachias, Ân.; Oliveira, M.ôn.C.; Matte, U.; Teixeira, H.F. 2015: PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type i murine model. Journal of Controlled Release: Official Journal of the Controlled Release Society 209: 37-46
Jones, C.H.; Chen, C.-K.; Chen, M.; Ravikrishnan, A.; Zhang, H.; Gollakota, A.; Chung, T.; Cheng, C.; Pfeifer, B.A. 2015: PEGylated cationic polylactides for hybrid biosynthetic gene delivery. Molecular Pharmaceutics 12(3): 846-856
Li, H.; Yang, Z-You.; Liu, C.; Zeng, Y-Ping.; Hao, Y-Hui.; Gu, Y.; Wang, W-Dong.; Li, R. 2015: PEGylated ceria nanoparticles used for radioprotection on human liver cells under γ-ray irradiation. Free Radical Biology and Medicine 87: 26-35
Agrawal, S.; Ahmad, H.; Dwivedi, M.; Shukla, M.; Arya, A.; Sharma, K.; Lal, J.; Dwivedi, A.Kumar. 2016: PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy. Nanomedicine 11(16): 2147-2169
Liu, G.; Li, K.; Luo, Q.; Wang, H.; Zhang, Z. 2017: PEGylated chitosan protected silver nanoparticles as water-borne coating for leather with antibacterial property. Journal of Colloid and Interface Science 490: 642-651
Sun, Z.; Tong, G.; Kim, T.H.; Ma, N.; Niu, G.; Cao, F.; Chen, X. 2015: PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction. Theranostics 5(3): 240-250
Abdelrasoul, G.N.; Magrassi, R.; Dante, S.; d'Amora, M.; d'Abbusco, M.S.; Pellegrino, T.; Diaspro, A. 2016: PEGylated gold nanorods as optical trackers for biomedical applications: an in vivo and in vitro comparative study. Nanotechnology 27(25): 255101
Xu, H.; Fan, M.; Elhissi, A.M.A.; Zhang, Z.; Wan, K.-W.; Ahmed, W.; Phoenix, D.A.; Sun, X. 2015: PEGylated graphene oxide for tumor-targeted delivery of paclitaxel. Nanomedicine 10(8): 1247-1262
Fahrländer, E.; Schelhaas, S.; Jacobs, A.H.; Langer, K. 2015: PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology 26(14): 145103
Chen, C.; Zheng, P.; Cao, Z.; Ma, Y.; Li, J.; Qian, H.; Tao, W.; Yang, X. 2016: PEGylated hyperbranched polyphosphoester based nanocarriers for redox-responsive delivery of doxorubicin. Biomaterials Science 4(3): 412-417
Landersdorfer, C.B.; Caliph, S.M.; Shackleford, D.M.; Ascher, D.B.; Kaminskas, L.M. 2015: PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice. Journal of Pharmaceutical Sciences 104(5): 1848-1855
Choi, J.Yeon.; Ramasamy, T.; Kim, S.Yub.; Kim, J.; Ku, S.Kwang.; Youn, Y.Seok.; Kim, J-Ryong.; Jeong, J-Heon.; Choi, H-Gon.; Yong, C.Soon.; Kim, J.Oh. 2016: PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. Acta Biomaterialia 39: 94-105
Shavi, G.V.; Sreenivasa Reddy, M.; Raghavendra, R.; Nayak, U.Y.; Kumar, A.R.; Deshpande, P.B.; Udupa, N.; Behl, G.; Dave, V.; Kushwaha, K. 2016: PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. Journal of Liposome Research 26(1): 28-46
Lee, W.; Park, E.J.; Kwak, S.; Kim, Y.; Na, D.H.; Bae, J.-S. 2015: PEGylated lysozymes with anti-septic effects in human endothelial cells and in mice. Biochemical and Biophysical Research Communications 459(4): 662-667
Zhao, Q.; Wang, C.; Liu, Y.; Wang, J.; Gao, Y.; Zhang, X.; Jiang, T.; Wang, S. 2014: PEGylated mesoporous silica as a redox-responsive drug delivery system for loading thiol-containing drugs. International Journal of Pharmaceutics 477(1-2): 613-622
Diou, O.; Brûlet, A.; Pehau-Arnaudet, G.ér.; Morvan, E.; Berti, R.; Astafyeva, K.; Taulier, N.; Fattal, E.; Tsapis, N. 2016: PEGylated nanocapsules of perfluorooctyl bromide: Mechanism of formation, influence of polymer concentration on morphology and mechanical properties. Colloids and Surfaces. B Biointerfaces 146: 762-769
Hwang, H.; Jeong, H.-S.; Oh, P.-S.; Kim, M.; Lee, T.-K.; Kwon, J.; Kim, H.-S.; Lim, S.T.; Sohn, M.-H.; Jeong, H.-J. 2016: PEGylated nanoliposomes encapsulating angiogenic peptides improve perfusion defects: Radionuclide imaging-based study. Nuclear Medicine and Biology 43(9): 552-558
He, R-Xi.; Ye, X.; Li, R.; Chen, W.; Ge, T.; Huang, T-Qing.; Nie, X-Jiang.; Chen, H-Jun-Tao.; Peng, D-Yin.; Chen, W-Dong. 2017: PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. Journal of Liposome Research 27(2): 161-170
Marslin, G.; Revina, A.Mary.; Khandelwal, V.Kumar.Megraj.; Balakumar, K.; Sheeba, C.J.; Franklin, G. 2015: PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens. Colloids and Surfaces. B Biointerfaces 132: 62-70
Omolo, C.A.; Kalhapure, R.S.; Jadhav, M.; Rambharose, S.; Mocktar, C.; Ndesendo, V.M.K.; Govender, T. 2017: Pegylated oleic acid: a promising amphiphilic polymer for nano-antibiotic delivery. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 112: 96-108
Ma, Y.; Zhang, W.; Wang, Z.; Wang, Z.; Xie, Q.; Niu, H.; Guo, H.; Yuan, Y.; Liu, C. 2016: PEGylated poly(glycerol sebacate)-modified calcium phosphate scaffolds with desirable mechanical behavior and enhanced osteogenic capacity. Acta Biomaterialia 44: 110-124
Zhou, B.; Xiong, Z.; Zhu, J.; Shen, M.; Tang, G.; Peng, C.; Shi, X. 2016: PEGylated polyethylenimine-entrapped gold nanoparticles loaded with gadolinium for dual-mode CT/MR imaging applications. Nanomedicine 11(13): 1639-1652
Zhou, B.; Yang, J.; Peng, C.; Zhu, J.; Tang, Y.; Zhu, X.; Shen, M.; Zhang, G.; Shi, X. 2016: PEGylated polyethylenimine-entrapped gold nanoparticles modified with folic acid for targeted tumor CT imaging. Colloids and Surfaces. B Biointerfaces 140: 489-496
Kim, J.; Ramasamy, T.; Choi, J.Y.; Kim, S.T.; Youn, Y.S.; Choi, H.-G.; Yong, C.S.; Kim, J.O. 2017: PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer. Colloids and Surfaces. B Biointerfaces 150: 393-401
Qi, K.K.; Wu, J.; Deng, B.; Li, Y.M.; Xu, Z.W. 2015: PEGylated porcine glucagon-like peptide-2 improved the intestinal digestive function and prevented inflammation of weaning piglets challenged with LPS. Animal: An International Journal of Animal Bioscience 9(9): 1481-1489
Mayolo-Deloisa, K.; González-Valdez, Jé.; Rito-Palomares, M. 2016: PEGylated protein separation using different hydrophobic interaction supports: Conventional and monolithic supports. Biotechnology Progress 32(3): 702-707
Belletti, D.; Tosi, G.; Forni, F.; Lagreca, I.; Barozzi, P.; Pederzoli, F.; Vandelli, M.A.; Riva, G.; Luppi, M.; Ruozi, B. 2016: PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: in vitro evidences of antitumoral activity. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 99: 7-17
Gaudin, A.; Song, E.; King, A.R.; Saucier-Sawyer, J.K.; Bindra, R.; Desmaële, D.; Couvreur, P.; Saltzman, W.Mark. 2016: PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 105: 136-144
Abu-Fayyad, A.; Behery, F.; Sallam, A.A.; Alqahtani, S.; Ebrahim, H.; El Sayed, K.A.; Kaddoumi, A.; Sylvester, P.W.; Carroll, J.L.; Cardelli, J.A.; Nazzal, S. 2015: PEGylated γ-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 96: 185-195
Bhattacharya, S.; Ahir, M.; Patra, P.; Mukherjee, S.; Ghosh, S.; Mazumdar, M.; Chattopadhyay, S.; Das, T.; Chattopadhyay, D.; Adhikary, A. 2015: PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials 51: 91-107
Song, I.T.; Lee, M.; Lee, H.; Han, J.; Jang, J.-H.; Lee, M.S.; Koh, G.Y.; Lee, H. 2016: PEGylation and HAylation via catechol: α-Amine-specific reaction at N-terminus of peptides and proteins. Acta Biomaterialia 43: 50-60
Zhang, L.; Liu, M.; Jamil, S.; Han, R.; Xu, G.; Ni, Y. 2015: PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida. Cancer Letters 357(1): 346-354
Suk, J.Soo.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L.M. 2016: PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews 99(Pt A): 28-51
Chan, L.J.; Bulitta, J.ür.B.; Ascher, D.B.; Haynes, J.M.; McLeod, V.M.; Porter, C.J.H.; Williams, C.C.; Kaminskas, L.M. 2015: PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. Molecular Pharmaceutics 12(3): 794-809
Altangerel, A.; Cai, J.; Liu, L.; Wu, Y.; Baigude, H.; Han, J. 2016: PEGylation of 6-amino-6-deoxy-curdlan for efficient in vivo siRNA delivery. Carbohydrate Polymers 141: 92-98
Turecek, P.L.; Bossard, M.J.; Schoetens, F.; Ivens, I.A. 2016: PEGylation of Biopharmaceuticals: a Review of Chemistry and Nonclinical Safety Information of Approved Drugs. Journal of Pharmaceutical Sciences 105(2): 460-475
Hashemi, M.; Ayatollahi, S.; Parhiz, H.; Mokhtarzadeh, A.; Javidi, S.; Ramezani, M. 2015: PEGylation of Polypropylenimine Dendrimer with Alkylcarboxylate Chain Linkage to Improve DNA Delivery and Cytotoxicity. Applied Biochemistry and Biotechnology 177(1): 1-17
Mendonça, M.C.P.; Soares, E.S.; de Jesus, M.B.; Ceragioli, H.J.é; Batista, Ân.G.; Nyúl-Tóth, Ád.ám.; Molnár, J.; Wilhelm, I.; Maróstica, M.ár.R.; Krizbai, I.án.; da Cruz-Höfling, M.A. 2016: PEGylation of Reduced Graphene Oxide Induces Toxicity in Cells of the Blood-Brain Barrier: An in Vitro and in Vivo Study. Molecular Pharmaceutics 13(11): 3913-3924
Sawhney, P.; Katare, K.; Sahni, G. 2016: PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes. Plos one 11(5): E0155831
Reichard, E.E.; Nanaware-Kharade, N.; Gonzalez, G.A.; Thakkar, S.; Owens, S.Michael.; Peterson, E.C. 2016: PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical Research 33(12): 2954-2966
Zhou, J.Q.; He, T.; Wang, J.W. 2016: PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase. Biotechnology Letters 38(7): 1121-1129
Lechanteur, A.; Furst, T.; Evrard, B.; Delvenne, P.; Hubert, P.; Piel, G.ér. 2016: PEGylation of lipoplexes: the right balance between cytotoxicity and siRNA effectiveness. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 93: 493-503
Jegatheeswaran, S.; Sundrarajan, M. 2015: PEGylation of novel hydroxyapatite/PEG/Ag nanocomposite particles to improve its antibacterial efficacy. Materials Science and Engineering. C Materials for Biological Applications 51: 174-181
Luo, T.; Loira-Pastoriza, C.; Patil, H.P.; Ucakar, B.; Muccioli, G.G.; Bosquillon, C.; Vanbever, R. 2016: PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. Journal of Controlled Release: Official Journal of the Controlled Release Society 239: 62-71
Benincasa, M.; Zahariev, S.; Pelillo, C.; Milan, A.; Gennaro, R.; Scocchi, M. 2015: PEGylation of the peptide Bac7(1-35) reduces renal clearance while retaining antibacterial activity and bacterial cell penetration capacity. European Journal of Medicinal Chemistry 95: 210-219
Lee, P.; Towslee, J.; Maia, J.ão.; Pokorski, J. 2015: PEGylation to Improve Protein Stability During Melt Processing. Macromolecular Bioscience 15(10): 1332-1337
Da-Silva-Freitas, D.éb.; Boldrini-França, J.; Arantes, E.C. 2015: PEGylation: a successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease. Protein and Peptide Letters 22(12): 1133-1139
Gawlinski, P.; Posmyk, R.; Gambin, T.; Sielicka, D.; Chorazy, M.; Nowakowska, B.; Jhangiani, S.N.; Muzny, D.M.; Bekiesinska-Figatowska, M.; Bal, J.; Boerwinkle, E.; Gibbs, R.A.; Lupski, J.R.; Wiszniewski, W. 2016: PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies. Pediatric Neurology 60: 83-87
Lv, J.; Hao, X.; Yang, J.; Feng, Y.; Behl, M.; Lendlein, A. 2015: PEi modified biodegradable complex micelles as gene transfer vector for proliferation of ECs. Journal of Controlled Release: Official Journal of the Controlled Release Society 213: E60
Moulton, D. 2016: PEi to finally offer abortions on the island. Cmaj: Canadian Medical Association Journal 188(9): E171
Li, Q.; Shi, C.; Fan, J.; Feng, Y. 2015: PEI-g-P(LA-co-MMD)-g-PEI nanoparticles as gene carriers to promote the proliferation of human vascular endothelial cells. Journal of Controlled Release: Official Journal of the Controlled Release Society 213: E89-E90
Nickchi, P.; Jafari, M.; Kalantari, S. 2015: PEIMAN 1.0: Post-translational modification Enrichment, Integration and Matching ANalysis. Database: the Journal of Biological Databases and Curation 2015: Bav037
Ohkubo, J.-I.; Hohchi, N.; Takeuchi, S.; Ikezaki, S.; Kise, Y.; Koizumi, H.; Suzuki, H. 2016: Treatment outcome of ion beam therapy in eight patients with head and neck cancers. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 273(12): 4397-4402
Chou, Y.-C.; Chang, M.-Y.; Wang, M.-J.; Harnod, T.; Hung, C.-H.; Lee, H.-T.; Shen, C.-C.; Chung, J.-G. 2015: PEITC induces apoptosis of Human Brain Glioblastoma GBM8401 Cells through the extrinsic- and intrinsic -signaling pathways. Neurochemistry International 81: 32-40
Chou, Y.-C.; Chang, M.-Y.; Wang, M.-J.; Yu, F.-S.; Liu, H.-C.; Harnod, T.; Hung, C.-H.; Lee, H.-T.; Chung, J.-G. 2015: PEITC inhibits human brain glioblastoma GBM 8401 cell migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 gene expression. Oncology Reports 34(5): 2489-2496
Gupta, P.; Wright, S.E.; Srivastava, S.K. 2015: PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth. Oncoimmunology 4(2): E981449
Yeomans, A.; Lemm, E.; Wilmore, S.; Cavell, B.E.; Valle-Argos, B.; Krysov, S.; Hidalgo, M.Sanchez.; Leonard, E.; Willis, A.E.; Forconi, F.; Stevenson, F.K.; Steele, A.J.; Coldwell, M.J.; Packham, G. 2016: PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells. Oncotarget 7(46): 74807-74819
Eisermann, D.é J.; Wenzel, U.; Fitzenberger, E. 2016: PEK-1 is crucial for hormesis induced by inhibition of the IRE-1/XBP-1 pathway in the Caenorhabditis elegans mev-1 mutant. Biochemical and Biophysical Research Communications 473(4): 1052-1057
Xu, X.; Qiu, S.; Zhang, Y.; Yin, J.; Min, S. 2017: PELA microspheres with encapsulated arginine-chitosan/pBMP-2 nanoparticles induce pBMP-2 controlled-release, transfected osteoblastic progenitor cells, and promoted osteogenic differentiation. Artificial Cells Nanomedicine and Biotechnology 45(2): 330-339
Meyer, A.; Schiemann, O. 2016: PELDOR and RIDME Measurements on a High-Spin Manganese(II) Bisnitroxide Model Complex. Journal of Physical Chemistry. a 120(20): 3463-3472
Borrelli, K.W.; Vitalis, A.; Alcantara, R.; Guallar, V. 2005: PELE:  Protein Energy Landscape Exploration. a Novel Monte Carlo Based Technique. Journal of Chemical Theory and Computation 1(6): 1304-1311
Van Bragt, S.; van den Bemt, L.; Cretier, R.; van Weel, C.; Merkus, P.; Schermer, T. 2016: PELICAN: Content evaluation of patient-centered care for children with asthma based on an online tool. Pediatric Pulmonology 51(10): 993-1003
Sareddy, G.R.; Vadlamudi, R.K. 2016: PELP1: Structure, biological function and clinical significance. Gene 585(1): 128-134
Martin, D.; Cockell, C.S. 2015: PELS (Planetary Environmental Liquid Simulator): a new type of simulation facility to study extraterrestrial aqueous environments. Astrobiology 15(2): 111-118
Zdanowski, P.ł; Królicki, L. 2016: PEM or MBI?. Annals of Nuclear Medicine 30(6): 450-451
Lumba-Brown, A.; Tat, S.; Auerbach, M.A.; Kessler, D.O.; Alletag, M.; Grover, P.; Schnadower, D.; Macias, C.G.; Chang, T.P. 2016: PEMNetwork: Barriers and Enablers to Collaboration and Multimedia Education in the Digital Age. Pediatric Emergency Care 32(8): 565-569
Moser, D.; Wittmann, S.K.; Kramer, J.; Blöcher, R.é; Achenbach, J.; Pogoryelov, D.; Proschak, E. 2015: PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H. Journal of Chemical Information and Modeling 55(2): 284-293
Keenan, P. 2016: PENNSYLVANIA Health Access Network Working to Expand Access. Pennsylvania Dental Journal 83(2): 29-31
Pernet, C.; Munoz, J.; Bessis, D. 2015: PENS (papular epidermal nevus with "skyline" basal cell layer). Annales de Dermatologie et de Venereologie 142(1): 41-45
Kirouac, N. 2016: PENS Position Statement on Transgender Youth. Journal of pediatric nursing 31(2): 230-231
Foote, J.M.; Kirouac, N.; Lipman, T.H. 2015: PENS position statement on linear growth measurement of children. Journal of pediatric nursing 30(2): 425-426
Rey-Rico, A.; Frisch, J.; Venkatesan, J.K.; Schmitt, G.; Rial-Hermida, I.; Taboada, P.; Concheiro, A.; Madry, H.; Alvarez-Lorenzo, C.; Cucchiarini, M. 2016: PEO-PPO-PEO Carriers for rAAV-Mediated Transduction of Human Articular Chondrocytes in Vitro and in a Human Osteochondral Defect Model. Acs Applied Materials and Interfaces 8(32): 20600-20613
Rey-Rico, A.; Venkatesan, J.K.; Frisch, J.; Rial-Hermida, I.; Schmitt, G.; Concheiro, A.; Madry, H.; Alvarez-Lorenzo, C.; Cucchiarini, M. 2015: PEO-PPO-PEO micelles as effective rAAV-mediated gene delivery systems to target human mesenchymal stem cells without altering their differentiation potency. Acta Biomaterialia 27: 42-52
Koliqi, R.; Dimchevska, S.; Geskovski, N.; Petruševski, G.; Chacorovska, M.; Pejova, B.; Hristov, D.R.; Ugarkovic, S.; Goracinova, K. 2016: PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions. Current Drug Delivery 13(3): 339-352
Pippa, N.; Deli, E.; Mentzali, E.; Pispas, S.; Demetzos, C. 2014: PEO-b-PCL grafted DPPC liposomes: physicochemical characterization and stability studies of novel bio-inspired advanced Drug Delivery nano Systems (aDDnSs). Journal of Nanoscience and Nanotechnology 14(8): 5676-5681
Jung, O.; Smeets, R.; Kopp, A.; Porchetta, D.; Hiester, P.; Heiland, M.; Friedrich, R.E.; Precht, C.; Hanken, H.; Gröbe, A.; Hartjen, P. 2016: PEO-generated Surfaces Support Attachment and Growth of Cells in Vitro with no Additional Benefit for Micro-roughness in Sa (0.2-4 μm). In Vivo 30(1): 27-33
Frencher, S.K.; Sharma, A.K.; Teklehaimanot, S.; Wadzani, D.; Ike, I.E.; Hart, A.; Norris, K. 2016: PEP Talk: Prostate Education Program, "Cutting Through the Uncertainty of Prostate Cancer for Black Men Using Decision Support Instruments in Barbershops". Journal of Cancer Education: the Official Journal of the American Association for Cancer Education 31(3): 506-513
Prati, G.; Zani, B.; Pietrantoni, L.; Scudiero, D.; Perone, P.; Cosmaro, L.; Cerioli, A.; Oldrini, M. 2016: PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social Correlates. Plos one 11(6): E0157339
Kim, D.W.; Lee, S.H.; Shin, M.J.; Kim, K.; Ku, S.K.; Youn, J.K.; Cho, S.B.; Park, J.H.; Lee, C.H.; Son, O.; Sohn, E.J.; Cho, S.-W.; Park, J.H.; Kim, H.A.; Han, K.H.; Park, J.; Eum, W.S.; Choi, S.Y. 2015: PEP-1-FK506BP inhibits alkali burn-induced corneal inflammation on the rat model of corneal alkali injury. Bmb Reports 48(11): 618-623
Hwang, H.S.; Park, I.Y.; Kim, D.W.; Choi, S.Y.; Jung, Y.O.; Kim, H.A. 2015: PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model. Bmb Reports 48(7): 407-412
Sohn, E.J.; Shin, M.J.; Kim, D.W.; Son, O.; Jo, H.S.; Cho, S.B.; Park, J.H.; Lee, C.H.; Yeo, E.J.; Choi, Y.J.; Yu, Y.H.; Kim, D.-S.; Cho, S.-W.; Kwon, O.S.; Cho, Y.-J.; Park, J.; Eum, W.S.; Choi, S.Y. 2016: PEP-1-GSTpi protein enhanced hippocampal neuronal cell survival after oxidative damage. Bmb Reports 49(7): 382-387
Wu, Y.; Xie, G.; Xu, Y.; Ma, L.; Tong, C.; Fan, D.; Du, F.; Yu, H. 2015: PEP-1-MsrA ameliorates inflammation and reduces atherosclerosis in apolipoprotein e deficient mice. Journal of Translational Medicine 13: 316
Eo, S.-H.; Kim, D.W.; Choi, S.Y.; Kim, H.A.; Kim, S.-J. 2015: PEP-1-SIRT2 causes dedifferentiation and COX-2 expression via the MAPK pathways in rabbit articular chondrocytes. Experimental Cell Research 339(2): 351-359
Eo, S.-H.; Choi, S.Y.; Kim, S.J. 2016: PEP-1-SIRT2-induced matrix metalloproteinase-1 and -13 modulates type Ii collagen expression via ERK signaling in rabbit articular chondrocytes. Experimental Cell Research 348(2): 201-208
Tan, L.-G.; Xiao, J.-H.; Yu, D.-L.; Zhang, L.; Zheng, F.; Guo, L.-Y.; Yang, J.-Y.; Tang, J.-M.; Chen, S.-Y.; Wang, J.-N. 2015: PEP-1-SOD1 fusion proteins block cardiac myofibroblast activation and angiotensin II-induced collagen production. Bmc Cardiovascular Disorders 15: 116
Lamiable, A.; Thévenet, P.; Rey, J.; Vavrusa, M.; Derreumaux, P.; Tufféry, P. 2016: PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Research 44(W1): W449-W454
Biyani, M.; Kawai, K.; Kitamura, K.; Chikae, M.; Biyani, M.; Ushijima, H.; Tamiya, E.; Yoneda, T.; Takamura, Y. 2016: PEP-on-DEP: a competitive peptide-based disposable electrochemical aptasensor for renin diagnostics. Biosensors and Bioelectronics 84: 120-125
Ding, J.; Holzwarth, G.; Bradford, C.S.; Cooley, B.; Yoshinaga, A.S.; Patton-Vogt, J.; Abeliovich, H.; Penner, M.H.; Bakalinsky, A.T. 2015: PEP3 overexpression shortens lag phase but does not alter growth rate in Saccharomyces cerevisiae exposed to acetic acid stress. Applied Microbiology and Biotechnology 99(20): 8667-8680
Montal, E.D.; Dewi, R.; Bhalla, K.; Ou, L.; Hwang, B.J.; Ropell, A.E.; Gordon, C.; Liu, W.-J.; DeBerardinis, R.J.; Sudderth, J.; Twaddel, W.; Boros, L.G.; Shroyer, K.R.; Duraisamy, S.; Drapkin, R.; Powers, R.S.; Rohde, J.M.; Boxer, M.B.; Wong, K.-K.; Girnun, G.D. 2015: PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Molecular Cell 60(4): 571-583
Leithner, K. 2015: PEPCK in cancer cell starvation. Oncoscience 2(10): 805-806
Semakova, J.; Hyroššová, P.; Méndez-Lucas, A.és.; Cutz, E.; Bermudez, J.; Burgess, S.; Alcántara, S.; Perales, J.é C. 2017: PEPCK-C reexpression in the liver counters neonatal hypoglycemia in Pck1 del/del mice, unmasking role in non-gluconeogenic tissues. Journal of Physiology and Biochemistry 73(1): 89-98
Chibaudel, B.; Maindrault-Gœbel, Fédérique.; Bachet, J-Baptiste.; Louvet, C.; Khalil, A.; Dupuis, O.; Hammel, P.; Garcia, M-Line.; Bennamoun, M.; Brusquant, D.; Tournigand, C.; André, T.; Arbaud, C.; Larsen, A.K.; Wang, Y-Wen.; Yeh, C.Grace.; Bonnetain, F.; de Gramont, A. 2016: PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Medicine 5(4): 676-683
Fätkenheuer, G.; Jessen, H.; Stoehr, A.; Jung, N.; Jessen, A.B.; Kümmerle, T.; Berger, M.; Bogner, J.R.; Spinner, C.D.; Stephan, C.; Degen, O.; Vogelmann, R.; Spornraft-Ragaller, P.; Schnaitmann, E.; Jensen, B.; Ulmer, A.; Kittner, J.M.; Härter, G.; Malfertheiner, P.; Rockstroh, J.; Knecht, G.; Scholten, S.; Harrer, T.; Kern, W.V.; Salzberger, B.; Schürmann, D.; Ranneberg, B. 2016: PEPDar: a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis. HIV Medicine 17(6): 453-459
Wagner, Z.; Barofsky, J.; Sood, N. 2015: PEPFAR Funding Associated with An Increase in Employment Among Males in Ten Sub-Saharan African Countries. Health Affairs 34(6): 946-953
Chin, R.J.; Sangmanee, D.; Piergallini, L. 2015: PEPFAR Funding and Reduction in HIV Infection Rates in 12 Focus Sub-Saharan African Countries: a Quantitative Analysis. International Journal of Mch and Aids 3(2): 150-158
Moucheraud, C.; Sparkes, S.; Nakamura, Y.; Gage, A.; Atun, R.; Bossert, T.J. 2016: PEPFAR Investments In Governance And Health Systems Were One-Fifth Of Countries' Budgeted Funds, 2004-14. Health Affairs 35(5): 847-855
Vogus, A.; Graff, K. 2015: PEPFAR Transitions to Country Ownership: Review of past Donor Transitions and Application of Lessons Learned to the Eastern Caribbean. Global Health Science and Practice 3(2): 274-286
Barnhart, S. 2016: PEPFAR: is 90-90-90 magical thinking?. Lancet 387(10022): 943-944
Zhang, W.; Dai, X.; Wang, Q.; Xu, S.; Zhao, P.X. 2016: PEPIS: A Pipeline for Estimating Epistatic Effects in Quantitative Trait Locus Mapping and Genome-Wide Association Studies. Plos Computational Biology 12(5): E1004925
Olson, N.D.; Zook, J.M.; Samarov, D.V.; Jackson, S.A.; Salit, M.L. 2016: PEPR: pipelines for evaluating prokaryotic references. Analytical and Bioanalytical Chemistry 408(11): 2975-2983
Tang, D.; Zhou, J-Min. 2016: PEPRs spice up plant immunity. EMBO Journal 35(1): 4-5
Neveu, E.; Ritchie, D.W.; Popov, P.; Grudinin, S. 2016: PEPSI-Dock: a detailed data-driven protein-protein interaction potential accelerated by polar Fourier correlation. Bioinformatics 32(17): I693-I701
Zhu, B.-H.; Song, Y.-N.; Xue, W.; Xu, G.-C.; Xiao, J.; Sun, M.-Y.; Sun, X.-W.; Li, J.-T. 2016: PEP_scaffolder: using (homologous) proteins to scaffold genomes. Bioinformatics 32(20): 3193-3195
Singh, S.; Singh, H.; Tuknait, A.; Chaudhary, K.; Singh, B.; Kumaran, S.; Raghava, G.P.S. 2015: PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues. Biology Direct 10: 73
Baranger, D.A.A.; Ifrah, C.é; Prather, A.A.; Carey, C.E.; Corral-Frías, N.S.; Drabant Conley, E.; Hariri, A.R.; Bogdan, R. 2016: PER1 rs3027172 Genotype Interacts with Early Life Stress to Predict Problematic Alcohol Use, but not Reward-Related Ventral Striatum Activity. Frontiers in Psychology 7: 464
Qin, X.; Mori, T.; Zhang, Y.; Johnson, C.Hirschie. 2015: PER2 Differentially Regulates Clock Phosphorylation versus Transcription by Reciprocal Switching of CK1ε Activity. Journal of Biological Rhythms 30(3): 206-216
Freund, Y.; Rousseau, A.; Guyot-Rousseau, F.; Claessens, Y.-E.; Hugli, O.; Sanchez, O.; Simon, T.; Riou, B. 2015: PERC rule to exclude the diagnosis of pulmonary embolism in emergency low-risk patients: study protocol for the PROPER randomized controlled study. Trials 16: 537
Ganz, A.; Schafer, J.M.; Tao, Y.; Wilson, C.; Robertson, M. 2014: PERCEPT-II: smartphone based indoor navigation system for the blind. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2014: 3662-3665
Wu, M.; Guan, J.; Xiao, Y.; Zhou, J.; Dai, X.; Wang, X.; Wang, Z.; Chen, X. 2015: Percutaneous Kirschner Wire Poking Reduction and Elastic Stable Intramedullary Nailing Fixation for Severe Displaced Radial Neck Fractures in Children. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 29(12): 1478-1482
Garg, P. 2016: PERFACT procedure to treat supralevator fistula-in-ano: a novel single stage sphincter sparing procedure. World Journal of Gastrointestinal Surgery 8(4): 326-334
Garg, P.; Garg, M. 2015: PERFACT procedure: a new concept to treat highly complex anal fistula. World Journal of Gastroenterology 21(13): 4020-4029
Ali, F.R.; Ghura, V. 2014: PERFECT-ing technique prior to facial reconstructive surgery: a convenient, inexpensive aid to dermatologic surgical teaching. Journal of the American Academy of Dermatology 71(5): E203-E204
Shah, C.M.; Gentile, R.C.; Mehta, M.C. 2016: Perfluorocarbon Liquids' Ability to Protect the Macula from Intraocular Dropping of Metallic Foreign Bodies: a Model Eye Study. Retina 36(7): 1285-1291
Lopes, E.Gallucci.; Geraldo Junior, C.Alberto.; Marcili, A.; Silva, R.Duarte.; Keid, L.Borges.; Oliveira, Tícia.Maria.Ferreira.da.Silva.; Soares, R.Martins. 2016: Performance of Conventional Pcrs Based on Primers Directed to Nuclear and Mitochondrial Genes for the Detection and Identification of Leishmania Spp. Revista do Instituto de Medicina Tropical de Sao Paulo 58: 41
Lee, Y.; Won, Y.; Kang, K. 2017: Performance test Results of Active Personal Dosemeters (Apds) Used in Nuclaer Power Plant in Korea: A Comparison with Thermo-Luminescence Dosemeters (Tlds). Radiation protection dosimetry 174(3): 431-437
Moore, A. 2015: Performance. how to Hit the A&e Target. Health Service Journal 125(6442): 22-25
Zhu, X.; Leung, H.C.M.; Chin, F.Y.L.; Yiu, S.M.; Quan, G.; Liu, B.; Wang, Y. 2014: PERGA: a paired-end read guided de novo assembler for extending contigs using SVM and look ahead approach. Plos one 9(12): E114253
Schwabe, T.; Sneskov, K.; Haugaard Olsen, J.óg.M.; Kongsted, J.; Christiansen, O.; Hättig, C. 2012: PERI-CC2: a Polarizable Embedded RI-CC2 Method. Journal of Chemical Theory and Computation 8(9): 3274-3283
Hong, C-Tai.; Wong, C-Shun.; Ma, H-Ping.; Wu, D.; Huang, Y-Hsien.; Wu, C-Che.; Lin, C-Min.; Su, Y-Kai.; Liao, K-Hsing.; Ou, J-Chi.; Hu, C-Jong. 2015: PERIOD3 polymorphism is associated with sleep quality recovery after a mild traumatic brain injury. Journal of the Neurological Sciences 358(1-2): 385-389
Wagley, S.; Marra, K.V.; Salhi, R.A.; Gautam, S.; Campo, R.; Veale, P.; Veale, J.; Arroyo, J.G. 2015: Periodontal Disease and Age-Related Macular Degeneration: Results from the National Health and Nutrition Examination Survey Iii. Retina 35(5): 982-988
Iqbal, N.; Hussain, M.; Idress, R.; Irfan, M. 2017: Disseminated hydatid cyst of liver and lung. BMJ Case Reports
Yun, C.; Oh, J.; Han, J.Y.; Hwang, S.-Y.; Moon, S.W.; Huh, K. 2015: Peripapillary Choroidal Thickness in Central Serous Chorioretinopathy: Is Choroid outside the Macula also Thick?. Retina 35(9): 1860-1866
Habib, A.M.; Elkitkat, R.S.; Saleh, M.I.; Abd El-Salam, M.M. 2016: Peripheral Avascular Retina with Disk Anomaly and high Myopia: A Novel Association in a Hereditary Isolated Ocular Disorder. Retina 36(2): 408-414
Agrawal, R.; Gunasekeran, D.V.; Gonzalez-Lopez, J.J.; Cardoso, J.; Gupta, B.; Addison, P.K.F.; Westcott, M.; Pavesio, C.E. 2017: Peripheral Retinal Vasculitis: Analysis of 110 Consecutive Cases and a Contemporary Reappraisal of Tubercular Etiology. Retina 37(1): 112-117
Ho, Y.; Li, X.; Jamison, S.; Harding, H.P.; McKinnon, P.J.; Ron, D.; Lin, W. 2016: PERK Activation Promotes Medulloblastoma Tumorigenesis by Attenuating Premalignant Granule Cell Precursor Apoptosis. American Journal of Pathology 186(7): 1939-1951
Bu, Y.; Diehl, J.A. 2016: PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. Journal of Cellular Physiology 231(10): 2088-2096
Zhang, Z.; Su, W.Y.; Owler, P.B.K. 2018: Disseminated Mycobacterium abscessus infection with spondylodiscitis of thoracic spine. Journal of Surgical Case Reports 6: Rjy141
Zhu, S.; Henninger, K.; McGrath, B.C.; Cavener, D.R. 2016: PERK Regulates Working Memory and Protein Synthesis-Dependent Memory Flexibility. Plos one 11(9): E0162766
Radford, H.; Moreno, J.A.; Verity, N.; Halliday, M.; Mallucci, G.R. 2015: PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathologica 130(5): 633-642
Philippe, Céline.; Dubrac, A.; Quelen, C.; Desquesnes, A.; Van Den Berghe, L.; Ségura, Cèle.; Filleron, T.; Pyronnet, Séphane.; Prats, Hé.; Brousset, P.; Touriol, C. 2016: PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress. Science Signaling 9(426): Ra44
Liu, J.; Du, L. 2015: PERK pathway is involved in oxygen-glucose-serum deprivation-induced NF-kB activation via ROS generation in spinal cord astrocytes. Biochemical and Biophysical Research Communications 467(2): 197-203
Zhu, S.; McGrath, B.C.; Bai, Y.; Tang, X.; Cavener, D.R. 2016: PERK regulates Gq protein-coupled intracellular Ca2+ dynamics in primary cortical neurons. Molecular Brain 9(1): 87
Yang, S.-Y.; Wei, F.-L.; Hu, L.-H.; Wang, C.-L. 2016: PERK-eIF2α-ATF4 pathway mediated by endoplasmic reticulum stress response is involved in osteodifferentiation of human periodontal ligament cells under cyclic mechanical force. Cellular Signalling 28(8): 880-886
Ji, G.-r.; Yu, N.-c.; Xue, X.; Li, Z.-g. 2015: PERK-mediated Autophagy in Osteosarcoma Cells Resists ER Stress-induced Cell Apoptosis. International Journal of Biological Sciences 11(7): 803-812
Bell, M.C.; Meier, S.E.; Ingram, A.L.; Abisambra, J.F. 2016: PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration. Current Alzheimer Research 13(2): 150-163
Wang, Y.; Kuramitsu, Y.; Baron, B.; Kitagawa, T.; Akada, J.; Tokuda, K.; Cui, D.; Nakamura, K. 2015: PERK/CHOP contributes to the CGK733-induced vesicular calcium sequestration which is accompanied by non-apoptotic cell death. Oncotarget 6(28): 25252-25265
Tang, Z-Zheng.; Chen, G.; Alekseyenko, A.V. 2016: PERMANOVA-S: association test for microbial community composition that accommodates confounders and multiple distances. Bioinformatics 32(17): 2618-2625
Jones, A.M.; Atkinson, J.T.; Silberg, J.J. 2017: PERMutation Using Transposase Engineering (PERMUTE): a Simple Approach for Constructing Circularly Permuted Protein Libraries. Methods in Molecular Biology 1498: 295-308
Declerck, S.ép.; Willems, A.; van der Heijden, M.G.A.; Varese, G.C.; Turkovskaya, O.; Evtushenko, L.; Ivshina, I.; Desmeth, P. 2015: PERN: an EU-Russia initiative for rhizosphere microbial resources. Trends in Biotechnology 33(7): 377-380
Hallstrom, K.N.; Srikanth, C.V.; Agbor, T.A.; Dumont, C.M.; Peters, K.N.; Paraoan, L.; Casanova, J.E.; Boll, E.J.; McCormick, B.A. 2015: PERP, a host tetraspanning membrane protein, is required for Salmonella-induced inflammation. Cellular Microbiology 17(6): 843-859
Buonaiuto, G.; De Mori, V.; Braus, A.; Balini, A.; Berzi, D.; Carpinteri, R.; Forloni, F.; Meregalli, G.; Ronco, G.Luca.; Bossi, A.C. 2016: PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. Bmj Open Diabetes Research and Care 4(1): E000216
Sitjar Martínez de Sas, S.; Aguilera de la Fuente, Mía.Teresa.; Combalía Romera, J.; Menacho Pascual, I.; González Martínez, S.; Altés Boronat, A. 2016: PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis. Atencion Primaria 48(5): 316-324
Salas-Prato, M.; Selye, H. 2014: Personal Recollections of Dr. Hans Selye and of his Institut de Mèdecine et de Chirurgie Expèrimentales (Imce). Ideggyogyaszati Szemle 67(3-4): 81-86
Chaibub Neto, E.; Bot, B.M.; Perumal, T.; Omberg, L.; Guinney, J.; Kellen, M.; Klein, A.; Friend, S.H.; Trister, A.D. 2016: Personalized Hypothesis tests for Detecting Medication Response in Parkinson Disease Patients using Iphone Sensor Data. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 21: 273-284
Mestre, J.é M.; Larrán, C.; Herrero, J.ín.; Guil, R.ío.; de la Torre, G.G. 2015: PERVALE-S: a new cognitive task to assess deaf people's ability to perceive basic and social emotions. Frontiers in Psychology 6: 1148
Nady, N. 2016: PES Surface Modification Using Green Chemistry: new Generation of Antifouling Membranes. Membranes 6(2)
Ghaemi, N.; Madaeni, S.S.; Daraei, P.; Rajabi, H.; Shojaeimehr, T.; Rahimpour, F.; Shirvani, B. 2015: PES mixed matrix nanofiltration membrane embedded with polymer wrapped MWCNT: Fabrication and performance optimization in dye removal by RSM. Journal of Hazardous Materials 298: 111-121
de Jong, Y.; Kouwenberg, J.; Boumans, L.; Hussey, C.; Hyam, R.; Nicolson, N.; Kirk, P.; Paton, A.; Michel, E.; Guiry, M.D.; Boegh, P.S.; Pedersen, H.Ærenlund.; Enghoff, H.; von Raab-Straube, E.; Güntsch, A.; Geoffroy, M.; Müller, A.; Kohlbecker, A.; Berendsohn, W.; Appeltans, W.; Arvanitidis, C.; Vanhoorne, B.; Declerck, J.; Vandepitte, L.; Hernandez, F.; Nash, Róisín.; Costello, M.John.; Ouvrard, D.; Bezard-Falgas, P.; Bourgoin, T.; Wetzel, F.Tobias.; Glöckler, F.; Korb, Günther.; Ring, C.; Hagedorn, G.; Häuser, C.; Aktaç, N.; Asan, A.; Ardelean, A.; B 2015: PESI - a taxonomic backbone for Europe. Biodiversity Data Journal 2015(3): E5848
Potoyan, D.A.; Zheng, W.; Ferreiro, D.U.; Wolynes, P.G.; Komives, E.A. 2016: PEST Control of Molecular Stripping of NFκB from DNA Transcription Sites. Journal of Physical Chemistry. B 120(33): 8532-8538
Wang, K.; Zhang, Q.; Li, D.; Ching, K.; Zhang, C.; Zheng, X.; Ozeck, M.; Shi, S.; Li, X.; Wang, H.; Rejto, P.; Christensen, J.; Olson, P. 2015: PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(6): 1487-1496
Frey, K.A.; Koeppe, R.A. 2016: PET Amyloid Analyses. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(8): 1168-1169
Reske, S. 2006: PET Assessment of Lymphoma: Beyond (18)F-Fluorodeoxyglucose. Pet Clinics 1(3): 275-281
Lin, P.L.; Maiello, P.; Gideon, H.P.; Coleman, M.T.; Cadena, A.M.; Rodgers, M.A.; Gregg, R.; O'Malley, M.; Tomko, J.; Fillmore, D.; Frye, L.J.; Rutledge, T.; DiFazio, R.M.; Janssen, C.; Klein, E.; Andersen, P.L.; Fortune, S.M.; Flynn, J.L. 2016: PET CT Identifies Reactivation Risk in Cynomolgus Macaques with Latent M. tuberculosis. Plos Pathogens 12(7): E1005739
Paydaş, S.; Sargın, Öz.ğu.; Gönlüşen, G.ül. 2011: PET CT imaging in extramedullary hematopoiesis and lung cancer surprise in a case with thalassemia intermedia. Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology 28(1): 60-62
Levin, D.; Shalev, A.; Lantzberg, S. 2016: PET CT in a 54 years old patient with hepatic angiosarcoma and an incidental heart finding. Harefuah 155(4): 247-248
Lim, I.; Joung, H.-Y.; Yu, A.R.; Shim, I.; Kim, J.S. 2016: PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain. Biomed Research International 2016: 6945415
Liu, H.; Jin, H.; Yue, X.; Luo, Z.; Liu, C.; Rosenberg, A.J.; Tu, Z. 2016: PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. Molecular Imaging and Biology 18(5): 724-732
Sonni, I.; Iagaru, A. 2016: PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. Pet Clinics 11(3): 261-272
Dubroff, J.G.; Newberg, A.B. 2010: PET Imaging for Traumatic Brain Injury. Pet Clinics 5(2): 199-207
Hottinger, A.F.; Levivier, M.; Negretti, L.; Homicsko, K.; Stupp, R. 2013: PET Imaging in Glioma: the Neuro-Oncologist's Expectations. Pet Clinics 8(2): 117-128
Van Dijk, L.K.; Boerman, O.C.; Kaanders, J.H.A.M.; Bussink, J. 2015: PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: a Future Role for EGFR-Targeted Imaging. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(16): 3602-3609
Roussakis, A.-A.; Piccini, P. 2015: PET Imaging in Huntington's Disease. Journal of Huntington's Disease 4(4): 287-296
Becher, S.; Oskouei, S. 2015: PET Imaging in Sarcoma. Orthopedic Clinics of North America 46(3): 409
Shi, S.; Orbay, H.; Yang, Y.; Graves, S.A.; Nayak, T.R.; Hong, H.; Hernandez, R.; Luo, H.; Goel, S.; Theuer, C.P.; Nickles, R.J.; Cai, W. 2015: PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(6): 927-932
Hustinx, R.; Malaise, M.G. 2006: PET Imaging of Arthritis. Pet Clinics 1(2): 131-139
Evans, N.R.; Tarkin, J.M.; Chowdhury, M.M.; Warburton, E.A.; Rudd, J.H.F. 2016: PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology. Current Atherosclerosis Reports 18(6): 30
Lebron, L.; Greenspan, D.; Pandit-Taskar, N. 2015: PET Imaging of Breast Cancer: Role in Patient Management. Pet Clinics 10(2): 159-195
Lau, J.; Zhang, Z.; Jenni, S.; Kuo, H.-T.; Liu, Z.; Vullo, D.; Supuran, C.T.; Lin, K.-S.; Bénard, F.ço. 2016: PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides. Molecular Pharmaceutics 13(3): 1137-1146
Torres, J.B.ña.; Andreozzi, E.M.; Dunn, J.T.; Siddique, M.; Szanda, I.; Howlett, D.R.; Sunassee, K.; Blower, P.J. 2016: PET Imaging of Copper Trafficking in a Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(1): 109-114
Zhou, B.; Wang, H.; Liu, R.; Wang, M.; Deng, H.; Giglio, B.C.; Gill, P.S.; Shan, H.; Li, Z. 2015: PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B. Molecular Pharmaceutics 12(10): 3527-3534
Couto, P.J.; Millis, R.M. 2015: PET Imaging of Epigenetic Influences on Alzheimer's Disease. International Journal of Alzheimer's Disease 2015: 575078
Demoin, D.W.; Wyatt, L.C.; Edwards, K.J.; Abdel-Atti, D.; Sarparanta, M.; Pourat, J.; Longo, V.A.; Carlin, S.D.; Engelman, D.M.; Andreev, O.A.; Reshetnyak, Y.K.; Viola-Villegas, N.; Lewis, J.S. 2016: PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: a Structure-Activity Optimization Study. Bioconjugate Chemistry 27(9): 2014-2023
Alavi, A.; Zhuang, H. 2012: PET Imaging of Infection and Inflammation. Pet Clinics 7(2): Xi
Nahrendorf, M.; Swirski, F.K. 2015: PET Imaging of Leukocytes in Patients with Acute Myocardial Infarction. JACC. Cardiovascular Imaging 8(12): 1427-1429
Elstrom, R.L.; Schuster, S.J. 2012: PET Imaging of Lymphoma. Pet Clinics 7(1): Xiii
Blykers, A.; Schoonooghe, S.; Xavier, C.; D'hoe, K.; Laoui, D.; D'Huyvetter, M.; Vaneycken, I.; Cleeren, F.; Bormans, G.; Heemskerk, J.; Raes, G.; De Baetselier, P.; Lahoutte, T.; Devoogdt, N.; Van Ginderachter, J.A.; Caveliers, V. 2015: PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(8): 1265-1271
Tsukada, H.; Kanazawa, M.; Ohba, H.; Nishiyama, S.; Harada, N.; Kakiuchi, T. 2016: PET Imaging of Mitochondrial Complex i with 18F-BCPP-EF in the Brains of MPTP-Treated Monkeys. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(6): 950-953
Khan, S.; Win, Z.; Szyszko, T.; Lloyd, C.; Dunn, J.; Alavi, A.; Al-Nahhas, A. 2007: PET Imaging of Pheochromocytoma. Pet Clinics 2(3): 341-349
Beheshti, M.; Langsteger, W. 2009: PET Imaging of Prostate Cancer Using Radiolabeled Choline. Pet Clinics 4(2): 173-184
Rohren, E.M.; Macapinlac, H.A. 2009: PET Imaging of Prostate Cancer: other Tracers. Pet Clinics 4(2): 185-192
Chiu, C.-H.; Li, I.-H.; Weng, S.-J.; Huang, Y.-S.; Wu, S.-C.; Chou, T.-K.; Huang, W.-S.; Liao, M.-H.; Shiue, C.-Y.; Cheng, C.-Y.; Ma, K.-H. 2016: PET Imaging of Serotonin Transporters with 4-[(18)F]-ADAM in a Parkinsonian Rat Model with Porcine Neural Xenografts. Cell Transplantation 25(2): 301-311
Mahajan, A.; Azad, G.K.; Cook, G.J. 2016: PET Imaging of Skeletal Metastases and its Role in Personalizing Further Management. Pet Clinics 11(3): 305-318
Mittra, E.S.; Iagaru, A.; Quon, A.; Fischbein, N. 2007: PET Imaging of Skull Base Neoplasms. Pet Clinics 2(4): 489-510
Allott, L.; Smith, G.; Aboagye, E.O.; Carroll, L. 2015: PET Imaging of Steroid Hormone Receptor Expression. Molecular Imaging 14(10): 534-550
Schöll, M.; Lockhart, S.N.; Schonhaut, D.R.; O'Neil, J.P.; Janabi, M.; Ossenkoppele, R.; Baker, S.L.; Vogel, J.W.; Faria, J.; Schwimmer, H.D.; Rabinovici, G.D.; Jagust, W.J. 2016: PET Imaging of Tau Deposition in the Aging Human Brain. Neuron 89(5): 971-982
James, O.G.; Doraiswamy, P.M.; Borges-Neto, S. 2015: PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies. Frontiers in Neurology 6: 38
Torigian, D.A.; Alavi, A. 2011: PET Imaging of Thoracic Disease. Pet Clinics 6(3): Xi
Nielsen, C.H.; Jeppesen, T.E.; Kristensen, L.K.; Jensen, M.M.; El Ali, H.H.; Madsen, J.; Wiinberg, B.; Petersen, L.C.; Kjaer, A. 2016: PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VIi. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(7): 1112-1119
Pérez-Medina, C.; Tang, J.; Abdel-Atti, D.; Hogstad, B.; Merad, M.; Fisher, E.A.; Fayad, Z.A.; Lewis, J.S.; Mulder, W.J.M.; Reiner, T. 2015: PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(8): 1272-1277
Luo, H.; England, C.G.; Graves, S.A.; Sun, H.; Liu, G.; Nickles, R.J.; Cai, W. 2016: PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(2): 285-290
Bauwens, M.; Mottaghy, F.M.; Bucerius, J. 2015: PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis. Current Cardiology Reports 17(8): 67
Domercq, M.; Szczupak, B.; Gejo, J.; Gómez-Vallejo, V.; Padro, D.; Gona, K.B.; Dollé, F.éd.ér.; Higuchi, M.; Matute, C.; Llop, J.; Martín, A. 2016: PET Imaging with [(18)F]FSPG Evidences the Role of System xc(-) on Brain Inflammation Following Cerebral Ischemia in Rats. Theranostics 6(11): 1753-1767
Dweck, M.R.; Newby, D.E. 2016: PET Imaging: Hot on the Trail of the HDL Particle. Jacc. Cardiovascular Imaging 9(8): 962-963
Yang, J.; Liu, X.; Ai, D.; Fan, J.; Zheng, Y.; Li, F.; Huo, L.; Wang, Y. 2015: PET Index of Bone Glucose Metabolism (PIBGM) Classification of PET/CT Data for Fever of Unknown Origin Diagnosis. PloS one 10(6): e0130173
Zhu, Y.; Xu, K.; Xu, C.; Zhang, J.; Ji, J.; Zheng, X.; Zhang, H.; Tian, M. 2016: PET Mapping for Brain-Computer Interface Stimulation of the Ventroposterior Medial Nucleus of the Thalamus in Rats with Implanted Electrodes. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(7): 1141-1145
Zhu, Y.; Du, R.; Zhu, Y.; Shen, Y.; Zhang, K.; Chen, Y.; Song, F.; Wu, S.; Zhang, H.; Tian, M. 2016: PET Mapping of Neurofunctional Changes in a Posttraumatic Stress Disorder Model. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(9): 1474-1477
Blaufox, M.D. 2016: PET Measurement of Renal Glomerular Filtration Rate: Is there a Role in Nuclear Medicine?. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(10): 1495-1496
Shoghi, K.I.; Gropler, R.J. 2015: PET Measurements of Organ Metabolism: the Devil Is in the Details. Diabetes 64(7): 2332-2334
Croteau, E.; Renaud, J.M.; Richard, M.A.; Ruddy, T.D.; Bénard, F.ço.; deKemp, R.A. 2016: PET Metabolic Biomarkers for Cancer. Biomarkers in Cancer 8(Suppl 2): 61-69
Placzek, M.S.; Zhao, W.; Wey, H.-Y.; Morin, T.M.; Hooker, J.M. 2016: PET Neurochemical Imaging Modes. Seminars in Nuclear Medicine 46(1): 20-27
Ellingson, B.M.; Chen, W.; Harris, R.J.; Pope, W.B.; Lai, A.; Nghiemphu, P.L.; Czernin, J.; Phelps, M.E.; Cloughesy, T.F. 2013: PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. Pet Clinics 8(2): 201-217
Kimura, Y.; Ichise, M.; Ito, H.; Shimada, H.; Ikoma, Y.; Seki, C.; Takano, H.; Kitamura, S.; Shinotoh, H.; Kawamura, K.; Zhang, M.-R.; Sahara, N.; Suhara, T.; Higuchi, M. 2015: PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(9): 1359-1365
Gomperts, S.N.; Marquie, M.; Locascio, J.J.; Bayer, S.; Johnson, K.A.; Growdon, J.H. 2016: PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neuro-Degenerative Diseases 16(1-2): 118-124
Choe, Y.S.; Lee, K.-H. 2015: PET Radioligands for Imaging of Tau Pathology: Current Status. Nuclear Medicine and Molecular Imaging 49(4): 251-257
Gropler, R.J. 2009: PET Radiotracers of the Cardiovascular System. Pet Clinics 4(1): 69-87
Ehrhardt, M.J.; Markiewicz, P.; Liljeroth, M.; Barnes, A.; Kolehmainen, V.; Duncan, J.S.; Pizarro, L.; Atkinson, D.; Hutton, B.F.; Ourselin, S.; Thielemans, K.; Arridge, S.R. 2016: PET Reconstruction with an Anatomical MRi Prior Using Parallel Level Sets. IEEE Transactions on Medical Imaging 35(9): 2189-2199
Urhan, M.; Basu, S.; Alavi, A. 2012: PET Scan in Thyroid Cancer. Pet Clinics 7(4): 453-461
Barrington, S.F.; Mikhaeel, N.G. 2016: PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Current Hematologic Malignancy Reports 11(3): 185-195
Yamane, H.; Ochi, N.; Honda, Y.; Takigawa, N. 2015: PET Superscan Caused by Lung Cancer. Internal Medicine 54(22): 2951
Schuster, D.M.; Nanni, C.; Fanti, S. 2016: PET Tracers Beyond FDG in Prostate Cancer. Seminars in Nuclear Medicine 46(6): 507-521
Testa, A.; Zanda, M.; Elmore, C.S.; Sharma, P. 2015: PET Tracers to Study Clinically Relevant Hepatic Transporters. Molecular Pharmaceutics 12(7): 2203-2216
Freudenberg, L.S.; Rosenbaum, S.J.; Beyer, T.; Bockisch, A.; Antoch, G. 2006: PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Pet Clinics 1(4): 347-352
Mayor, S. 2015: PET after chemotherapy identifies Hodgkin's lymphoma patients who can avoid radiotherapy. Bmj 350: H2190
Goldberg, M.F.; Chawla, S.; Alavi, A.; Torigian, D.A.; Melhem, E.R. 2008: PET and MR Imaging of Brain Tumors. Pet Clinics 3(3): 293-315
Su, Y.Y.; Yang, G.F.; Lu, G.M.; Wu, S.; Zhang, L.J. 2015: PET and MR imaging of neuroinflammation in hepatic encephalopathy. Metabolic Brain Disease 30(1): 31-45
Aguiar, P.; Pardo, J.; Arias, M.; Quintáns, B.; Fernández-Prieto, M.; Martínez-Regueiro, R.ío.; Pumar, J.é-M.; Silva-Rodríguez, J.ús.; Ruibal, Ál.; Sobrido, M.ía.-J.ús.; Cortés, J. 2017: PET and MRi detection of early and progressive neurodegeneration in spinocerebellar ataxia type 36. Movement Disorders: Official Journal of the Movement Disorder Society 32(2): 264-273
Gillies, R.J.; Beyer, T. 2016: PET and MRI: Is the Whole Greater than the Sum of its Parts?. Cancer Research 76(21): 6163-6166
Kumar, R.; Chawla, M.; Basu, S.; Alavi, A. 2009: PET and PET-CT Imaging in Treatment Monitoring of Breast Cancer. Pet Clinics 4(4): 359-369
Basu, S.; Kwee, T.C.; Alavi, A. 2010: PET and PET/CT Assessment of Gynecologic Malignancies: Beyond FDG. Pet Clinics 5(4): 477-482
Delbeke, D.; Martin, W.H. 2008: PET and PET/CT for Pancreatic Malignancies. Pet Clinics 3(2): 155-167
Podoloff, D.A.; Macapinlac, H.A. 2006: PET and PET/CT in Management of the Lymphomas. Pet Clinics 1(3): 243-250
Chamroonrat, W.; Houseni, M.; Li, G.; Alavi, A.; Zhuang, H. 2008: PET and PET/CT in Pediatric Gastrointestinal Tract Oncology. Pet Clinics 3(2): 227-238
McCarville, M.B. 2008: PET and PET/CT in Pediatric Sarcomas. Pet Clinics 3(4): 563-575
Erasmus, J.J.; Rohren, E.M.; Hustinx, R. 2008: PET and PET/CT in the Diagnosis and Staging of Esophageal and Gastric Cancers. Pet Clinics 3(2): 135-145
Moroni, M.; Mei, A.; Leonardi, A.; Lupo, E.; Marca, F.L. 2015: PET and PVC separation with hyperspectral imagery. Sensors 15(1): 2205-2227
Grassetto, G.; Alavi, A.; Rubello, D. 2007: PET and Parathyroid. Pet Clinics 2(3): 385-393
Vapiwala, N.; Lin, A. 2009: PET and Radiation Therapy Planning and Delivery for Prostate Cancer. Pet Clinics 4(2): 193-207
Hillyar, C.R.T.; Knight, J.C.; Vallis, K.A.; Cornelissen, B. 2015: PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development. Current Drug Targets 16(6): 582-591
Oukoloff, K.; Cieslikiewicz-Bouet, M.; Chao, S.; Da Costa Branquinho, E.; Bouteiller, C.; Jean, L.; Renard, P.-Y. 2015: PET and SPECT Radiotracers for Alzheimer's Disease. Current Medicinal Chemistry 22(28): 3278-3304
Juhász, C.; Bosnyák, E. 2016: PET and SPECT studies in children with hemispheric low-grade gliomas. Child's Nervous System: Chns: Official Journal of the International Society for Pediatric Neurosurgery 32(10): 1823-1832
Tunsupon, P.; Mador, M.J. 2015: PET artefact masquerading as a PET positive lung mass. BMJ Case Reports
Chen, W.; Dilsizian, V. 2015: PET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR?. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(4): 503-504
Brouwers, A.H.; Glaudemans, A.W.; De Vries, E.F. 2015: PET beyond ¹⁸F-FDG: second generation PET tracers in clinical oncology. Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 59(1): 1-3
García-Ribas, G.; Arbizu, J.; Carrió, I.; Garrastachu, P.; Martinez-Lage, P. 2017: PET biomarkers: use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis. Neurologia 32(5): 275-277
Terauchi, T. 2007: PET diagnosis at the Cancer Prevention and Examination Research Center, National Cancer Center. Nihon Hoshasen Gijutsu Gakkai Zasshi 63(3 Suppl): 19-22
Hicks, R.J. 2008: PET for Therapeutic Response Monitoring in Oncology. Pet Clinics 3(1): 89-99
Cattaneo, G.M.; Bettinardi, V.; Mapelli, P.; Picchio, M. 2016: PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment. Physica Medica: Pm: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics 32(3): 452-458
Bansal, L.; Miller, I.; Hyslop, A.; Bhatia, S.; Duchowny, M.; Jayakar, P. 2016: PET hypermetabolism in medically resistant childhood epilepsy: Incidence, associations, and surgical outcome. Epilepsia 57(3): 436-444
Layer, T.; Blaickner, M.; Knäusl, B.; Georg, D.; Neuwirth, J.; Baum, R.P.; Schuchardt, C.; Wiessalla, S.; Matz, G. 2015: PET image segmentation using a Gaussian mixture model and Markov random fields. Ejnmmi Physics 2(1): 9
Chen, D.L.; Schiebler, M.L.; Goo, J.M.; van Beek, E.J.R. 2017: PET imaging approaches for inflammatory lung diseases: Current concepts and future directions. European Journal of Radiology 86: 371-376
Differding, S.; Hanin, F.ço.-X.; Grégoire, V. 2015: PET imaging biomarkers in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging 42(4): 613-622
Zhang, Y.; Kundu, B.; Zhong, M.; Huang, T.; Li, J.; Chordia, M.D.; Chen, M.-H.; Pan, D.; He, J.; Shi, W. 2015: PET imaging detection of macrophages with a formyl peptide receptor antagonist. Nuclear Medicine and Biology 42(4): 381-386
Hillmer, A.T.; Zheng, M.-Q.; Li, S.; Scheunemann, M.; Lin, S.-f.; Holden, D.; Labaree, D.; Ropchan, J.; Teodoro, R.; Deuther-Conrad, W.; Carson, R.E.; Brust, P.; Huang, Y. 2016: PET imaging evaluation of [(18)F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging 43(3): 537-547
Wiers, C.E.; Cabrera, E.; Skarda, E.; Volkow, N.D.; Wang, G.-J. 2016: PET imaging for addiction medicine: from neural mechanisms to clinical considerations. Progress in Brain Research 224: 175-201
Incerti, E.; Mapelli, P.; Gianolli, L.; Picchio, M. 2017: PET imaging for lymph node dissection in prostate cancer. World Journal of Urology 35(4): 507-515
Santhanam, P.; Taieb, D.; Giovanella, L.; Treglia, G. 2015: PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine 50(2): 297-305
Hartl, E.; Rémi, J.; Vollmar, C.; Goc, J.; Loesch, A.M.; Rominger, A.; Noachtar, S. 2016: PET imaging in extratemporal epilepsy requires consideration of electroclinical findings. Epilepsy Research 125: 72-76
Watts, C.; Langen, K.-J. 2016: PET imaging in glioma: is it time for mainstream practice?. Neuro-Oncology 18(9): 1193-1194
Sarikaya, I. 2015: PET imaging in neurology: Alzheimer's and Parkinson's diseases. Nuclear Medicine Communications 36(8): 775-781
Okano, K.; Oshima, M.; Yamamoto, N.; Suzuki, Y. 2015: PET imaging in the diagnosis of pancreatic cancer. Nihon Rinsho. Japanese Journal of Clinical Medicine 73(Suppl 3): 79-83
Knight, J.C.; Topping, C.ío.; Mosley, M.; Kersemans, V.; Falzone, N.; Fernández-Varea, J.é M.; Cornelissen, B. 2015: PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging 42(11): 1707-1717
Ory, D.; Planas, A.; Dresselaers, T.; Gsell, W.; Postnov, A.; Celen, S.; Casteels, C.; Himmelreich, U.; Debyser, Z.; Van Laere, K.; Verbruggen, A.; Bormans, G. 2015: PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nuclear Medicine and Biology 42(10): 753-761
Ahmadi, A.; Thorn, S.L.; Alarcon, E.I.; Kordos, M.; Padavan, D.T.; Hadizad, T.; Cron, G.O.; Beanlands, R.S.; DaSilva, J.N.; Ruel, M.; deKemp, R.A.; Suuronen, E.J. 2015: PET imaging of a collagen matrix reveals its effective injection and targeted retention in a mouse model of myocardial infarction. Biomaterials 49: 18-26
Qin, H.; Zhang, M.-R.; Xie, L.; Hou, Y.; Hua, Z.; Hu, M.; Wang, Z.; Wang, F. 2015: PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V. American Journal of Nuclear Medicine and Molecular Imaging 5(1): 27-37
Tarkin, J.M.; Joshi, F.R.; Rajani, N.K.; Rudd, J.H.F. 2015: PET imaging of atherosclerosis. Future Cardiology 11(1): 115-131
Tietz, O.; Wuest, M.; Marshall, A.; Glubrecht, D.; Hamann, I.; Wang, M.; Bergman, C.; Way, J.D.; Wuest, F. 2016: PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model. Ejnmmi Research 6(1): 37
Bang, J.-I.; Jung, I.S.; Song, Y.S.; Park, H.S.; Moon, B.S.; Lee, B.C.; Kim, S.E. 2016: PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs. Nuclear Medicine and Biology 43(2): 158-164
Garousi, J.; Andersson, K.G.; Mitran, B.; Pichl, M.-L.; Ståhl, S.; Orlova, A.; Löfblom, J.; Tolmachev, V. 2016: PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology 48(4): 1325-1332
Wehrenberg-Klee, E.; Redjal, N.; Leece, A.; Turker, N.S.; Heidari, P.; Shah, K.; Mahmood, U. 2015: PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. American Journal of Nuclear Medicine and Molecular Imaging 5(4): 379-389
Cheeseman, C. 2016: PET imaging of glucose movement into tissues in vivo sheds new light on an old problem. Journal of Physiology 594(15): 4089-4090
Thukkani, A.K.; Shoghi, K.I.; Zhou, D.; Xu, J.; Chu, W.; Novak, E.; Chen, D.L.; Gropler, R.J.; Mach, R.H. 2016: PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116. American Journal of Nuclear Medicine and Molecular Imaging 6(2): 110-119
Su, X.; Cheng, K.; Liu, Y.; Hu, X.; Meng, S.; Cheng, Z. 2015: PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule. Amino Acids 47(7): 1409-1419
Mertan, F.V.; Lindenberg, L.; Choyke, P.L.; Turkbey, B. 2016: PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncology 12(21): 2463-2477
Healy, G.M.; Redmond, C.E.; Kinsella, J.; Killeen, R.P. 2017: PET imaging of subclinical seizure associated with intracranial cavernous malformations. Qjm: Monthly Journal of the Association of Physicians 110(1): 45-46
Higuchi, M. 2015: PET imaging of tau lesions. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 145(5): 268
Jacobson, O.; Yan, X.; Niu, G.; Weiss, I.D.; Ma, Y.; Szajek, L.P.; Shen, B.; Kiesewetter, D.O.; Chen, X. 2015: PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(4): 616-621
Noordzij, W.; Slart, R.H.J.A. 2015: PET imaging of the autonomic myocardial function: methods and interpretation. Clinical and Translational Imaging 3(5): 365-372
Thackeray, J.T.; Bengel, F.M. 2016: PET imaging of the autonomic nervous system. Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 60(4): 362-382
James, M.L.; Belichenko, N.P.; Nguyen, T.-V.V.; Andrews, L.E.; Ding, Z.; Liu, H.; Bodapati, D.; Arksey, N.; Shen, B.; Cheng, Z.; Wyss-Coray, T.; Gambhir, S.S.; Longo, F.M.; Chin, F.T. 2015: PET imaging of translocator protein (18 kDa) in a mouse model of Alzheimer's disease using N-(2,5-dimethoxybenzyl)-2-18F-fluoro-N-(2-phenoxyphenyl)acetamide. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(2): 311-316
Witney, T.H.; James, M.L.; Shen, B.; Chang, E.; Pohling, C.; Arksey, N.; Hoehne, A.; Shuhendler, A.; Park, J.-H.; Bodapati, D.; Weber, J.; Gowrishankar, G.; Rao, J.; Chin, F.T.; Gambhir, S.S. 2015: PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2. Science Translational Medicine 7(310): 310ra169
Skovgaard, D.; Persson, M.; Kjaer, A. 2016: PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives. Clinical and Translational Imaging 4(6): 457-465
Ouchi, Y. 2015: PET imaging of α7 nicotinic receptor. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 145(5): 266-267
Vijay, A.; Wang, S.; Worhunsky, P.; Zheng, M.-Q.; Nabulsi, N.; Ropchan, J.; Krishnan-Sarin, S.; Huang, Y.; Morris, E.D. 2016: PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. American Journal of Nuclear Medicine and Molecular Imaging 6(4): 205-214
Brownell, A.-L.; Kuruppu, D.; Kil, K.-E.; Jokivarsi, K.; Poutiainen, P.; Zhu, A.; Maxwell, M. 2015: PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. Journal of Neuroinflammation 12: 217
Braad, P.E.N.; Hansen, S.B.; Thisgaard, H.; Høilund-Carlsen, P.F. 2015: PET imaging with the non-pure positron emitters: (55)Co, (86)Y and (124)i. Physics in Medicine and Biology 60(9): 3479-3497
Hustinx, R.; Fosse, P.ôm. 2010: PET in Brain Tumors. Pet Clinics 5(2): 185-197
Adams, G.; Porceddu, S.V. 2012: PET in Decision Making for Neck Dissection After Radiation Treatment. Pet Clinics 7(4): 411-423
Alavi, A.; Newberg, A.B. 2010: PET in Epilepsy and other Seizure Disorders. Pet Clinics 5(2): 209-221
Fanti, S.; Zinzani, P. 2015: PET in natural killer/T-cell lymphoma: the debate continues. Lancet. Haematology 2(2): E50-E51
Kumar, A.; Chugani, H.T. 2008: PET in the Assessment of Pediatric Brain Development and Developmental Disorders. Pet Clinics 3(4): 487-515
Bertolli, O.; Eleftheriou, A.; Cecchetti, M.; Camarlinghi, Nò.; Belcari, N.; Tsoumpas, C. 2016: PET iterative reconstruction incorporating an efficient positron range correction method. Physica Medica: Pm: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics 32(2): 323-330
Shimada, H.; Hirano, S.; Shinotoh, H.; Irie, T.; Suhara, T. 2016: PET measurement of brain acetylcholinesterase activities in cortex and subcortical areas. International Journal of Geriatric Psychiatry 31(8): 952-953
Kim, W.; Park, H.S.; Moon, B.S.; Lee, B.C.; Kim, S.E. 2017: PET measurement of "GABA shift" in the rat brain: a preclinical application of bolus plus constant infusion paradigm of [18F]flumazenil. Nuclear Medicine and Biology 45: 30-34
Cai, M.; Ren, L.; Yin, X.; Guo, Z.; Li, Y.; He, T.; Tang, Y.; Long, T.; Liu, Y.; Liu, G.; Zhang, X.; Hu, S. 2016: PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells. Amino Acids 48(3): 811-820
Bailey, D.L.; Lee, A.; Li, B.T.; Clarke, S.J. 2016: PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer. BMJ Case Reports
Bickell, M.; Koesters, T.; Boada, F.; Nuyts, J. 2014: PET motion correction using MR-derived motion parameters. Ejnmmi Physics 1(Suppl. 1): A53
Botelho, M.; Caldeira, L.; Scheins, J.; Matela, N.; Kops, E.Rota.; Shah, N.Jon. 2014: PET motion correction using PRESTO with ITK motion estimation. Ejnmmi Physics 1(Suppl. 1): A59
Liang, S.H.; Holland, J.P.; Stephenson, N.A.; Kassenbrock, A.; Rotstein, B.H.; Daignault, C.P.; Lewis, R.; Collier, L.; Hooker, J.M.; Vasdev, N. 2015: PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates. Acs Chemical Neuroscience 6(4): 535-541
Van Dijk, L.K.; Yim, C.-B.; Franssen, G.M.; Kaanders, J.H.A.M.; Rajander, J.; Solin, O.; Grönroos, T.J.; Boerman, O.C.; Bussink, J. 2016: PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media and Molecular Imaging 11(1): 65-70
Jadvar, H. 2016: PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(Suppl 3): 25s-29s
Michel, L.S.; Dyroff, S.; Brooks, F.J.; Spayd, K.J.; Lim, S.; Engle, J.T.; Phillips, S.; Tan, B.; Wang-Gillam, A.; Bognar, C.; Chu, W.; Zhou, D.; Mach, R.H.; Laforest, R.; Chen, D.L. 2017: PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and first In-Human Studies. Radiology 282(2): 453-463
Luo, H.; Hong, H.; Slater, M.R.; Graves, S.A.; Shi, S.; Yang, Y.; Nickles, R.J.; Fan, F.; Cai, W. 2015: PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(5): 758-763
Hong, H.; Yan, Y.; Shi, S.; Graves, S.A.; Krasteva, L.K.; Nickles, R.J.; Yang, M.; Cai, W. 2015: PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging. Molecular Pharmaceutics 12(2): 403-410
Schug, D.; Wehner, J.; Dueppenbecker, P.M.; Weissler, B.; Gebhardt, P.; Goldschmidt, B.; Salomon, A.; Kiessling, F.; Schulz, V. 2015: PET performance and MRi compatibility evaluation of a digital, ToF-capable PET/MRi insert equipped with clinical scintillators. Physics in Medicine and Biology 60(18): 7045-7067
Schug, D.; Lerche, C.; Dueppenbecker, P.; Gebhardt, P.; Goldschmidt, B.; Salomon, A.; Wehner, J.; Weissler, B.; Kiessling, F.; Schulz, V. 2014: PET performance evaluation of a preclinical digital PET/MRi insert. Ejnmmi Physics 1(Suppl 1): A3
Jiang, L.; Tu, Y.; Shi, H.; Cheng, Z. 2014: PET probes beyond (18)F-FDG. Journal of Biomedical Research 28(6): 435-446
Környei, J.óz.; Mikecz, P.ál.; Tóth, G. 2014: PET radiopharmaceuticals: novelties and new possibilities. Magyar Onkologia 58(4): 245-250
Mukherjee, J.; Majji, D.; Kaur, J.; Constantinescu, C.C.; Narayanan, T.K.; Shi, B.; Nour, M.T.; Pan, M-Liang. 2017: PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. Synapse 71(3)
Hou, Q.; Huang, J.; Bian, Z.; Chen, W.; Ma, J. 2015: PET reconstruction via nonlocal means induced prior. Journal of X-Ray Science and Technology 23(3): 331-348
Fendler, W.P.; Lehmann, M.; Todica, A.; Herrmann, K.; Knösel, T.; Angele, M.K.; Dürr, H.R.; Rauch, J.; Bartenstein, P.; Cyran, C.C.; Hacker, M.; Lindner, L.H. 2015: PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 56(4): 530-537
Safaie, E.; Matthews, R.; Bergamaschi, R. 2015: PET scan findings can be false positive. Techniques in Coloproctology 19(6): 329-330
Lewis, D.A.; Tann, M.; McCool, A.; Kessler, K.; Einhorn, L. 2016: PET scan's clinical utility in detecting residual disease in postchemotherapy germ cell cancer patients. Journal of Clinical Oncology 23(16_Suppl): 4574-4574
Choi, M.; Kollepara, S.L.S.; Heilbrun, L.K.; Smith, D.; Shields, A.F.; Philip, P.A. 2015: PET scans as a predictive marker of survival in advanced colorectal cancer. Clinical Colorectal Cancer 14(1): 35-40
Müller, T. 2014: PET study. Winter blues: serotonin transporter is responsible. MMW Fortschritte der Medizin 156(19): 26
Chalon, S.; Vercouillie, J.; Guilloteau, D.; Suzenet, F.; Routier, S. 2015: PET tracers for imaging brain α7 nicotinic receptors: an update. Chemical Communications 51(80): 14826-14831
Johnbeck, C.Bardram.; Knigge, U.; Kjær, A. 2014: PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncology 10(14): 2259-2277
Kwee, R.M.; Marcus, C.; Sheikhbahaei, S.; Subramaniam, R.M. 2015: PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. Pet Clinics 10(2): 197-205
Hasselbalch, S.G. 2015: PET with amyloid ligands should not be applied routinely in early diagnostics of Alzheimer's disease. Ugeskrift for Laeger 177(32): V11140610
Rasera, C.C.; Gewehr, P.M.; Domingues, A.M.T. 2015: PET(CO2) measurement and feature extraction of capnogram signals for extubation outcomes from mechanical ventilation. Physiological Measurement 36(2): 231-242
Katz, S.; Ferrara, T.; Alavi, A.; Torigian, D.A. 2008: PET, CT, and MR Imaging for Assessment of Thoracic Malignancy: Structure Meets Function. Pet Clinics 3(3): 395-410
Puttick, S.; Bell, C.; Dowson, N.; Rose, S.; Fay, M. 2015: PET, MRI, and simultaneous PET/MRi in the development of diagnostic and therapeutic strategies for glioma. Drug Discovery Today 20(3): 306-317
Ahmed Shamim, S.; Torigian, D.A.; Kumar, R. 2008: PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer. Pet Clinics 3(3): 381-393
Constantinesco, A.é; Choquet, P.; Goetz, C.; Monassier, L. 2012: PET, SPECT, CT, and MRi in Mouse Cardiac Phenotyping: An Overview. Current Protocols in Mouse Biology 2(2): 129-144
López-Rodríguez, V.; Galindo-Sarco, C.; García-Pérez, F.O.; Ferro-Flores, G.; Arrieta, O.; Ávila-Rodríguez, M.A. 2016: PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 57(3): 404-409
Basu, S.; Ranade, R.; Ostwal, V.; Shrikhande, S.V. 2016: PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. Pet Clinics 11(3): 233-241
El-Haddad, G. 2016: PET-Based Percutaneous Needle Biopsy. Pet Clinics 11(3): 333-349
Basu, S.; Alavi, A. 2016: PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future. Pet Clinics 11(3): 203-207
Hess, S.ør.; Alavi, A.; Basu, S. 2016: PET-Based Personalized Management of Infectious and Inflammatory Disorders. Pet Clinics 11(3): 351-361
Simone, C.B.; Houshmand, S.; Kalbasi, A.; Salavati, A.; Alavi, A. 2016: PET-Based Thoracic Radiation Oncology. Pet Clinics 11(3): 319-332
Cohen, D.; Hartung, H.; Evans, P.; Friedman, D.F.; Chou, S.T. 2016: Red blood cell alloimmunization in transfused patients with bone marrow failure syndromes. Transfusion 56(6): 1314-1319
Nguyen, D.; Maheshwary, R.; Rajput, A.; Tran, C.; Kudithipudi, V. 2017: PET-CT Post-Hepatic Radiation Changes in Gastroesophageal Adenocarcinoma. Clinical Nuclear Medicine 42(1): E54-E55
Granato, F.; Felicio, A.C.; Yamaga, L.Y.I.; Nogueira, S.A.; Vitor, T. 2017: PET-CT as an Alternative to Fiducial Markers Guidance in Liver Metastasis Treatment. Clinical Nuclear Medicine 42(1): E49-E50
Htet, S.; Lane, S.; Kipp, D.; Rose, H.; Campbell, P. 2016: PET-CT confirmed complete remission and MRD negativity in mantle cell lymphoma patients treated with R-hyper-CVAD results in excellent outcome in the absence of autologous stem cell transplantation: a single-centre case for a transplant-free approach. Internal Medicine Journal 46(9): 1113-1114
Li, Z.-Y.; Li, X.-C.; Wu, Q. 2014: PET-CT diagnosis of cardiac cavernous hemangioma with large pericardial effusion. European Review for Medical and Pharmacological Sciences 18(21): 3256-3259
Adam, Zěk.; Szturz, P.; Koukalová, R.; Řehák, Zěk.; Pour, Lěk.; Krejčí, M.; Šmardová, L.; Eid, M.; Volfová, Pína.; Čermáková, Zňka.; Křen, Lš.; Sokol, F.; Hanke, I.; Michalková, E.; Král, Zěk.; Mayer, Jří. 2015: PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review. Vnitrni Lekarstvi 61(3): 251-259
Flamini, R.d.C.; Yamaga, L.Y.I.; Osawa, A.; Nomura, C.; Guerra, J.ão.C.d.C.; Pasternak, J.; Cunha, M.L.d.; Campos Neto, G.d.C.; Wagner, J.; Funari, M.B.d.G.ão. 2010: PET-CT findings in arteritis. Einstein 8(4): 498-499
Rao, L.; Wang, X.; Zong, Z.; Chen, Z.; Shi, X.; Yi, C.; Zhang, X.; Yang, Z. 2016: PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma. Medicine 95(20): E3750
Akin, S.; den Uil, C.A.; Groeninx van Zoelen, C.E.; Gommers, D. 2016: PET-CT for detecting the undetected in the ICU. Intensive Care Medicine 42(1): 111-112
Barrington, S.F.; Kirkwood, A.A.; Franceschetto, A.; Fulham, M.J.; Roberts, T.H.; Almquist, H.én.; Brun, E.; Hjorthaug, K.; Viney, Z.N.; Pike, L.C.; Federico, M.; Luminari, S.; Radford, J.; Trotman, J.; Fosså, A.; Berkahn, L.; Molin, D.; D'Amore, F.; Sinclair, D.A.; Smith, P.; O'Doherty, M.J.; Stevens, L.; Johnson, P.W. 2016: PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 127(12): 1531-1538
Ulger, S.; Demirci, N.Y.; Aydinkarahaliloglu, E.; Kahraman, F.C.; Ozmen, O.; Erdogan, Y.; Cetin, E.; Avci, E.; Cengiz, M. 2015: PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer. Journal of Thoracic Disease 7(3): 295-302
Belezia, A.B.; Marussi, V.H.R.; Yared, J.; Pedroso, J.é L.; Barsottini, O.G.; Oliveira, A.S.B.; Amaral, L.áz.L.F.d. 2015: PET-CT imaging in a patient with progressive supranuclear palsy. Arquivos de Neuro-Psiquiatria 73(4): 364-365
Read, C.; Branford, O.A.; Verjee, L.S.; Wood, S.H. 2015: PET-CT imaging in patients with chronic sternal wound infections prior to reconstructive surgery: a case series. Journal of Plastic Reconstructive and Aesthetic Surgery: Jpras 68(8): 1132-1137
Vlaming, M.L.H.; Läppchen, T.; Jansen, H.T.; Kivits, S.; van Driel, A.; van de Steeg, E.; van der Hoorn, J.é W.; Sio, C.F.; Steinbach, O.C.; DeGroot, J. 2015: PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier. Nuclear Medicine and Biology 42(11): 833-841
Thanarajasingam, G.; Bennani-Baiti, N.; Thompson, C.A. 2016: PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. Current Treatment Options in Oncology 17(5): 24
Scarsbrook, A.F.; Barrington, S.F. 2016: PET-CT in the UK: current status and future directions. Clinical Radiology 71(7): 673-690
Norum, J.; Søndergaard, U.; Traasdahl, E.; Nieder, C.; Tollåli, G.; Andersen, G.; Sundset, R. 2015: PET-CT in the sub-arctic region of Norway 2010-2013. At the edge of what is possible?. BMC medical imaging 15: 36
Kepka, L.; Socha, J. 2015: PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?. Journal of Thoracic Disease 7(11): 1887-1890
Yoshida, H.; Takahashi, H.; Kanda, Y.; Chiba, K. 2017: PET-CT observations of cortical activity in pre-lingually deaf adolescent and adult patients with cochlear implantation. Acta Oto-Laryngologica 137(5): 464-470
Rollins, K.E.; Lucas, E.; Tewari, N.; James, E.; Hughes, S.; Catton, J.A. 2015: PET-CT offers accurate assessment of tumour length in oesophageal malignancy. European Journal of Radiology 84(2): 195-200
Cheson, B.D. 2014: PET-CT restaging: a surrogate for follicular lymphoma?. Lancet. Haematology 1(1): E2-E3
Kepka, L.; Socha, J. 2015: PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung cancer: a systematic review. RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 115(2): 151-156